coumestrol - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	coumestrol	go back to main search page
Accession:	CHEBI:3908	browse the term
Definition:	A member of the class of coumestans that is coumestan with hydroxy substituents at positions 3 and 9.
Synonyms:	related_synonym:	3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; 3,9-dihydroxycoumestan; Chrysanthin; Formula=C15H8O5; InChI=1S/C15H8O5/c16-7-1-3-9-11(5-7)19-14-10-4-2-8(17)6-12(10)20-15(18)13(9)14/h1-6,16-17H; InChIKey=ZZIALNLLNHEQPJ-UHFFFAOYSA-N; SMILES=Oc1ccc2c(c1)oc1c3ccc(O)cc3oc(=O)c21
	xref:	CAS:479-13-0; HMDB:HMDB0002326; KEGG:C10205; KNApSAcK:C00002514; LINCS:LSM-4202; LIPID_MAPS_instance:LMPK12090018
	xref_mesh:	MESH:D003375
	xref:	MetaCyc:CPD-11779; PMID:22644850; PMID:22694330; PMID:22824334; PMID:22926873; PMID:23348407; Reaxys:266702; Wikipedia:Coumestrol

show annotations for term's descendants Sort by:
Rat (1767) Mouse (1771) Human (1813) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (1767)

coumestrol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 6430548M08 gene like

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KIAA0513 mRNA
Coumestrol results in decreased expression of KIAA0513 mRNA

NCBI chr19:48,168,651...48,216,571
Ensembl chr19:48,198,209...48,216,575

G

aladin WD repeat nucleoporin

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AAAS mRNA
Coumestrol results in increased expression of AAAS mRNA

NCBI chr 7:135,342,901...135,362,545
Ensembl chr 7:133,464,315...133,483,961

G

alanyl-tRNA synthetase 1

increases expression

Coumestrol results in increased expression of AARS1 mRNA

NCBI chr19:55,906,694...55,930,499
Ensembl chr19:38,999,163...39,021,147

G

4-aminobutyrate aminotransferase

increases expression

Coumestrol results in increased expression of ABAT mRNA

NCBI chr10:7,503,351...7,599,474
Ensembl chr10:6,999,819...7,092,835

G

ATP binding cassette subfamily C member 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABCC5 mRNA

NCBI chr11:93,975,579...94,071,659
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily D member 3

decreases expression

Coumestrol results in decreased expression of ABCD3 mRNA

NCBI chr 2:212,536,791...212,590,379
Ensembl chr 2:209,852,087...209,906,020

G

ATP binding cassette subfamily E member 1

increases expression

Coumestrol results in increased expression of ABCE1 mRNA

NCBI chr19:28,205,566...28,230,489
Ensembl chr19:28,205,555...28,230,489

G

ATP binding cassette subfamily F member 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ABCF1 mRNA
Coumestrol results in increased expression of ABCF1 mRNA

NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,802,488...2,815,433

G

ATP binding cassette subfamily G member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABCG1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ABCG1 mRNA

NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,126,687...9,182,948

G

abhydrolase domain containing 11

decreases expression
multiple interactions

Coumestrol results in decreased expression of ABHD11 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABHD11 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ABHD11 mRNA

NCBI chr12:27,318,739...27,322,016
Ensembl chr12:21,682,202...21,685,398

G

abhydrolase domain containing 12, lysophospholipase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ABHD12 mRNA

NCBI chr 3:160,119,724...160,179,959
Ensembl chr 3:139,659,317...139,719,564

G

abhydrolase domain containing 16A, phospholipase

decreases expression

Coumestrol results in decreased expression of ABHD16A mRNA

NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927

G

abl-interactor 1

decreases expression

Coumestrol results in decreased expression of ABI1 mRNA

NCBI chr17:90,006,917...90,088,002
Ensembl chr17:85,098,550...85,179,792

G

abraxas 1, BRCA1 A complex subunit

decreases expression

Coumestrol results in decreased expression of ABRAXAS1 mRNA

NCBI chr14:9,100,650...9,115,012
Ensembl chr14:8,796,266...8,810,622

G

acetyl-CoA acyltransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACAA2 mRNA

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA acetyltransferase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACAT2 mRNA
Coumestrol results in increased expression of ACAT2 mRNA

NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:47,695,788...47,752,821

G

acyl-CoA binding domain containing 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACBD3 mRNA

NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380

G

atypical chemokine receptor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACKR3 mRNA

NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:90,799,686...90,811,237

G

ATP citrate lyase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACLY mRNA
Coumestrol results in increased expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,412,049...85,463,320

G

acyl-CoA thioesterase 4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACOT4 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ACOT4 mRNA
Coumestrol results in increased expression of ACOT4 mRNA

NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:103,668,753...103,673,917

G

acyl-CoA thioesterase 7

increases expression
multiple interactions

Coumestrol results in increased expression of ACOT7 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACOT7 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ACOT7 mRNA

NCBI chr 5:167,969,284...168,062,033
Ensembl chr 5:162,684,645...162,779,309

G

acyl-CoA synthetase long-chain family member 3

decreases expression

Coumestrol results in decreased expression of ACSL3 mRNA

NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:80,115,112...80,164,627

G

acyl-CoA synthetase short-chain family member 3

decreases expression

Coumestrol results in decreased expression of ACSS3 mRNA

NCBI chr 7:44,127,725...44,336,707
Ensembl chr 7:42,242,652...42,450,230

G

activin A receptor type 1

decreases expression

Coumestrol results in decreased expression of ACVR1 mRNA

NCBI chr 3:63,387,378...63,506,980
Ensembl chr 3:42,978,561...43,098,241

G

acylphosphatase 1

increases expression
multiple interactions

Coumestrol results in increased expression of ACYP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACYP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ACYP1 mRNA

NCBI chr 6:110,650,213...110,663,404
Ensembl chr 6:104,919,162...104,932,387

G

adenosine deaminase, tRNA-specific 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ADAT1 mRNA

NCBI chr19:39,918,083...39,956,886
Ensembl chr19:39,918,227...39,956,883

G

adducin 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ADD3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ADD3 mRNA
Coumestrol results in increased expression of ADD3 mRNA

NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124

G

adenosine kinase

increases expression

Coumestrol results in increased expression of ADK mRNA

NCBI chr15:2,912,543...3,295,745
Ensembl chr15:2,863,244...3,246,510

G

adrenoceptor alpha 2A

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA]

NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:253,060,218...253,064,365

G

actin filament associated protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AFAP1 mRNA

NCBI chr14:74,743,322...74,856,300
Ensembl chr14:74,743,320...74,856,263

G

ALF transcription elongation factor 4

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AFF4 mRNA
Coumestrol results in decreased expression of AFF4 mRNA

NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751

G

alpha-fetoprotein

affects binding

Coumestrol binds to AFP protein

PMID:23013281 PMID:25349334

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 1

decreases expression

Coumestrol results in decreased expression of AGAP1 mRNA

NCBI chr 9:90,039,720...90,475,196
Ensembl chr 9:90,039,605...90,470,958

G

argonaute RISC catalytic component 2

decreases expression

Coumestrol results in decreased expression of AGO2 mRNA

NCBI chr 7:106,907,209...106,994,124
Ensembl chr 7:105,029,120...105,104,974

G

1-acylglycerol-3-phosphate O-acyltransferase 3

decreases expression

Coumestrol results in decreased expression of AGPAT3 mRNA

NCBI chr20:10,330,960...10,415,358
Ensembl chr20:10,384,507...10,415,358

G

anterior gradient 2, protein disulphide isomerase family member

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AGR2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AGR2 mRNA
Coumestrol results in increased expression of AGR2 mRNA

NCBI chr 6:58,435,908...58,456,678
Ensembl chr 6:52,708,602...52,729,371

G

anterior gradient 3, protein disulphide isomerase family member

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AGR3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AGR3 mRNA
Coumestrol results in increased expression of AGR3 mRNA

NCBI chr 6:52,643,391...52,666,638
Ensembl chr 6:52,643,391...52,666,638

G

angiotensin II receptor-associated protein

increases expression

Coumestrol results in increased expression of AGTRAP mRNA

NCBI chr 5:163,790,565...163,802,174
Ensembl chr 5:158,508,749...158,519,036

G

adenosylhomocysteinase-like 1

decreases expression

Coumestrol results in decreased expression of AHCYL1 mRNA

NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:195,294,153...195,345,815

G

activator of Hsp90 ATPase activity 1

increases expression

Coumestrol results in increased expression of AHSA1 mRNA

NCBI chr 6:106,913,296...106,921,347
Ensembl chr 6:106,913,530...106,921,345

G

ajuba LIM protein

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AJUBA mRNA
Coumestrol results in decreased expression of AJUBA mRNA

NCBI chr15:31,989,796...32,000,042
Ensembl chr15:28,019,778...28,030,021

G

A-kinase anchoring protein 13

decreases expression
multiple interactions

Coumestrol results in decreased expression of AKAP13 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AKAP13 mRNA

NCBI chr 1:138,722,445...139,029,401
Ensembl chr 1:129,314,402...129,619,646

G

activated leukocyte cell adhesion molecule

decreases expression

Coumestrol results in decreased expression of ALCAM mRNA

NCBI chr11:61,804,932...62,005,250
Ensembl chr11:48,336,169...48,537,954

G

aldehyde dehydrogenase 16 family, member A1

increases expression

Coumestrol results in increased expression of ALDH16A1 mRNA

NCBI chr 1:95,626,727...95,639,808
Ensembl chr 1:95,613,558...95,640,131

G

aldehyde dehydrogenase 3 family, member B2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of ALDH3B2 mRNA
Coumestrol results in decreased expression of ALDH3B2 mRNA

NCBI chr 1:210,679,749...210,694,187
Ensembl chr 1:201,253,157...201,264,705
Ensembl chr 1:201,253,157...201,264,705

G

aldehyde dehydrogenase 3 family, member B3

multiple interactions
decreases expression

[Coumestrol co-treated with Resveratrol] results in decreased expression of ALDH3B2 mRNA
Coumestrol results in decreased expression of ALDH3B2 mRNA

NCBI chr 1:210,617,090...210,629,886
Ensembl chr 1:201,187,962...201,250,204

G

aldehyde dehydrogenase 4 family, member A1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of ALDH4A1 mRNA

NCBI chr 5:157,163,189...157,188,673
Ensembl chr 5:151,830,701...151,925,345

G

ALG6, alpha-1,3-glucosyltransferase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ALG6 mRNA
Coumestrol results in increased expression of ALG6 mRNA

NCBI chr 5:114,404,972...114,454,440
Ensembl chr 5:114,405,010...114,454,439

G

ALG8, alpha-1,3-glucosyltransferase

increases expression
multiple interactions

Coumestrol results in increased expression of ALG8 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ALG8 mRNA

NCBI chr 1:151,684,344...151,704,310
Ensembl chr 1:151,684,396...151,704,302

G

alkB homolog 7

decreases expression

Coumestrol results in decreased expression of ALKBH7 mRNA

NCBI chr 9:1,838,886...1,841,044
Ensembl chr 9:1,838,811...1,841,044

G

alkaline phosphatase, biomineralization associated

multiple interactions

[Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein; fulvestrant inhibits the reaction [[Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein]

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:149,951,409...150,006,446

G

alsin Rho guanine nucleotide exchange factor ALS2

decreases expression

Coumestrol results in decreased expression of ALS2 mRNA

NCBI chr 9:68,107,310...68,180,192
Ensembl chr 9:60,613,167...60,670,737

G

Aly/REF export factor

increases expression

Coumestrol results in increased expression of ALYREF mRNA

NCBI chr10:106,369,750...106,373,395
Ensembl chr10:105,871,306...105,875,069

G

adenosylmethionine decarboxylase 1

increases expression
multiple interactions

Coumestrol results in increased expression of AMD1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AMD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AMD1 mRNA

NCBI chr20:45,250,289...45,324,939
Ensembl chr20:43,697,237...43,711,476

G

autocrine motility factor receptor

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of AMFR mRNA

NCBI chr19:11,002,451...11,038,182
Ensembl chr19:10,996,099...11,032,247

G

AMMECR nuclear protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AMMECR1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AMMECR1 mRNA
Coumestrol results in increased expression of AMMECR1 mRNA

NCBI chr X:111,262,792...111,368,099
Ensembl chr X:106,466,699...106,571,487

G

angiomotin like 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of AMOTL2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AMOTL2 mRNA

NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910

G

anaphase-promoting complex subunit 5

increases expression

Coumestrol results in increased expression of ANAPC5 mRNA

NCBI chr12:39,409,519...39,442,518
Ensembl chr12:33,748,735...33,781,781

G

anaphase promoting complex subunit 7

increases expression

Coumestrol results in increased expression of ANAPC7 mRNA

NCBI chr12:39,793,518...39,821,614
Ensembl chr12:34,133,429...34,160,005

G

anillin, actin binding protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANLN mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ANLN mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA]
Coumestrol results in increased expression of ANLN mRNA

PMID:18310284 PMID:19167446

NCBI chr 8:29,134,222...29,197,513
Ensembl chr 8:20,858,228...20,921,538

G

anoctamin 6

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANO6 mRNA
Coumestrol results in decreased expression of ANO6 mRNA

NCBI chr 7:128,812,842...128,992,805
Ensembl chr 7:126,933,936...127,113,589

G

acidic nuclear phosphoprotein 32 family member A

increases expression

Coumestrol results in increased expression of ANP32A mRNA

NCBI chr 8:71,724,578...71,760,922
Ensembl chr 8:62,827,456...62,865,443

G

acidic nuclear phosphoprotein 32 family member E

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANP32E mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ANP32E mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA]
Coumestrol results in increased expression of ANP32E mRNA

PMID:18310284 PMID:19167446

NCBI chr 2:186,161,520...186,177,984
Ensembl chr 2:183,472,609...183,489,054

G

annexin A2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANXA2 mRNA

NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:70,105,253...70,141,658

G

annexin A3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANXA3 mRNA

NCBI chr14:13,031,675...13,085,678
Ensembl chr14:12,719,795...12,781,617

G

annexin A9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANXA9 mRNA

NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374

G

adaptor related protein complex 1 subunit beta 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AP1B1 mRNA

NCBI chr14:84,093,529...84,144,835
Ensembl chr14:79,879,533...79,930,778

G

adaptor related protein complex 1 subunit mu 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AP1M1 mRNA

NCBI chr16:17,620,910...17,636,431
Ensembl chr16:17,584,730...17,602,403

G

adaptor related protein complex 2 subunit sigma 1

increases expression

Coumestrol results in increased expression of AP2S1 mRNA

NCBI chr 1:86,545,601...86,557,007
Ensembl chr 1:77,417,477...77,428,905

G

amyloid beta precursor protein binding family B member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of APBB2 mRNA

NCBI chr14:41,557,918...41,878,622
Ensembl chr14:41,557,972...41,877,495

G

apolipoprotein D

decreases expression

Coumestrol results in decreased expression of APOD mRNA

NCBI chr11:82,936,216...82,957,264
Ensembl chr11:69,431,260...69,452,305

G

amyloid beta precursor protein

decreases expression

Coumestrol results in decreased expression of APP mRNA

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 3 (Gill blood group)

decreases expression
multiple interactions

Coumestrol results in decreased expression of AQP3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AQP3 mRNA

NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:56,239,201...56,244,720

G

androgen receptor

decreases expression
multiple interactions

Coumestrol results in decreased expression of AR mRNA
Coumestrol inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein]

PMID:11867264 PMID:29162470

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925

G

ARF guanine nucleotide exchange factor 2

decreases expression

Coumestrol results in decreased expression of ARFGEF2 mRNA

NCBI chr 3:175,966,575...176,052,715
Ensembl chr 3:155,547,538...155,630,856

G

ARFGEF family member 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARFGEF3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ARFGEF3 mRNA
Coumestrol results in decreased expression of ARFGEF3 mRNA

NCBI chr 1:15,058,574...15,223,742
Ensembl chr 1:13,244,830...13,404,084

G

Rho GTPase activating protein 19

increases expression

Coumestrol results in increased expression of ARHGAP19 mRNA

NCBI chr 1:240,571,554...240,617,361
Ensembl chr 1:240,580,871...240,617,287

G

Rho GTPase activating protein 39

decreases expression

Coumestrol results in decreased expression of ARHGAP39 mRNA

NCBI chr 7:108,446,280...108,538,875
Ensembl chr 7:108,446,282...108,538,831

G

Rho GDP dissociation inhibitor alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARHGDIA mRNA

NCBI chr10:106,352,858...106,356,347
Ensembl chr10:105,854,533...105,858,023

G

Rho guanine nucleotide exchange factor 26

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARHGEF26 mRNA
Coumestrol results in increased expression of ARHGEF26 mRNA

NCBI chr 2:148,889,405...149,000,538
Ensembl chr 2:146,739,631...146,850,819

G

Rho guanine nucleotide exchange factor 37

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARHGEF37 mRNA

NCBI chr18:54,935,256...55,001,017
Ensembl chr18:54,949,110...55,000,669

G

Rho guanine nucleotide exchange factor 39

increases expression

Coumestrol results in increased expression of ARHGEF39 mRNA

NCBI chr 5:62,548,300...62,551,870
Ensembl chr 5:57,752,509...57,756,109

G

AT-rich interaction domain 4B

decreases expression

Coumestrol results in decreased expression of ARID4B mRNA

NCBI chr17:51,138,419...51,262,894
Ensembl chr17:51,138,535...51,262,906

G

ARF like GTPase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARL3 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ARL3 mRNA

NCBI chr 1:255,342,078...255,388,087
Ensembl chr 1:245,400,550...245,446,820

G

allregulin

decreases expression

Coumestrol results in decreased expression of ARLN mRNA

NCBI chr 2:211,055,925...211,057,685
Ensembl chr 2:211,055,911...211,057,681

G

aryl hydrocarbon receptor nuclear translocator

decreases expression

Coumestrol results in decreased expression of ARNT mRNA

NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:182,997,736...183,056,580

G

arrestin domain containing 3

decreases expression

Coumestrol results in decreased expression of ARRDC3 mRNA

NCBI chr 2:12,873,202...12,885,716
Ensembl chr 2:11,137,460...11,149,978

G

aristaless related homeobox

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARX mRNA

NCBI chr X:62,010,097...62,022,009
Ensembl chr X:58,016,233...58,028,142

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of ASAP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ASAP1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ASAP1 mRNA

NCBI chr 7:97,675,354...97,982,523
Ensembl chr 7:95,787,818...96,092,754

G

anti-silencing function 1B histone chaperone

increases expression
multiple interactions

Coumestrol results in increased expression of ASF1B mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ASF1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ASF1B mRNA

NCBI chr19:41,085,786...41,100,352
Ensembl chr19:24,181,028...24,195,549

G

assembly factor for spindle microtubules

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ASPM mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ASPM mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA]
Coumestrol results in increased expression of ASPM mRNA

PMID:18310284 PMID:19167446

NCBI chr13:53,625,584...53,674,489
Ensembl chr13:51,074,849...51,123,755

G

ATPase family, AAA domain containing 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATAD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ATAD2 mRNA
Coumestrol results in increased expression of ATAD2 mRNA

NCBI chr 7:91,523,626...91,566,238
Ensembl chr 7:89,634,123...89,676,738

G

activating transcription factor 2

increases expression

Coumestrol results in increased expression of ATF2 mRNA

NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:58,718,332...58,795,236

G

activating transcription factor 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATF3 mRNA
Coumestrol results in decreased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATF5 mRNA

NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:95,295,610...95,299,707

G

autophagy related 14

decreases expression

Coumestrol results in decreased expression of ATG14 mRNA

NCBI chr15:20,795,750...20,827,113
Ensembl chr15:20,795,750...20,827,113

G

atos homolog A

decreases expression
multiple interactions

Coumestrol results in decreased expression of ATOSA mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATOSA mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of ATOSA mRNA

NCBI chr 8:84,575,360...84,653,103
Ensembl chr 8:75,695,022...75,772,549

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP1B1 mRNA

NCBI chr13:79,319,708...79,340,226
Ensembl chr13:76,786,578...76,807,459

G

ATP23 metallopeptidase and ATP synthase assembly factor homolog

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATP23 mRNA
Coumestrol results in increased expression of ATP23 mRNA

NCBI chr 7:62,714,752...62,729,893
Ensembl chr 7:62,714,785...62,729,862

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of ATP2A3 mRNA

NCBI chr10:58,079,710...58,111,279
Ensembl chr10:57,582,128...57,612,748

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP2B1 mRNA
Coumestrol results in decreased expression of ATP2B1 mRNA

NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:33,735,871...33,843,295

G

ATPase secretory pathway Ca2+ transporting 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP2C1 mRNA
Coumestrol results in decreased expression of ATP2C1 mRNA

NCBI chr 8:114,913,551...115,034,706
Ensembl chr 8:106,034,636...106,156,006

G

ATP synthase membrane subunit c locus 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATP5MC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ATP5MC1 mRNA
Coumestrol results in increased expression of ATP5MC1 mRNA

NCBI chr10:81,520,762...81,523,735
Ensembl chr10:81,023,925...81,027,124
Ensembl chr10:81,023,925...81,027,124

G

ATPase H+ transporting V0 subunit e1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP6V0E1 mRNA
Coumestrol results in decreased expression of ATP6V0E1 mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

ATPase phospholipid transporting 8B1

decreases expression

Coumestrol results in decreased expression of ATP8B1 mRNA

NCBI chr18:60,286,605...60,427,862
Ensembl chr18:58,018,268...58,157,396

G

ATPase phospholipid transporting 8B2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of ATP8B2 mRNA
Coumestrol results in decreased expression of ATP8B2 mRNA

NCBI chr 2:177,676,205...177,699,575
Ensembl chr 2:175,378,517...175,401,883

G

ATPase phospholipid transporting 9A (putative)

decreases expression
multiple interactions

Coumestrol results in decreased expression of ATP9A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP9A mRNA

NCBI chr 3:177,779,203...177,886,431
Ensembl chr 3:157,360,359...157,467,818

G

ataxin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATXN1 mRNA

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

aurora kinase A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AURKA mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AURKA mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA]
Coumestrol results in increased expression of AURKA mRNA

PMID:18310284 PMID:19167446

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:161,128,313...161,144,390

G

aurora kinase B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AURKB mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AURKB mRNA
Coumestrol results in increased expression of AURKB mRNA

NCBI chr10:54,243,116...54,249,675
Ensembl chr10:53,745,142...53,750,837

G

activator of transcription and developmental regulator AUTS2

decreases expression
multiple interactions

Coumestrol results in decreased expression of AUTS2 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of AUTS2 mRNA

NCBI chr12:24,104,187...25,194,123
Ensembl chr12:24,104,192...25,194,416

G

beta-2 microglobulin

increases expression

Coumestrol results in increased expression of B2M mRNA

NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:109,095,729...109,101,766

G

beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of B3GALNT1 mRNA

NCBI chr 2:156,157,234...156,187,037
Ensembl chr 2:153,846,474...153,877,332

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of B3GNT5 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of B3GNT5 mRNA
Coumestrol results in decreased expression of B3GNT5 mRNA

NCBI chr11:81,141,102...81,153,206
Ensembl chr11:81,140,599...81,156,166

G

beta-secretase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BACE1 mRNA

NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:46,142,116...46,165,876

G

beta-secretase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BACE2 mRNA

NCBI chr11:50,176,852...50,258,948
Ensembl chr11:36,707,458...36,789,546

G

BAG cochaperone 2

increases expression
multiple interactions

Coumestrol results in increased expression of BAG2 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of BAG2 mRNA

NCBI chr 9:43,465,993...43,476,637
Ensembl chr 9:35,970,033...35,980,721

G

BAG cochaperone 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BAG3 mRNA
Coumestrol results in decreased expression of BAG3 mRNA

NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:183,102,871...183,126,858

G

BAG cochaperone 5

decreases expression

Coumestrol results in decreased expression of BAG5 mRNA

NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970

G

barrier to autointegration nuclear assembly factor 1

increases expression

Coumestrol results in increased expression of BANF1 mRNA

NCBI chr 1:212,101,523...212,103,568
Ensembl chr 1:202,671,305...202,674,188

G

BRCA1 associated RING domain 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BARD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BARD1 mRNA
Coumestrol results in increased expression of BARD1 mRNA

NCBI chr 9:80,069,960...80,144,167
Ensembl chr 9:72,623,155...72,694,265

G

BCL2 associated X, apoptosis regulator

increases expression
affects binding

Coumestrol results in increased expression of BAX protein
Coumestrol binds to BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

bromodomain adjacent to zinc finger domain, 2A

decreases expression

Coumestrol results in decreased expression of BAZ2A mRNA

NCBI chr 7:523,204...560,911
Ensembl chr 7:523,265...560,659

G

Bardet-Biedl syndrome 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of BBS1 mRNA

NCBI chr 1:211,614,195...211,633,504
Ensembl chr 1:202,186,125...202,204,086

G

BCAR3 adaptor protein, NSP family member

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCAR3 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of BCAR3 mRNA

NCBI chr 2:213,209,907...213,323,305
Ensembl chr 2:210,525,260...210,638,798

G

BCAS3, microtubule associated cell migration factor

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of BCAS3 mRNA

NCBI chr10:70,711,084...71,170,492
Ensembl chr10:70,214,098...70,673,080

G

branched chain keto acid dehydrogenase E1 subunit beta

decreases expression

Coumestrol results in decreased expression of BCKDHB mRNA

NCBI chr 8:93,725,277...93,907,799
Ensembl chr 8:84,845,264...85,027,812

G

BCL2, apoptosis regulator

decreases expression
affects binding
multiple interactions

Coumestrol results in decreased expression of BCL2 protein
Coumestrol binds to BCL2 protein
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BCL2 mRNA

PMID:19167446 PMID:20623010 PMID:28986287

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2 like 12

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BCL2L12 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BCL2L12 mRNA
Coumestrol results in increased expression of BCL2L12 mRNA

NCBI chr 1:104,608,753...104,617,472
Ensembl chr 1:95,472,272...95,480,991

G

BCL3, transcription coactivator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCL3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BCL3 mRNA

NCBI chr 1:88,599,321...88,613,555
Ensembl chr 1:79,471,369...79,485,607

G

BCL9, transcription coactivator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCL9 mRNA

NCBI chr 2:187,449,425...187,475,241
Ensembl chr 2:184,760,618...184,786,435

G

BCL9 like

decreases expression

Coumestrol results in decreased expression of BCL9L mRNA

NCBI chr 8:53,708,770...53,738,880
Ensembl chr 8:44,811,977...44,840,611

G

BCL2-associated transcription factor 1

increases expression

Coumestrol results in increased expression of BCLAF1 mRNA

NCBI chr 1:16,904,572...16,937,106
Ensembl chr 1:15,070,894...15,148,832

G

BCLAF1 and THRAP3 family member 3

decreases expression

Coumestrol results in decreased expression of BCLAF3 mRNA

NCBI chr X:39,065,842...39,137,521
Ensembl chr X:35,263,576...35,328,816

G

BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone

increases expression

Coumestrol results in increased expression of BCS1L mRNA

NCBI chr 9:83,614,045...83,618,052
Ensembl chr 9:76,164,932...76,168,938

G

brain expressed X-linked 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BEX2 mRNA

NCBI chr X:104,010,639...104,012,143
Ensembl chr X:99,219,014...99,220,958

G

basic helix-loop-helix family, member e40

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BHLHE40 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BHLHE40 mRNA
Coumestrol results in decreased expression of BHLHE40 mRNA

NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:141,618,476...141,624,774

G

BCL2-interacting killer

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of BIK mRNA

NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:114,672,277...114,691,296

G

bridging integrator 3

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA]

NCBI chr15:51,583,474...51,622,329
Ensembl chr15:45,173,732...45,212,604

G

baculoviral IAP repeat-containing 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BIRC5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BIRC5 mRNA
Coumestrol results in increased expression of BIRC5 mRNA

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380

G

BLM RecQ like helicase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BLM mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BLM mRNA
Coumestrol results in increased expression of BLM mRNA

NCBI chr 1:143,819,072...143,905,300
Ensembl chr 1:134,409,857...134,484,312

G

B-cell linker

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BLNK mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BLNK mRNA

NCBI chr 1:239,753,640...239,821,113
Ensembl chr 1:239,753,648...239,821,113

G

biogenesis of lysosomal organelles complex 1 subunit 6

decreases expression

Coumestrol results in decreased expression of BLOC1S6 mRNA

NCBI chr 3:130,269,979...130,280,109
Ensembl chr 3:109,816,366...109,828,308

G

bridge-like lipid transfer protein family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BLTP2 mRNA

NCBI chr10:63,155,999...63,185,213
Ensembl chr10:63,156,044...63,191,141

G

biliverdin reductase B

increases expression

Coumestrol results in increased expression of BLVRB mRNA

NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375

G

basic leucine zipper nuclear factor 1

decreases expression

Coumestrol results in decreased expression of BLZF1 mRNA

NCBI chr13:76,641,757...76,656,977
Ensembl chr13:76,641,515...76,656,999

G

bMERB domain containing 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMERB1 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of BMERB1 mRNA
Coumestrol results in decreased expression of BMERB1 mRNA

NCBI chr10:1,779,834...1,946,586
Ensembl chr10:1,779,835...1,946,575

G

Bcl2 modifying factor

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMF mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BMF mRNA
Coumestrol results in decreased expression of BMF mRNA

NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:105,499,538...105,520,145

G

bone morphogenetic protein 2

multiple interactions

Coumestrol inhibits the reaction [menatetrenone promotes the reaction [Phosphates results in increased expression of BMP2 mRNA]]; Coumestrol inhibits the reaction [menatetrenone results in increased expression of BMP2 mRNA]; Coumestrol inhibits the reaction [menatetrenone results in increased susceptibility to BMP2 protein]; Coumestrol inhibits the reaction [Phosphates promotes the reaction [menatetrenone results in increased expression of BMP2 mRNA]]

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 5

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of BMP5 mRNA

NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:76,517,164...76,639,925

G

bone morphogenetic protein 7

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMP7 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BMP7 mRNA
Coumestrol results in decreased expression of BMP7 mRNA

NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:161,516,462...161,716,788

G

bone morphogenetic protein receptor type 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMPR2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BMPR2 mRNA

NCBI chr 9:68,685,942...68,801,353
Ensembl chr 9:61,190,566...61,301,809

G

BCL2 interacting protein 3 like

decreases expression

Coumestrol results in decreased expression of BNIP3L mRNA

NCBI chr15:45,350,081...45,373,213
Ensembl chr15:41,174,594...41,197,803

G

bora, aurora kinase A activator

increases expression
multiple interactions

Coumestrol results in increased expression of BORA mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of BORA mRNA

NCBI chr15:82,205,467...82,243,499
Ensembl chr15:75,797,891...75,821,322

G

BRCA1-associated ATM activator 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRAT1 mRNA

NCBI chr12:19,043,004...19,065,686
Ensembl chr12:13,928,898...13,941,248

G

BRCA1, DNA repair associated

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BRCA1 mRNA
Coumestrol results in increased expression of BRCA1 mRNA

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,418,000...86,477,304

G

BRCA2, DNA repair associated

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BRCA2 mRNA
Coumestrol results in increased expression of BRCA2 mRNA

NCBI chr12:4,895,092...4,939,340
Ensembl chr12:59,819...100,567

G

bromodomain containing 3

decreases expression

Coumestrol results in decreased expression of BRD3 mRNA

NCBI chr 3:10,773,163...10,829,675
Ensembl chr 3:10,775,272...10,829,577

G

brain protein I3

decreases expression

Coumestrol results in decreased expression of BRI3 mRNA

NCBI chr12:10,341,007...10,364,655
Ensembl chr12:10,341,011...10,364,735

G

Bri3 binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRI3BP mRNA

NCBI chr12:36,838,098...36,849,919
Ensembl chr12:31,173,971...31,188,572

G

bromodomain and WD repeat domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BRWD1 mRNA

NCBI chr11:35,286,364...35,378,768
Ensembl chr11:35,288,313...35,378,768

G

BSD domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BSDC1 mRNA

NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092

G

basigin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BSG mRNA

NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:9,993,170...10,000,387

G

BTB domain containing 7

decreases expression

Coumestrol results in decreased expression of BTBD7 mRNA

NCBI chr 6:121,920,365...122,010,114
Ensembl chr 6:121,923,023...121,972,405

G

BTG anti-proliferation factor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BTG1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BTG1 mRNA
Coumestrol results in decreased expression of BTG1 mRNA

NCBI chr 7:33,228,149...33,230,406
Ensembl chr 7:31,341,027...31,343,649

G

BTG anti-proliferation factor 2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of BTG2 mRNA
Coumestrol results in decreased expression of BTG2 mRNA

NCBI chr13:48,083,931...48,087,690
Ensembl chr13:45,531,925...45,535,628

G

BUB1 mitotic checkpoint serine/threonine kinase

increases expression
multiple interactions

Coumestrol results in increased expression of BUB1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of BUB1 mRNA

NCBI chr 3:135,473,525...135,504,921
Ensembl chr 3:115,020,254...115,051,650

G

BUB1 mitotic checkpoint serine/threonine kinase B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BUB1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BUB1B mRNA
Coumestrol results in increased expression of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:105,563,138...105,615,547

G

similar to human chromosome 3 open reading frame 52

decreases expression

Coumestrol results in decreased expression of C3ORF52 mRNA

NCBI chr11:55,166,986...55,192,273
Ensembl chr11:55,166,678...55,192,292

G

similar to human chromosome 1 open reading frame 115

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of C1ORF115 mRNA
Coumestrol results in decreased expression of C1ORF115 mRNA

NCBI chr13:98,953,841...98,963,577
Ensembl chr13:96,422,302...96,432,068

G

similar to human chromosome 18 open reading frame 32

decreases expression

Coumestrol results in decreased expression of C18ORF32 mRNA

NCBI chr18:68,586,278...68,594,851
Ensembl chr18:68,586,211...68,596,787

G

similar to human chromosome 9 open reading frame 40

increases expression
multiple interactions

Coumestrol results in increased expression of C9ORF40 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C9ORF40 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of C9ORF40 mRNA

NCBI chr 1:216,128,687...216,132,896
Ensembl chr 1:216,128,651...216,133,045

G

similar to human chromosome 4 open reading frame 46

increases expression
multiple interactions

Coumestrol results in increased expression of C4ORF46 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of C4ORF46 mRNA

NCBI chr 2:164,762,994...164,766,126
Ensembl chr 2:164,762,960...164,766,128

G

similar to human chromosome 5 open reading frame 34

increases expression
multiple interactions

Coumestrol results in increased expression of C5ORF34 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C5ORF34 mRNA

NCBI chr 2:51,553,223...51,577,090
Ensembl chr 2:51,555,432...51,577,085

G

complement C5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C5 mRNA

NCBI chr 3:38,668,174...38,759,468
Ensembl chr 3:18,270,696...18,361,994

G

similar to human chromosome 9 open reading frame 152

decreases expression
multiple interactions

Coumestrol results in decreased expression of C9ORF152 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of C9ORF152 mRNA

NCBI chr 5:72,660,573...72,667,941
Ensembl chr 5:72,660,573...72,668,379

G

similar to human chromosome 2 open reading frame 69

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of C2ORF69 mRNA
Coumestrol results in increased expression of C2ORF69 mRNA

NCBI chr 9:58,949,821...58,958,456
Ensembl chr 9:58,949,846...58,958,561

G

calcyclin binding protein

increases expression
multiple interactions

Coumestrol results in increased expression of CACYBP mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CACYBP mRNA

NCBI chr13:74,970,917...74,981,298
Ensembl chr13:72,437,490...72,450,177

G

cell adhesion molecule 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CADM1 mRNA
Coumestrol results in decreased expression of CADM1 mRNA

NCBI chr 8:56,744,374...57,075,264
Ensembl chr 8:47,847,325...48,182,833

G

calcitonin receptor

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CALCR mRNA

NCBI chr 4:32,615,955...32,691,075
Ensembl chr 4:31,661,273...31,736,392

G

calmodulin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CALM3 mRNA

NCBI chr 1:86,718,761...86,725,869
Ensembl chr 1:77,589,230...77,592,207

G

calumenin

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CALU mRNA
Coumestrol results in increased expression of CALU mRNA

NCBI chr 4:58,914,456...58,941,957
Ensembl chr 4:57,948,997...57,976,593

G

calcium/calmodulin-dependent protein kinase ID

decreases expression

Coumestrol results in decreased expression of CAMK1D mRNA

NCBI chr17:72,581,899...72,982,704
Ensembl chr17:72,581,979...72,980,556

G

calcium/calmodulin-dependent protein kinase II delta

decreases expression
multiple interactions

Coumestrol results in decreased expression of CAMK2D mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAMK2D mRNA

NCBI chr 2:217,698,324...217,961,898
Ensembl chr 2:215,024,004...215,286,178

G

calcium/calmodulin-dependent protein kinase II inhibitor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAMK2N1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CAMK2N1 mRNA
Coumestrol results in decreased expression of CAMK2N1 mRNA

NCBI chr 5:155,958,116...155,959,897
Ensembl chr 5:150,673,507...150,676,600

G

calcium activated nucleotidase 1

increases expression

Coumestrol results in increased expression of CANT1 mRNA

NCBI chr10:103,637,079...103,650,240
Ensembl chr10:103,531,504...103,650,109

G

carbonic anhydrase 12

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CA12 mRNA

NCBI chr 8:76,169,723...76,225,465
Ensembl chr 8:67,274,359...67,330,440

G

carbonic anhydrase 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CA2 mRNA

NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:86,741,626...86,756,818

G

calcium regulated heat stable protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CARHSP1 mRNA
Coumestrol results in increased expression of CARHSP1 mRNA

NCBI chr10:7,453,602...7,467,218
Ensembl chr10:6,946,959...7,020,019

G

caspase 3

increases expression

Coumestrol results in increased expression of CASP3 protein

PMID:19165469 PMID:28986287

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases expression

Coumestrol results in increased expression of CASP7 protein

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8 associated protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CASP8AP2 mRNA

NCBI chr 5:51,809,366...51,848,633
Ensembl chr 5:47,014,667...47,052,275

G

caspase 9

increases expression

Coumestrol results in increased expression of CASP9 protein

Ensembl chr 5:154,109,046...154,126,626

G

calpastatin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAST mRNA

NCBI chr 2:5,707,633...5,817,213
Ensembl chr 2:3,973,112...4,082,659

G

caveolin 1

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CAV1 mRNA
Coumestrol results in increased expression of CAV1 mRNA

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:45,634,918...45,673,705

G

core-binding factor subunit beta

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CBFB mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CBFB mRNA
Coumestrol results in increased expression of CBFB mRNA

NCBI chr19:49,955,133...50,002,661
Ensembl chr19:33,049,172...33,092,751

G

Cbl proto-oncogene B

decreases expression
multiple interactions

Coumestrol results in decreased expression of CBLB mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CBLB mRNA

NCBI chr11:62,058,829...62,225,904
Ensembl chr11:48,592,703...48,756,839

G

carbonyl reductase 1

increases expression

Coumestrol results in increased expression of CBR1 mRNA

NCBI chr11:46,346,405...46,348,815
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393

G

chromobox 4

decreases expression

Coumestrol results in decreased expression of CBX4 mRNA

NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706

G

chromobox 5

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CBX5 mRNA
Coumestrol results in increased expression of CBX5 mRNA

NCBI chr 7:136,203,827...136,254,575
Ensembl chr 7:134,331,335...134,375,022

G

coiled-coil domain containing 117

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CCDC117 mRNA

NCBI chr14:84,614,282...84,623,648
Ensembl chr14:80,400,294...80,409,659

G

coiled-coil domain containing 14

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCDC14 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCDC14 mRNA

NCBI chr11:79,557,267...79,593,128
Ensembl chr11:66,052,620...66,087,956

G

coiled-coil domain containing 167

increases expression

Coumestrol results in increased expression of CCDC167 mRNA

NCBI chr20:7,763,927...7,782,090
Ensembl chr20:7,751,782...7,781,613

G

coiled-coil domain containing 34

increases expression
multiple interactions

Coumestrol results in increased expression of CCDC34 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCDC34 mRNA

NCBI chr 3:117,007,652...117,042,885
Ensembl chr 3:96,552,992...96,588,146

G

coiled-coil domain containing 47

increases expression

Coumestrol results in increased expression of CCDC47 mRNA

NCBI chr10:91,630,101...91,648,626
Ensembl chr10:91,130,303...91,148,881

G

coiled-coil domain containing 51

increases expression

Coumestrol results in increased expression of CCDC51 mRNA

NCBI chr 8:118,601,002...118,619,943
Ensembl chr 8:109,722,557...109,741,472

G

coiled-coil domain containing 88C

decreases expression

Coumestrol results in decreased expression of CCDC88C mRNA

NCBI chr 6:125,899,337...126,019,162
Ensembl chr 6:120,169,738...120,289,555

G

cellular communication network factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CCN1 mRNA

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCN5 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CCN5 mRNA; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CCN5 mRNA]

PMID:19167446 PMID:23384675

NCBI chr 3:172,910,670...172,922,064
Ensembl chr 3:152,491,220...152,502,636

G

cyclin A2

decreases expression
increases expression
multiple interactions

Coumestrol results in decreased expression of CCNA2 protein
Coumestrol results in increased expression of CCNA2 protein
[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA]

PMID:18310284 PMID:20623010

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNB1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCNB1 mRNA
Coumestrol results in increased expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172

G

cyclin B2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNB2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCNB2 mRNA
Coumestrol results in increased expression of CCNB2 mRNA

NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:71,087,595...71,100,874

G

cyclin D1

multiple interactions
increases expression

CCND1 protein promotes the reaction [Coumestrol results in increased activity of ESR1 protein]
Coumestrol results in increased expression of CCND1 mRNA

PMID:16328721 PMID:19800779

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

decreases expression

Coumestrol results in decreased expression of CCNE1 protein

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:90,781,949...90,791,101

G

cyclin E2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNE2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCNE2 mRNA
Coumestrol results in increased expression of CCNE2 mRNA

NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:24,284,922...24,297,632

G

cyclin F

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNF mRNA
Coumestrol results in increased expression of CCNF mRNA

NCBI chr10:13,757,884...13,783,669
Ensembl chr10:13,253,380...13,279,101

G

cyclin G2

decreases expression

Coumestrol results in decreased expression of CCNG2 mRNA

NCBI chr14:15,088,694...15,097,190
Ensembl chr14:14,804,322...14,812,830

G

cyclin I

decreases expression

Coumestrol results in decreased expression of CCNI mRNA

NCBI chr14:14,879,698...14,902,510
Ensembl chr14:14,879,717...14,902,510

G

centriolar coiled-coil protein 110

multiple interactions

[Coumestrol co-treated with Resveratrol] results in increased expression of CCP110 mRNA

NCBI chr 1:182,475,571...182,504,235
Ensembl chr 1:173,042,310...173,072,873

G

cell cycle progression 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CCPG1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CCPG1 mRNA

NCBI chr 8:82,600,677...82,633,082
Ensembl chr 8:73,719,955...73,752,430

G

CD24 molecule

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CD24 mRNA

NCBI chr20:48,655,549...48,661,786
Ensembl chr20:47,073,512...47,079,662

G

CD320 molecule

increases expression

Coumestrol results in increased expression of CD320 mRNA

NCBI chr 7:15,328,320...15,334,138
Ensembl chr 7:14,609,146...14,631,976

G

CD44 molecule

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CD44 mRNA
Coumestrol results in increased expression of CD44 mRNA

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:89,157,058...89,244,620

G

CD55 molecule (Cromer blood group)

decreases expression
multiple interactions

Coumestrol results in decreased expression of CD55 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CD55 mRNA

NCBI chr13:44,409,574...44,438,913
Ensembl chr13:41,857,395...41,885,831

G

CD59b molecule

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CD59 mRNA

NCBI chr 3:110,914,008...110,932,489
Ensembl chr 3:90,459,162...90,478,847

G

cell division cycle 14B

decreases expression

Coumestrol results in decreased expression of CDC14B mRNA

NCBI chr17:850,272...938,972
Ensembl chr17:844,685...933,235

G

cell division cycle 25A

increases expression
multiple interactions

Coumestrol results in increased expression of CDC25A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC25A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC25A mRNA

NCBI chr 8:118,742,824...118,761,190
Ensembl chr 8:109,864,478...109,882,701

G

cell division cycle 25C

increases expression
multiple interactions

Coumestrol results in increased expression of CDC25C mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC25C mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC25C mRNA

NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,335,834...26,356,185

G

cell division cycle 27

increases expression
multiple interactions

Coumestrol results in increased expression of CDC27 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC27 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC27 mRNA

NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736

G

CDC42 binding protein kinase beta

decreases expression

Coumestrol results in decreased expression of CDC42BPB mRNA

NCBI chr 6:130,333,712...130,416,631
Ensembl chr 6:130,333,712...130,416,377

G

cell division cycle 45

increases expression
multiple interactions

Coumestrol results in increased expression of CDC45 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC45 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CDC45 mRNA

NCBI chr11:95,689,702...95,714,980
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle 5-like

increases expression

Coumestrol results in increased expression of CDC5L mRNA

NCBI chr 9:23,062,397...23,100,901
Ensembl chr 9:15,564,767...15,603,450

G

cell division cycle 6

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC6 mRNA
Coumestrol results in increased expression of CDC6 mRNA

NCBI chr10:84,360,361...84,374,239
Ensembl chr10:83,864,638...83,878,011

G

cell division cycle 7

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC7 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC7 mRNA
Coumestrol results in increased expression of CDC7 mRNA

NCBI chr14:2,949,538...2,969,656
Ensembl chr14:2,804,661...2,824,778

G

cell division cycle associated 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA2 mRNA
Coumestrol results in increased expression of CDCA2 mRNA

NCBI chr15:46,071,360...46,117,524
Ensembl chr15:41,895,901...41,941,611

G

cell division cycle associated 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA3 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA]
Coumestrol results in increased expression of CDCA3 mRNA

PMID:18310284 PMID:19167446

NCBI chr 4:159,321,203...159,325,072
Ensembl chr 4:157,634,928...157,638,799

G

cell division cycle associated 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA4 mRNA

NCBI chr 6:137,713,390...137,722,652
Ensembl chr 6:131,892,087...131,901,564

G

cell division cycle associated 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA5 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CDCA5 mRNA
Coumestrol results in increased expression of CDCA5 mRNA

NCBI chr 1:212,807,863...212,821,313
Ensembl chr 1:203,378,577...203,392,023

G

cell division cycle associated 7 like

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA7L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA7L mRNA
Coumestrol results in increased expression of CDCA7L mRNA

NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888

G

cell division cycle associated 8

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA8 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA8 mRNA
Coumestrol results in increased expression of CDCA8 mRNA

NCBI chr 5:142,461,082...142,483,336
Ensembl chr 5:137,176,417...137,198,629

G

cadherin 12

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDH12 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDH12 mRNA

NCBI chr 2:70,474,679...71,705,369
Ensembl chr 2:70,475,043...71,700,572

G

cyclin-dependent kinase 1

increases expression
multiple interactions

Coumestrol results in increased expression of CDK1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase 13

decreases expression

Coumestrol results in decreased expression of CDK13 mRNA

NCBI chr17:51,945,975...52,040,218
Ensembl chr17:47,251,163...47,341,721

G

cyclin-dependent kinase 17

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PCTK2 mRNA

NCBI chr 7:27,683,890...27,765,814
Ensembl chr 7:27,683,890...27,764,910

G

cyclin dependent kinase 2

decreases expression

Coumestrol results in decreased expression of CDK2 protein

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 2 associated protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK2AP2 mRNA

NCBI chr 1:210,819,155...210,822,604
Ensembl chr 1:201,391,466...201,393,137

G

CDK5 regulatory subunit associated protein 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK5RAP2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDK5RAP2 mRNA
Coumestrol results in increased expression of CDK5RAP2 mRNA

NCBI chr 5:88,807,402...88,976,005
Ensembl chr 5:83,792,284...83,960,782

G

cyclin-dependent kinase-like 5

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CDKL5 mRNA

NCBI chr X:33,757,605...33,988,075
Ensembl chr X:33,821,257...33,986,582

G

cyclin-dependent kinase inhibitor 1A

decreases expression
multiple interactions

Coumestrol results in decreased expression of CDKN1A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN1A mRNA

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1C

decreases expression

Coumestrol results in decreased expression of CDKN1C mRNA

NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:198,655,407...198,658,048

G

CDKN2A interacting protein

decreases expression

Coumestrol results in decreased expression of CDKN2AIP mRNA

NCBI chr16:44,536,147...44,546,216
Ensembl chr16:44,536,234...44,540,033

G

cyclin-dependent kinase inhibitor 2B

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN2B mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CDKN2B mRNA
Coumestrol results in decreased expression of CDKN2B mRNA

NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:104,010,680...104,019,050

G

cyclin-dependent kinase inhibitor 2C

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDKN2C mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA]
Coumestrol results in increased expression of CDKN2C mRNA

PMID:18310284 PMID:19167446

NCBI chr 5:129,639,736...129,645,564
Ensembl chr 5:124,411,124...124,416,278

G

cyclin-dependent kinase inhibitor 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDKN3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDKN3 mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA]
Coumestrol results in increased expression of CDKN3 mRNA

PMID:18310284 PMID:19167446

NCBI chr15:22,502,299...22,513,725
Ensembl chr15:20,022,664...20,033,945

G

CDP-diacylglycerol synthase 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CDS1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDS1 mRNA

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

chromatin licensing and DNA replication factor 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDT1 mRNA
Coumestrol results in increased expression of CDT1 mRNA

NCBI chr19:67,529,249...67,534,195
Ensembl chr19:50,620,713...50,625,659

G

carnitine deficiency-associated gene expressed in ventricle 3

increases expression
multiple interactions

Coumestrol results in increased expression of CDV3 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CDV3 mRNA

NCBI chr 8:112,812,898...112,826,073
Ensembl chr 8:103,933,996...103,947,192

G

chromodomain Y-like

decreases expression

Coumestrol results in decreased expression of CDYL mRNA

NCBI chr17:29,188,697...29,409,805
Ensembl chr17:28,982,037...29,204,313

G

CCAAT/enhancer binding protein delta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CEBPD mRNA

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:84,764,565...84,765,829

G

cadherin, EGF LAG seven-pass G-type receptor 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CELSR2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CELSR2 mRNA
Coumestrol results in increased expression of CELSR2 mRNA

NCBI chr 2:198,717,333...198,741,689
Ensembl chr 2:196,029,434...196,053,845

G

centromere protein A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPA mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CENPA mRNA
Coumestrol results in increased expression of CENPA mRNA

NCBI chr 6:31,420,062...31,431,703
Ensembl chr 6:25,700,142...25,711,675

G

centromere protein E

increases expression
multiple interactions

Coumestrol results in increased expression of CENPE mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CENPE mRNA

NCBI chr 2:226,310,970...226,369,636
Ensembl chr 2:223,636,998...223,695,669

G

centromere protein F

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPF mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPF mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA]
Coumestrol results in increased expression of CENPF mRNA

PMID:18310284 PMID:19167446

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

centromere protein H

increases expression
multiple interactions

Coumestrol results in increased expression of CENPH mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPH mRNA

NCBI chr 2:33,630,738...33,644,258
Ensembl chr 2:31,894,667...31,910,154

G

centromere protein I

increases expression
multiple interactions

Coumestrol results in increased expression of CENPI mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPI mRNA

NCBI chr X:101,809,192...101,860,935
Ensembl chr X:97,515,972...97,567,657

G

centromere protein L

increases expression
multiple interactions

Coumestrol results in increased expression of CENPL mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPL mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPL mRNA

NCBI chr13:75,870,479...75,885,466
Ensembl chr13:73,337,257...73,352,114

G

centromere protein M

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CENPM mRNA
Coumestrol results in increased expression of CENPM mRNA

NCBI chr 7:115,628,117...115,639,401
Ensembl chr 7:113,747,516...113,764,258

G

centromere protein N

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPN mRNA
Coumestrol results in increased expression of CENPN mRNA

NCBI chr19:61,880,101...61,902,850
Ensembl chr19:44,968,308...44,994,012

G

centromere protein O

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPO mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPO mRNA
Coumestrol results in increased expression of CENPO mRNA

NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314

G

centromere protein Q

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPQ mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPQ mRNA
Coumestrol results in increased expression of CENPQ mRNA

NCBI chr 9:27,454,339...27,469,371
Ensembl chr 9:19,957,048...19,972,789

G

centromere protein S

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPS mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CENPS mRNA
Coumestrol results in increased expression of CENPS mRNA

NCBI chr 5:164,847,009...164,856,705

G

centromere protein U

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPU mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPU mRNA
Coumestrol results in increased expression of CENPU mRNA

NCBI chr16:52,448,446...52,471,662
Ensembl chr16:45,714,294...45,738,823

G

centromere protein W

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPW mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPW mRNA
Coumestrol results in increased expression of CENPW mRNA

NCBI chr 1:29,353,939...29,359,109
Ensembl chr 1:27,525,324...27,530,464

G

centrosomal protein 128

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CEP128 mRNA

NCBI chr 6:109,951,009...110,328,686
Ensembl chr 6:109,951,061...110,328,713

G

centrosomal protein 15

increases expression

Coumestrol results in increased expression of CEP15 mRNA

NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838

G

centrosomal protein 152

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CEP152 mRNA
Coumestrol results in increased expression of CEP152 mRNA

NCBI chr 3:133,243,979...133,332,271
Ensembl chr 3:112,810,425...112,878,458
Ensembl chr 3:112,810,425...112,878,458

G

centrosomal protein 192

increases expression

Coumestrol results in increased expression of CEP192 mRNA

NCBI chr18:63,643,816...63,728,264
Ensembl chr18:61,332,158...61,458,379

G

centrosomal protein 55

increases expression
multiple interactions

Coumestrol results in increased expression of CEP55 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP55 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CEP55 mRNA

NCBI chr 1:245,245,272...245,260,835
Ensembl chr 1:235,832,878...235,848,394

G

centrosomal protein 57

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CEP57 mRNA
Coumestrol results in increased expression of CEP57 mRNA

NCBI chr 8:10,669,588...10,689,257
Ensembl chr 8:10,669,590...10,689,249

G

centrosomal protein 57-like 1

increases expression

Coumestrol results in increased expression of CEP57L1 mRNA

NCBI chr20:45,238,039...45,294,575
Ensembl chr20:45,238,044...45,294,540

G

centrosomal protein 78

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP78 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CEP78 mRNA
Coumestrol results in increased expression of CEP78 mRNA

NCBI chr 1:213,246,183...213,275,275
Ensembl chr 1:213,246,187...213,275,181

G

centrosomal protein 85

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP85 mRNA
Coumestrol results in increased expression of CEP85 mRNA

NCBI chr 5:151,640,316...151,687,891
Ensembl chr 5:146,356,576...146,404,060

G

cilia and flagella associated protein 20

increases expression

Coumestrol results in increased expression of CFAP20 mRNA

NCBI chr19:9,608,867...9,622,558
Ensembl chr19:9,608,859...9,622,558

G

CASP8 and FADD-like apoptosis regulator

decreases expression

Coumestrol results in decreased expression of CFLAR mRNA

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:60,185,452...60,237,034

G

cingulin

decreases expression

Coumestrol results in decreased expression of CGN mRNA

NCBI chr 2:184,997,425...185,024,785
Ensembl chr 2:182,308,714...182,334,645

G

ChaC glutathione specific gamma-glutamylcyclotransferase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAC2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHAC2 mRNA
Coumestrol results in increased expression of CHAC2 mRNA

NCBI chr14:108,921,669...108,929,215
Ensembl chr14:104,720,758...104,728,301

G

chromatin assembly factor 1 subunit A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAF1A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHAF1A mRNA
Coumestrol results in increased expression of CHAF1A mRNA

NCBI chr 9:961,225...987,825
Ensembl chr 9:874,051...900,654

G

chromatin assembly factor 1 subunit B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAF1B mRNA
Coumestrol results in increased expression of CHAF1B mRNA

NCBI chr11:46,670,560...46,690,739
Ensembl chr11:33,200,981...33,221,070

G

chromodomain helicase DNA binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CHD2 mRNA

NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:127,190,059...127,300,502

G

chromodomain helicase DNA binding protein 6

decreases expression

Coumestrol results in decreased expression of CHD6 mRNA

NCBI chr 3:149,596,509...149,757,765
Ensembl chr 3:149,596,509...149,757,755

G

checkpoint kinase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHEK1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHEK1 mRNA
Coumestrol results in increased expression of CHEK1 mRNA

NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:36,420,569...36,441,009

G

checkpoint kinase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHEK2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHEK2 mRNA

NCBI chr12:51,448,838...51,481,159
Ensembl chr12:45,788,827...45,821,286

G

chimerin 1

increases expression

Coumestrol results in increased expression of CHN1 mRNA

NCBI chr 3:78,917,329...79,084,040
Ensembl chr 3:58,510,536...58,676,490

G

choline phosphotransferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHPT1 mRNA

NCBI chr 7:24,753,880...24,802,529
Ensembl chr 7:22,863,027...22,915,103

G

cholinergic receptor nicotinic alpha 5 subunit

increases expression

Coumestrol results in increased expression of CHRNA5 mRNA

NCBI chr 8:64,265,879...64,294,233
Ensembl chr 8:55,369,794...55,398,146

G

cellular inhibitor of PP2A

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CIP2A mRNA

NCBI chr11:65,255,123...65,285,914
Ensembl chr11:51,795,024...51,822,938

G

CDGSH iron sulfur domain 1

increases expression

Coumestrol results in increased expression of CISD1 mRNA

NCBI chr20:17,254,462...17,267,843
Ensembl chr20:17,255,151...17,284,924

G

citron rho-interacting serine/threonine kinase

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CIT mRNA

NCBI chr12:46,263,881...46,425,642
Ensembl chr12:40,605,563...40,763,860

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CITED2 mRNA

NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:12,312,160...12,314,897

G

cytoskeleton associated protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of CKAP2 mRNA

NCBI chr16:76,542,114...76,567,297
Ensembl chr16:69,839,630...69,864,913

G

cytoskeleton associated protein 2-like

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of CKAP2L mRNA
Coumestrol results in increased expression of CKAP2L mRNA

NCBI chr 3:136,950,390...136,977,503
Ensembl chr 3:116,498,022...116,524,366

G

cytoskeleton-associated protein 4

decreases expression

Coumestrol results in decreased expression of CKAP4 mRNA

NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914

G

cytoskeleton associated protein 5

increases expression
multiple interactions

Coumestrol results in increased expression of CKAP5 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKAP5 mRNA

NCBI chr 3:97,946,966...98,049,050
Ensembl chr 3:77,491,276...77,593,264

G

chemokine-like factor

increases expression
multiple interactions

Coumestrol results in increased expression of CKLF mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKLF mRNA

NCBI chr19:704,528...712,998
Ensembl chr19:698,033...706,570

G

CDC28 protein kinase regulatory subunit 1B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKS1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CKS1B mRNA
Coumestrol results in increased expression of CKS1B mRNA

NCBI chr 2:177,130,751...177,135,333
Ensembl chr 2:174,833,050...174,837,636

G

CDC28 protein kinase regulatory subunit 2

increases expression
multiple interactions

Coumestrol results in increased expression of CKS2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKS2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CKS2 mRNA

NCBI chr17:13,722,360...13,727,519

G

chloride channel CLIC-like 1

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA]

NCBI chr 2:198,984,455...199,015,015
Ensembl chr 2:196,296,393...196,326,913

G

claudin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLDN1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CLDN1 mRNA

NCBI chr11:87,926,376...87,941,533
Ensembl chr11:74,421,569...74,436,724

G

claudin 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLDN4 mRNA

NCBI chr12:27,388,160...27,389,958
Ensembl chr12:21,751,331...21,753,436

G

CAP-GLY domain containing linker protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLIP1 mRNA

NCBI chr12:38,571,533...38,678,779
Ensembl chr12:32,910,977...33,017,884

G

CLN6, transmembrane ER protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CLN6 mRNA

NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360

G

CLN8, transmembrane ER and ERGIC protein

decreases expression

Coumestrol results in decreased expression of CLN8 mRNA

NCBI chr16:81,451,941...81,462,046
Ensembl chr16:74,749,662...74,759,774

G

collectrin, amino acid transport regulator

decreases expression

Coumestrol results in decreased expression of CLTRN mRNA

NCBI chr X:33,993,825...34,027,124
Ensembl chr X:30,361,967...30,395,349

G

clusterin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLU mRNA

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:40,174,617...40,200,315

G

C-x(9)-C motif containing 2

increases expression
multiple interactions

Coumestrol results in increased expression of CMC2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CMC2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CMC2 mRNA

NCBI chr19:44,943,283...44,971,930
Ensembl chr19:44,943,285...44,971,983

G

cms1 ribosomal small subunit homolog

increases expression
multiple interactions

Coumestrol results in increased expression of CMSS1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CMSS1 mRNA

NCBI chr11:42,934,390...43,232,624
Ensembl chr11:42,934,440...43,232,624

G

CKLF-like MARVEL transmembrane domain containing 8

decreases expression

Coumestrol results in decreased expression of CMTM8 mRNA

NCBI chr 8:114,481,730...114,547,107
Ensembl chr 8:114,481,982...114,547,083

G

cordon-bleu WH2 repeat protein

decreases expression

Coumestrol results in decreased expression of COBL mRNA

NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800

G

cochlin

increases expression

Coumestrol results in increased expression of COCH mRNA

NCBI chr 6:74,766,485...74,780,504
Ensembl chr 6:69,031,167...69,045,109

G

component of oligomeric golgi complex 4

increases expression

Coumestrol results in increased expression of COG4 mRNA

NCBI chr19:55,729,854...55,763,902
Ensembl chr19:38,820,501...38,854,796

G

component of oligomeric golgi complex 5

decreases expression

Coumestrol results in decreased expression of COG5 mRNA

NCBI chr 6:53,969,967...54,267,869
Ensembl chr 6:48,242,482...48,529,009

G

component of oligomeric golgi complex 6

decreases expression

Coumestrol results in decreased expression of COG6 mRNA

NCBI chr 2:137,062,127...137,099,176
Ensembl chr 2:137,061,346...137,099,190

G

COMM domain containing 4

increases expression

Coumestrol results in increased expression of COMMD4 mRNA

NCBI chr 8:57,566,236...57,569,701
Ensembl chr 8:57,566,236...57,569,760

G

catechol-O-methyltransferase

decreases expression
multiple interactions

Coumestrol results in decreased expression of COMT mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of COMT mRNA

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:82,568,025...82,587,642

G

COP9 signalosome subunit 2

decreases expression

Coumestrol results in decreased expression of COPS2 mRNA

NCBI chr 3:133,537,729...133,563,493
Ensembl chr 3:113,084,176...113,109,947

G

coenzyme Q2, polyprenyltransferase

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of COQ2 mRNA

NCBI chr14:8,941,429...8,961,418
Ensembl chr14:8,941,461...8,960,891

G

coenzyme Q7, hydroxylase

increases expression

Coumestrol results in increased expression of COQ7 mRNA

NCBI chr 1:182,270,570...182,285,959
Ensembl chr 1:172,835,188...172,851,158

G

coronin 1B

decreases expression
multiple interactions

Coumestrol results in decreased expression of CORO1B mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CORO1B mRNA

NCBI chr 1:210,872,437...210,877,876
Ensembl chr 1:201,443,014...201,448,416

G

coronin 1C

increases expression

Coumestrol results in increased expression of CORO1C mRNA

NCBI chr12:48,373,573...48,445,718
Ensembl chr12:42,712,991...42,785,179

G

coronin 2A

decreases expression
multiple interactions

Coumestrol results in decreased expression of CORO2A mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CORO2A mRNA

NCBI chr 5:65,623,820...65,677,483
Ensembl chr 5:60,828,247...60,859,035

G

centrosome assembly and centriole elongation protein

increases expression

Coumestrol results in increased expression of CPAP mRNA

NCBI chr15:34,742,838...34,806,020
Ensembl chr15:30,627,224...30,686,791

G

carboxypeptidase E

decreases expression

Coumestrol results in decreased expression of CPE mRNA

NCBI chr16:29,796,707...29,908,647
Ensembl chr16:25,030,276...25,142,233

G

cytoplasmic polyadenylation element binding protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CPEB2 mRNA

NCBI chr14:67,787,503...67,839,973
Ensembl chr14:67,787,507...67,840,743

G

cleavage and polyadenylation specific factor 3

increases expression

Coumestrol results in increased expression of CPSF3 mRNA

NCBI chr 6:40,836,121...40,864,129
Ensembl chr 6:40,836,097...40,864,128

G

capping protein inhibiting regulator of actin dynamics

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CRACD mRNA
Coumestrol results in decreased expression of CRACD mRNA

NCBI chr14:31,638,328...31,874,391
Ensembl chr14:31,284,184...31,522,431

G

cAMP responsive element binding protein 3-like 4

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CREB3L4 mRNA

NCBI chr 2:175,690,340...175,695,846
Ensembl chr 2:175,690,335...175,695,932

G

cysteine-rich protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of CRIP2 mRNA

NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065

G

cryptochrome circadian regulator 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CRY1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CRY1 mRNA

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:18,529,823...18,594,091

G

chromosome segregation 1 like

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CSE1L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CSE1L mRNA
Coumestrol results in increased expression of CSE1L mRNA

NCBI chr 3:176,060,183...176,097,909
Ensembl chr 3:155,641,166...155,678,865

G

casein kinase 1, alpha 1

decreases expression

Coumestrol results in decreased expression of CSNK1A1 mRNA

NCBI chr18:57,285,156...57,320,540
Ensembl chr18:55,017,055...55,049,271

G

casein kinase 1, gamma 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CSNK1G1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CSNK1G1 mRNA

NCBI chr 8:75,334,751...75,472,339
Ensembl chr 8:66,439,864...66,572,826

G

casein kinase 1, gamma 3

decreases expression

Coumestrol results in decreased expression of CSNK1G3 mRNA

NCBI chr18:47,299,547...47,386,538
Ensembl chr18:47,299,579...47,386,535

G

casein kinase 2 alpha 2

decreases expression

Coumestrol results in decreased expression of CSNK2A2 mRNA

NCBI chr19:9,562,340...9,602,136
Ensembl chr19:9,556,260...9,596,080

G

chondroitin sulfate proteoglycan 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CSPG5 mRNA

NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758

G

cysteine and serine rich nuclear protein 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AXUD1 mRNA
Coumestrol results in decreased expression of AXUD1 mRNA

NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183

G

cysteine and serine rich nuclear protein 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of CSRNP2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CSRNP2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CSRNP2 mRNA

NCBI chr 7:131,594,232...131,610,075
Ensembl chr 7:131,594,232...131,610,075

G

cystatin A

decreases expression
multiple interactions

Coumestrol results in decreased expression of CSTA mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CSTA mRNA

NCBI chr11:78,125,813...78,136,818
Ensembl chr11:64,620,483...64,631,488

G

cleavage stimulation factor subunit 1

increases expression

Coumestrol results in increased expression of CSTF1 mRNA

NCBI chr 3:161,144,522...161,156,294
Ensembl chr 3:161,144,548...161,156,300

G

cleavage stimulation factor subunit 2

increases expression

Coumestrol results in increased expression of CSTF2 mRNA

NCBI chr X:101,546,809...101,572,760
Ensembl chr X:97,253,586...97,279,476

G

C-terminal binding protein 1

decreases expression

Coumestrol results in decreased expression of CTBP1 mRNA

NCBI chr14:81,679,956...81,707,331
Ensembl chr14:77,455,696...77,482,821

G

CTD small phosphatase like 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTDSPL2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CTDSPL2 mRNA
Coumestrol results in increased expression of CTDSPL2 mRNA

NCBI chr 3:129,365,709...129,424,232
Ensembl chr 3:108,915,280...108,967,227

G

catenin alpha-like 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTNNAL1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CTNNAL1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA]
Coumestrol results in increased expression of CTNNAL1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431

G

catenin delta 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of CTNND1 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CTNND1 mRNA

NCBI chr 3:90,090,025...90,141,247
Ensembl chr 3:69,683,313...69,734,516

G

catenin delta 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of CTNND2 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of CTNND2 mRNA

NCBI chr 2:81,168,525...82,016,495
Ensembl chr 2:81,167,117...82,015,764

G

CTP synthase 1

increases expression
multiple interactions

Coumestrol results in increased expression of CTPS1 mRNA
[Coumestrol co-treated with Resveratrol] results in increased expression of CTPS1 mRNA

NCBI chr 5:139,372,349...139,440,441
Ensembl chr 5:134,125,025...134,154,180

G

CTR9 homolog, Paf1/RNA polymerase II complex component

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTR9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CTR9 mRNA

NCBI chr 1:174,571,952...174,601,974
Ensembl chr 1:165,137,215...165,167,303

G

cathepsin B

decreases expression

Coumestrol results in decreased expression of CTSB mRNA

NCBI chr15:41,565,607...41,586,479
Ensembl chr15:37,389,629...37,410,500

G

cathepsin C

increases expression

Coumestrol results in increased expression of CTSC mRNA

NCBI chr 1:151,440,860...151,472,430
Ensembl chr 1:142,028,392...142,060,387

G

cathepsin H

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of CTSH mRNA
Coumestrol results in decreased expression of CTSH mRNA

NCBI chr 8:99,488,756...99,507,639
Ensembl chr 8:90,608,941...90,627,824

G

cortactin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CTTN mRNA

NCBI chr 1:209,029,048...209,064,577
Ensembl chr 1:199,599,710...199,635,164

G

CTTNBP2 N-terminal like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CTTNBP2NL mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of CTTNBP2NL mRNA

NCBI chr 2:195,196,318...195,244,792
Ensembl chr 2:192,507,963...192,541,101

G

C-X-C motif chemokine ligand 12

multiple interactions
increases expression

[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CXCL12 mRNA; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CXCL12 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA]

PMID:18310284 PMID:19167446 PMID:23384675 PMID:28396216

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168

G

CXXC finger protein 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CXXC5 mRNA

NCBI chr18:27,427,591...27,458,579
Ensembl chr18:27,427,230...27,458,673

G

cytochrome b5 type B

increases expression

Coumestrol results in increased expression of CYB5B mRNA

NCBI chr19:51,972,611...52,006,477
Ensembl chr19:35,062,813...35,098,249

G

cytochrome b5 reductase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CYB5R1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CYB5R1 mRNA

NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458

G

cytoplasmic FMR1 interacting protein 2

decreases expression

Coumestrol results in decreased expression of CYFIP2 mRNA

NCBI chr10:31,122,653...31,242,440
Ensembl chr10:30,621,318...30,741,113

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
multiple interactions

Coumestrol results in increased expression of CYP1B1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of CYP1B1 mRNA

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CYP2R1 mRNA

NCBI chr 1:178,166,984...178,232,191
Ensembl chr 1:168,751,038...168,797,759

G

cytochrome P450, family 51

increases expression

Coumestrol results in increased expression of CYP51A1 mRNA

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

cell cycle regulator of NHEJ

increases expression

Coumestrol results in increased expression of CYREN mRNA

NCBI chr 4:64,514,477...64,519,896
Ensembl chr 4:63,547,335...63,551,602

G

CYFIP related Rac1 interactor B

decreases expression
multiple interactions

Coumestrol results in decreased expression of CYRIB mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CYRIB mRNA

NCBI chr 7:97,524,941...97,649,846
Ensembl chr 7:95,633,876...95,697,686

G

cytohesin 2

decreases expression

Coumestrol results in decreased expression of CYTH2 mRNA

NCBI chr 1:96,283,182...96,291,094
Ensembl chr 1:96,284,252...96,291,092

G

dishevelled associated activator of morphogenesis 1

decreases expression

Coumestrol results in decreased expression of DAAM1 mRNA

NCBI chr 6:90,389,544...90,550,114
Ensembl chr 6:90,389,688...90,550,114

G

differentiation antagonizing non-protein coding RNA

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DANCR mRNA

NCBI chr14:34,126,956...34,127,936

G

aspartyl-tRNA synthetase 2 (mitochondrial)

increases expression
multiple interactions

Coumestrol results in increased expression of DARS2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DARS2 mRNA

NCBI chr13:73,308,726...73,336,558
Ensembl chr13:73,308,726...73,336,934

G

DBF4-CDC7 kinase regulatory subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DBF4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DBF4 mRNA
Coumestrol results in increased expression of DBF4 mRNA

NCBI chr 4:26,631,491...26,656,080
Ensembl chr 4:25,676,634...25,701,066

G

drebrin 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DBN1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DBN1 mRNA
Coumestrol results in decreased expression of DBN1 mRNA

NCBI chr17:9,155,729...9,170,121
Ensembl chr17:9,150,659...9,164,984

G

DDB1 and CUL4 associated factor 15

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCAF15 mRNA

NCBI chr19:24,053,925...24,061,277
Ensembl chr19:24,053,925...24,061,277

G

DDB1 and CUL4 associated factor 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCAF4 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DCAF4 mRNA

NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982

G

DDB1 and CUL4 associated factor 5

decreases expression
multiple interactions

Coumestrol results in decreased expression of DCAF5 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCAF5 mRNA

NCBI chr 6:99,171,506...99,260,183
Ensembl chr 6:99,171,506...99,260,110

G

deoxycytidine kinase

increases expression
multiple interactions

Coumestrol results in increased expression of DCK mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of DCK mRNA

NCBI chr14:19,589,298...19,610,326
Ensembl chr14:19,305,218...19,326,247

G

doublecortin-like kinase 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of DCLK1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCLK1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DCLK1 mRNA

NCBI chr 2:141,567,215...141,861,088
Ensembl chr 2:139,417,163...139,710,956

G

DNA cross-link repair 1A

increases expression
multiple interactions

Coumestrol results in increased expression of DCLRE1A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCLRE1A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DCLRE1A mRNA

NCBI chr 1:255,569,911...255,589,815
Ensembl chr 1:255,569,919...255,589,678

G

DNA cross-link repair 1B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCLRE1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DCLRE1B mRNA
Coumestrol results in increased expression of DCLRE1B mRNA

NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423

G

decapping enzyme, scavenger

increases expression

Coumestrol results in increased expression of DCPS mRNA

NCBI chr 8:41,729,507...41,782,222
Ensembl chr 8:33,415,671...33,524,389

G

dCTP pyrophosphatase 1

increases expression

Coumestrol results in increased expression of DCTPP1 mRNA

NCBI chr 1:191,307,933...191,311,326
Ensembl chr 1:181,877,437...181,880,839

G

DDAH family member 2, ADMA-independent

decreases expression
multiple interactions

Coumestrol results in decreased expression of DDAH2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DDAH2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DDAH2 mRNA

NCBI chr20:3,766,115...3,769,161
Ensembl chr20:3,761,465...3,764,511

G

damage specific DNA binding protein 2

increases expression
multiple interactions

Coumestrol results in increased expression of DDB2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDB2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DDB2 mRNA

NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631

G

DNA damage-induced apoptosis suppressor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDIAS mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DDIAS mRNA
Coumestrol results in increased expression of DDIAS mRNA

NCBI chr 1:156,318,559...156,342,869
Ensembl chr 1:146,906,154...146,930,462

G

DNA-damage-inducible transcript 4

decreases expression
multiple interactions

Coumestrol results in decreased expression of DDIT4 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of DDIT4 mRNA

NCBI chr20:28,434,938...28,437,037
Ensembl chr20:27,891,998...27,894,105

G

DEAD/H-box helicase 11

increases expression

Coumestrol results in increased expression of DDX11 mRNA

NCBI chr 9:113,204,886...113,309,692
Ensembl chr 9:105,833,504...105,862,550

G

DExD-box helicase 39A

increases expression

Coumestrol results in increased expression of DDX39A mRNA

NCBI chr19:41,323,465...41,331,413
Ensembl chr19:24,418,114...24,426,954

G

DExD-box helicase 39B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDX39B mRNA

NCBI chr20:3,577,200...3,589,651
Ensembl chr20:3,572,056...3,584,996

G

DEAD-box helicase 56

increases expression

Coumestrol results in increased expression of DDX56 mRNA

NCBI chr14:85,325,942...85,336,262
Ensembl chr14:81,112,012...81,122,333

G

DEK proto-oncogene

increases expression
multiple interactions

Coumestrol results in increased expression of DEK mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of DEK mRNA

NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,580,843...17,602,808

G

DENN domain containing 11

decreases expression
multiple interactions

Coumestrol results in decreased expression of DENND11 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DENND11 mRNA

NCBI chr 4:69,197,161...69,266,013
Ensembl chr 4:69,198,068...69,228,821

G

DENN domain containing 1A

increases expression

Coumestrol results in increased expression of DENND1A mRNA

NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062

G

DENN domain containing 1B

decreases expression

Coumestrol results in decreased expression of DENND1B mRNA

NCBI chr13:50,545,324...50,772,922
Ensembl chr13:50,545,836...50,770,601

G

DENN domain containing 1C

decreases expression

Coumestrol results in decreased expression of DENND1C mRNA

NCBI chr 9:1,904,040...1,916,329
Ensembl chr 9:1,904,045...1,916,187

G

density regulated reinitiation and release factor

increases expression

Coumestrol results in increased expression of DENR mRNA

NCBI chr12:38,323,433...38,346,207
Ensembl chr12:32,662,516...32,683,843

G

DEP domain containing 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DEPDC1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DEPDC1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA]
Coumestrol results in increased expression of DEPDC1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 2:251,343,250...251,376,709
Ensembl chr 2:248,684,523...248,717,951

G

DEP domain containing 1B

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA]

NCBI chr 2:41,605,686...41,697,207
Ensembl chr 2:39,891,481...39,963,779

G

DEP domain containing MTOR-interacting protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DEPTOR mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of DEPTOR mRNA
Coumestrol results in increased expression of DEPTOR mRNA

NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:86,514,988...86,667,773

G

deoxyribose-phosphate aldolase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DERA mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DERA mRNA
Coumestrol results in increased expression of DERA mRNA

NCBI chr 4:172,394,971...172,473,746
Ensembl chr 4:170,663,665...170,758,865

G

desumoylating isopeptidase 2

increases expression

Coumestrol results in increased expression of DESI2 mRNA

NCBI chr13:92,493,765...92,543,307
Ensembl chr13:89,961,934...90,016,416

G

7-dehydrocholesterol reductase

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of DHCR7 mRNA
Coumestrol results in increased expression of DHCR7 mRNA

NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:199,015,081...199,031,055

G

dihydrofolate reductase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHFR mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of DHFR mRNA
Coumestrol results in increased expression of DHFR mRNA

NCBI chr 2:25,320,895...25,346,004
Ensembl chr 2:23,586,031...23,613,713

G

dehydrogenase/reductase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHRS2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DHRS2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA]
Coumestrol results in increased expression of DHRS2 mRNA

PMID:18310284 PMID:19167446

NCBI chr15:32,658,855...32,673,591
Ensembl chr15:28,688,940...28,703,644

G

dehydrogenase/reductase 7

decreases expression

Coumestrol results in decreased expression of DHRS7 mRNA

NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892

G

dehydrogenase E1 and transketolase domain containing 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHTKD1 mRNA
Coumestrol results in increased expression of DHTKD1 mRNA

NCBI chr17:77,242,512...77,316,074
Ensembl chr17:72,355,201...72,406,723

G

diaphanous-related formin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DIAPH3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DIAPH3 mRNA

NCBI chr15:68,951,992...69,421,623
Ensembl chr15:62,543,375...63,012,975

G

dicer 1 ribonuclease III

decreases expression

Coumestrol results in decreased expression of DICER1 mRNA

NCBI chr 6:129,392,298...129,457,252
Ensembl chr 6:123,631,250...123,693,965

G

disco-interacting protein 2 homolog C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DIP2C mRNA

NCBI chr17:60,647,346...61,032,467
Ensembl chr17:60,649,065...61,032,305

G

DIX domain containing 1

decreases expression

Coumestrol results in decreased expression of DIXDC1 mRNA

NCBI chr 8:51,007,835...51,081,191
Ensembl chr 8:51,007,838...51,081,090

G

dyskerin pseudouridine synthase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DKC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DKC1 mRNA
Coumestrol results in increased expression of DKC1 mRNA

NCBI chr X:157,751,651...157,757,796

G

dihydrolipoamide S-acetyltransferase

increases expression

Coumestrol results in increased expression of DLAT mRNA

NCBI chr 8:59,875,537...59,900,947
Ensembl chr 8:50,978,051...51,004,479
Ensembl chr 1:50,978,051...51,004,479

G

DLG associated protein 5

increases expression
multiple interactions

Coumestrol results in increased expression of DLGAP5 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DLGAP5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DLGAP5 mRNA

NCBI chr15:23,113,678...23,144,281
Ensembl chr15:20,633,966...20,664,518

G

distal-less homeobox 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DLX2 mRNA

NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597

G

distal membrane arm assembly component 2 like

decreases expression

Coumestrol results in decreased expression of DMAC2L mRNA

NCBI chr 6:88,205,580...88,223,934
Ensembl chr 6:88,205,700...88,223,933

G

Dmx-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DMXL1 mRNA

NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456

G

DnaJ heat shock protein family (Hsp40) member A2

decreases expression
multiple interactions

Coumestrol results in decreased expression of DNAJA2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNAJA2 mRNA

NCBI chr19:37,671,019...37,689,163
Ensembl chr19:21,497,729...21,516,901

G

DnaJ heat shock protein family (Hsp40) member B9

decreases expression
multiple interactions

Coumestrol results in decreased expression of DNAJB9 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNAJB9 mRNA

NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C1

decreases expression

Coumestrol results in decreased expression of DNAJC1 mRNA

NCBI chr17:85,863,651...86,020,954
Ensembl chr17:80,955,237...81,111,988

G

DnaJ heat shock protein family (Hsp40) member C16

decreases expression

Coumestrol results in decreased expression of DNAJC16 mRNA

NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136

G

DnaJ heat shock protein family (Hsp40) member C9

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNAJC9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DNAJC9 mRNA
Coumestrol results in increased expression of DNAJC9 mRNA

NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118

G

deoxyribonuclease 2, lysosomal

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNASE2 mRNA

NCBI chr19:40,149,505...40,152,225
Ensembl chr19:23,244,664...23,247,376

G

dynamin 1-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNM1L mRNA

NCBI chr11:98,084,049...98,135,663
Ensembl chr11:84,581,216...84,631,482

G

DNA methyltransferase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNMT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DNMT1 mRNA
Coumestrol results in increased expression of DNMT1 mRNA

NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:19,440,611...19,486,659

G

dedicator of cytokinesis 8

decreases expression

Coumestrol results in decreased expression of DOCK8 mRNA

NCBI chr 1:232,075,468...232,268,830
Ensembl chr 1:222,649,309...222,842,474

G

DNA replication fork stabilization factor DONSON

increases expression
multiple interactions

Coumestrol results in increased expression of DONSON mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DONSON mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DONSON mRNA

NCBI chr11:44,405,794...44,419,099
Ensembl chr11:30,923,239...30,932,889

G

DOP1 leucine zipper like protein B

decreases expression

Coumestrol results in decreased expression of DOP1B mRNA

NCBI chr11:46,494,058...46,595,601
Ensembl chr11:33,024,411...33,125,931

G

dolichyl-phosphate N-acetylglucosaminephosphotransferase 1

increases expression

Coumestrol results in increased expression of DPAGT1 mRNA

NCBI chr 8:44,664,055...44,671,102
Ensembl chr 8:44,664,071...44,671,087

G

dolichyl-phosphate mannosyltransferase subunit 2, regulatory

increases expression

Coumestrol results in increased expression of DPM2 mRNA

NCBI chr 3:15,855,952...15,858,867
Ensembl chr 3:15,856,182...15,869,165
Ensembl chr 3:15,856,182...15,869,165

G

dpy-19 like C-mannosyltransferase 1

increases expression

Coumestrol results in increased expression of DPY19L1 mRNA

NCBI chr 8:22,933,163...23,021,461
Ensembl chr 8:22,933,163...23,021,751

G

desmocollin 2

decreases expression

Coumestrol results in decreased expression of DSC2 mRNA

NCBI chr18:11,725,466...11,757,591
Ensembl chr18:11,450,390...11,482,392

G

DNA replication and sister chromatid cohesion 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DSCC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DSCC1 mRNA
Coumestrol results in increased expression of DSCC1 mRNA

NCBI chr 7:88,372,349...88,390,815
Ensembl chr 7:86,482,588...86,498,212

G

DSN1 component of MIS12 kinetochore complex

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DSN1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DSN1 mRNA
Coumestrol results in increased expression of DSN1 mRNA

NCBI chr 3:166,072,775...166,089,029
Ensembl chr 3:145,652,737...145,665,856

G

dystrobrevin, alpha

decreases expression
multiple interactions

Coumestrol results in decreased expression of DTNA mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DTNA mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DTNA mRNA

NCBI chr18:14,687,193...14,944,232
Ensembl chr18:14,587,852...14,944,261

G

dual specificity phosphatase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DUSP1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646

G

dual specificity phosphatase 10

decreases expression
multiple interactions

Coumestrol results in decreased expression of DUSP10 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of DUSP10 mRNA

NCBI chr13:98,145,317...98,183,304
Ensembl chr13:95,614,292...95,651,716

G

dual specificity phosphatase 22

decreases expression

Coumestrol results in decreased expression of DUSP22 mRNA

NCBI chr17:33,989,637...34,040,021
Ensembl chr17:33,780,981...33,831,321

G

deoxyuridine triphosphatase

increases expression
multiple interactions

Coumestrol results in increased expression of DUT mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DUT mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of DUT mRNA

NCBI chr 3:132,952,258...132,963,433
Ensembl chr 3:112,498,982...112,510,771

G

dynein cytoplasmic 1 light intermediate chain 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of DYNC1LI1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DYNC1LI1 mRNA

NCBI chr 8:123,254,823...123,288,496
Ensembl chr 8:114,376,662...114,410,934

G

dynein 2 intermediate chain 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DYNC2I2 mRNA

NCBI chr 3:13,306,039...13,322,121
Ensembl chr 3:13,306,039...13,322,121

G

dynein light chain Tctex-type 3

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of DYNLT3 mRNA

NCBI chr X:16,000,425...16,009,632
Ensembl chr X:13,327,892...13,337,139

G

E2F transcription factor 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of E2F1 mRNA

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:143,049,478...143,075,361

G

E2F transcription factor 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of E2F2 mRNA
Coumestrol results in increased expression of E2F2 mRNA

NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:148,399,642...148,421,217

G

E2F transcription factor 5

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of E2F5 mRNA
Coumestrol results in decreased expression of E2F5 mRNA

NCBI chr 2:86,997,331...87,012,908
Ensembl chr 2:86,997,332...87,012,990

G

E2F transcription factor 7

increases expression
multiple interactions

Coumestrol results in increased expression of E2F7 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F7 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of E2F7 mRNA

NCBI chr 7:48,036,881...48,079,055
Ensembl chr 7:46,151,293...46,192,734

G

E2F transcription factor 8

increases expression
multiple interactions

Coumestrol results in increased expression of E2F8 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F8 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of E2F8 mRNA

NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:98,565,717...98,584,098

G

EBP, cholestenol delta-isomerase

increases expression
multiple interactions

Coumestrol results in increased expression of EBP mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EBP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EBP mRNA

NCBI chr X:16,971,372...16,977,782
Ensembl chr X:14,299,448...14,305,826

G

epithelial cell transforming 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ECT2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ECT2 mRNA
Coumestrol results in increased expression of ECT2 mRNA

NCBI chr 2:111,904,522...111,966,786
Ensembl chr 2:109,975,813...110,037,911

G

ER degradation enhancing alpha-mannosidase like protein 3

decreases expression

Coumestrol results in decreased expression of EDEM3 mRNA

NCBI chr13:63,858,282...63,920,538
Ensembl chr13:63,858,716...63,920,523

G

EGF like repeats and discoidin domains 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EDIL3 mRNA

NCBI chr 2:19,890,396...20,405,028
Ensembl chr 2:19,890,373...20,405,008

G

endothelin 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of EDN1 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of EDN1 mRNA

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885

G

embryonic ectoderm development

increases expression
multiple interactions

Coumestrol results in increased expression of EED mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EED mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EED mRNA

NCBI chr 1:143,867,875...143,895,008
Ensembl chr 1:143,867,875...143,894,974

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EEF1A1 mRNA

NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:79,341,557...79,344,839

G

EGF containing fibulin extracellular matrix protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFEMP1 mRNA

NCBI chr14:106,811,769...106,890,961
Ensembl chr14:102,610,908...102,690,018

G

EF-hand domain family, member D1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFHD1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EFHD1 mRNA
Coumestrol results in decreased expression of EFHD1 mRNA

NCBI chr 9:95,386,155...95,432,800
Ensembl chr 9:87,938,284...87,984,917

G

ephrin A1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFNA1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EFNA1 mRNA
Coumestrol results in decreased expression of EFNA1 mRNA

NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:174,681,682...174,690,866

G

ephrin B2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFNB2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EFNB2 mRNA
Coumestrol results in decreased expression of EFNB2 mRNA

NCBI chr16:87,485,215...87,529,224
Ensembl chr16:80,783,417...80,824,391

G

ephrin B3

decreases expression

Coumestrol results in decreased expression of EFNB3 mRNA

NCBI chr10:54,773,282...54,780,727
Ensembl chr10:54,274,506...54,280,471

G

elongation factor Tu GTP binding domain containing 2

increases expression

Coumestrol results in increased expression of EFTUD2 mRNA

NCBI chr10:88,304,992...88,352,229
Ensembl chr10:87,804,892...87,846,079

G

early growth response 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EGR1 mRNA

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766

G

early growth response 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EGR3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EGR3 mRNA

NCBI chr15:51,560,482...51,565,778
Ensembl chr15:45,150,567...45,154,627

G

euchromatic histone lysine methyltransferase 1

decreases expression

Coumestrol results in decreased expression of EHMT1 mRNA

NCBI chr 3:27,978,888...28,127,178
Ensembl chr 3:7,580,683...7,729,007

G

eukaryotic translation initiation factor 2 alpha kinase 3

decreases expression

Coumestrol results in decreased expression of EIF2AK3 mRNA

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases expression

Coumestrol results in increased expression of EIF2S1 mRNA

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:97,672,766...97,706,225

G

eukaryotic translation initiation factor 4E binding protein 2

increases expression

Coumestrol results in increased expression of EIF4EBP2 mRNA

NCBI chr20:29,379,444...29,400,110
Ensembl chr20:29,382,668...29,399,946

G

eukaryotic translation initiation factor 4 gamma, 3

decreases expression

Coumestrol results in decreased expression of EIF4G3 mRNA

NCBI chr 5:155,481,378...155,702,194
Ensembl chr 5:150,195,226...150,418,363

G

endosome-lysosome associated apoptosis and autophagy regulator 1

multiple interactions

[Coumestrol co-treated with Resveratrol] results in decreased expression of ELAPOR1 mRNA

NCBI chr 2:196,089,199...196,169,055
Ensembl chr 2:196,091,646...196,168,716

G

E74 like ETS transcription factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ELF5 mRNA

NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973

G

ETS transcription factor ELK1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELK1 mRNA

NCBI chr X:3,692,367...3,709,252
Ensembl chr X:1,139,756...1,155,713

G

ETS transcription factor ELK3

decreases expression

Coumestrol results in decreased expression of ELK3 mRNA

NCBI chr 7:29,655,676...29,718,163
Ensembl chr 7:27,768,599...27,804,084

G

engulfment and cell motility 2

decreases expression

Coumestrol results in decreased expression of ELMO2 mRNA

NCBI chr 3:174,442,965...174,716,723
Ensembl chr 3:154,023,661...154,061,185

G

ELOVL fatty acid elongase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ELOVL2 mRNA
Coumestrol results in increased expression of ELOVL2 mRNA

NCBI chr17:23,750,350...23,790,601
Ensembl chr17:23,544,568...23,584,848

G

ELOVL fatty acid elongase 5

increases expression
multiple interactions

Coumestrol results in increased expression of ELOVL5 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of ELOVL5 mRNA

NCBI chr 8:87,671,164...87,737,618
Ensembl chr 8:78,790,846...78,857,284

G

ELOVL fatty acid elongase 6

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ELOVL6 mRNA
Coumestrol results in increased expression of ELOVL6 mRNA

NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:218,063,804...218,171,186

G

ELOVL fatty acid elongase 7

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL7 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ELOVL7 mRNA
Coumestrol results in increased expression of ELOVL7 mRNA

NCBI chr 2:41,522,695...41,592,021
Ensembl chr 2:39,789,250...39,856,845

G

elongator acetyltransferase complex subunit 5

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of ELP5 mRNA
Coumestrol results in increased expression of ELP5 mRNA

NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923

G

elongator acetyltransferase complex subunit 6

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELP6 mRNA
Coumestrol results in increased expression of ELP6 mRNA

NCBI chr 8:119,158,380...119,173,483
Ensembl chr 8:110,279,979...110,295,067

G

ER membrane protein complex subunit 9

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EMC9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EMC9 mRNA
Coumestrol results in increased expression of EMC9 mRNA

NCBI chr15:33,041,840...33,046,056
Ensembl chr15:29,071,883...29,076,098

G

emerin

increases expression

Coumestrol results in increased expression of EMD mRNA

NCBI chr X:157,190,438...157,193,479
Ensembl chr X:152,038,998...152,045,807

G

essential meiotic structure-specific endonuclease 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EME1 mRNA

NCBI chr10:80,083,585...80,092,450
Ensembl chr10:79,586,729...79,595,435

G

ectodermal-neural cortex 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of ENC1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ENC1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ENC1 mRNA

NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713

G

endonuclease domain containing 1

increases expression
multiple interactions

Coumestrol results in increased expression of ENDOD1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ENDOD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ENDOD1 mRNA

NCBI chr 8:19,490,615...19,520,007
Ensembl chr 8:11,211,110...11,238,892

G

enolase superfamily member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ENOSF1 mRNA

G

ectonucleoside triphosphate diphosphohydrolase 2

decreases expression

Coumestrol results in decreased expression of ENTPD2 mRNA

NCBI chr 3:28,611,722...28,617,237
Ensembl chr 3:8,213,663...8,226,866

G

ectonucleoside triphosphate diphosphohydrolase 4

decreases expression

Coumestrol results in decreased expression of ENTPD4 mRNA

NCBI chr15:44,630,878...44,658,654
Ensembl chr15:44,630,873...44,658,706

G

endosomal transmembrane epsin interactor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ENTREP1 mRNA

NCBI chr 1:231,018,987...231,073,474
Ensembl chr 1:221,592,503...221,646,758

G

erythrocyte membrane protein band 4.1-like 2

decreases expression

Coumestrol results in decreased expression of EPB41L2 mRNA

NCBI chr 1:19,863,010...20,037,795
Ensembl chr 1:19,863,009...20,037,721

G

erythrocyte membrane protein band 4.1 like 5

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EPB41L5 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EPB41L5 mRNA
Coumestrol results in decreased expression of EPB41L5 mRNA

NCBI chr13:33,221,705...33,321,400
Ensembl chr13:30,669,764...30,768,360

G

Eph receptor A4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EPHA4 mRNA

NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:78,815,460...78,958,139

G

epidermal growth factor receptor pathway substrate 15-like 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EPS15L1 mRNA
Coumestrol results in increased expression of EPS15L1 mRNA

NCBI chr16:17,426,345...17,501,677
Ensembl chr16:17,426,421...17,501,677

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 3

decreases expression

Coumestrol results in decreased expression of ERBB3 mRNA

NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:996,225...1,015,525

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB4 mRNA

NCBI chr 9:76,973,386...78,045,633
Ensembl chr 9:69,531,481...70,596,595

G

ERCC excision repair 6 like, spindle assembly checkpoint helicase

increases expression
multiple interactions

Coumestrol results in increased expression of ERCC6L mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ERCC6L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ERCC6L mRNA

NCBI chr X:71,285,380...71,301,186
Ensembl chr X:67,245,414...67,280,756

G

ERI1 exoribonuclease family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ERI2 mRNA

NCBI chr 1:174,140,831...174,168,757
Ensembl chr 1:174,141,993...174,168,665

G

ERBB receptor feedback inhibitor 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of ERRFI1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ERRFI1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ERRFI1 mRNA

NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:161,323,998...161,337,282

G

establishment of sister chromatid cohesion N-acetyltransferase 2

increases expression

Coumestrol results in increased expression of ESCO2 mRNA

NCBI chr15:44,210,124...44,230,785
Ensembl chr15:40,034,568...40,055,306
Ensembl chr15:40,034,568...40,055,306

G

extra spindle pole bodies like 1, separase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ESPL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ESPL1 mRNA
Coumestrol results in increased expression of ESPL1 mRNA

NCBI chr 7:135,302,460...135,329,570
Ensembl chr 7:133,424,130...133,450,984

G

estrogen receptor 1

multiple interactions
decreases expression
affects response to substance
increases activity
affects binding

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; [Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein; [Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA; Benzo(a)pyrene inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; bisphenol A diglycidyl ether analog inhibits the reaction [Coumestrol binds to ESR1 protein]; bisphenol A diglycidyl ether inhibits the reaction [Coumestrol binds to ESR1 protein]; bisphenol AF inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; bisphenol F diglycidyl ether analog inhibits the reaction [Coumestrol binds to ESR1 protein]; bisphenol F diglycidyl ether inhibits the reaction [Coumestrol binds to ESR1 protein]; CCND1 protein promotes the reaction [Coumestrol results in increased activity of ESR1 protein]; Coumestrol binds to and results in increased activity of ESR1 protein; Coumestrol inhibits the reaction [16 alpha-iodoestradiol binds to ESR1 protein]; Coumestrol inhibits the reaction [Estradiol binds to ESR1 protein]; Coumestrol promotes the reaction [NCOA2 protein binds to ESR1 protein]; Diethylstilbestrol inhibits the reaction [Coumestrol binds to ESR1 protein]; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CCN5 mRNA]; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CXCL12 mRNA]; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of PGR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA]; Estradiol inhibits the reaction [Coumestrol binds to ESR1 protein]; Fulvestrant inhibits the reaction [[Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein]; Fulvestrant inhibits the reaction [Coumestrol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [Coumestrol results in increased activity of ESR1 protein]; Tamoxifen promotes the reaction [Coumestrol results in increased activity of ESR1 protein mutant form]; tetrabromobisphenol A inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; tetrachlorodian inhibits the reaction [Coumestrol binds to ESR1 protein modified form]
Coumestrol results in decreased expression of ESR1 protein
[Fulvestrant co-treated with Coumestrol] results in increased expression of ESR1 mRNA; Fulvestrant inhibits the reaction [Coumestrol results in decreased expression of ESR1 protein]
ESR1 protein affects the susceptibility to Coumestrol
Coumestrol binds to ESR1 protein; Coumestrol binds to ESR1 protein modified form

PMID:9048584 PMID:9751507 PMID:10397250 PMID:11162928 PMID:11518614 More...

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions
increases expression
affects binding
affects response to substance
increases activity

Coumestrol binds to and results in increased activity of ESR2 protein; Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA]
Coumestrol results in increased expression of ESR2 mRNA
Coumestrol binds to Esr2 protein
Coumestrol results in increased expression of ESR2 protein; Coumestrol results in increased expression of ESR2 protein alternative form
ESR2 protein affects the susceptibility to Coumestrol
ESR2 protein affects the reaction [Coumestrol results in increased expression of SOD2 protein]
Coumestrol binds to ESR2 protein
[Fulvestrant co-treated with Coumestrol] results in increased expression of ESR2 mRNA; Coumestrol inhibits the reaction [16 alpha-iodoestradiol binds to ESR2 protein]; Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein alternative form]
Coumestrol results in increased activity of ESR2 protein

CTD
RGD

PMID:9048584 PMID:9492041 PMID:9751507 PMID:11518614 PMID:12224631 More...

RGD:8694130, RGD:8694130

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919

G

extended synaptotagmin 2

decreases expression

Coumestrol results in decreased expression of ESYT2 mRNA

NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590

G

ethanolamine kinase 1

decreases expression

Coumestrol results in decreased expression of ETNK1 mRNA

NCBI chr 4:177,857,001...177,901,278
Ensembl chr 4:176,126,180...176,193,770

G

ecotropic viral integration site 5

decreases expression

Coumestrol results in decreased expression of EVI5 mRNA

NCBI chr14:1,875,601...2,021,678
Ensembl chr14:1,875,647...2,021,678

G

exonuclease 1

increases expression
multiple interactions

Coumestrol results in increased expression of EXO1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EXO1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EXO1 mRNA

NCBI chr13:90,341,947...90,366,861
Ensembl chr13:87,809,810...87,834,654

G

exocyst complex component 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EXOC2 mRNA

NCBI chr17:33,714,949...33,906,901
Ensembl chr17:33,506,338...33,693,289

G

exosome component 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of EXOSC2 mRNA

NCBI chr 3:35,360,652...35,370,948
Ensembl chr 3:14,962,917...14,973,575

G

exosome component 3

increases expression

Coumestrol results in increased expression of EXOSC3 mRNA

NCBI chr 5:64,369,495...64,374,711
Ensembl chr 5:59,573,886...59,579,060

G

exosome component 8

increases expression

Coumestrol results in increased expression of EXOSC8 mRNA

NCBI chr 2:141,080,568...141,087,112
Ensembl chr 2:138,930,405...138,936,928

G

exosome component 9

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA]

NCBI chr 2:121,344,154...121,355,110
Ensembl chr 2:119,388,715...119,427,051

G

exostosin glycosyltransferase 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EXT1 mRNA
Coumestrol results in decreased expression of EXT1 mRNA

NCBI chr 7:86,265,651...86,544,488
Ensembl chr 7:84,375,784...84,655,357

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

increases expression
multiple interactions

Coumestrol results in increased expression of EZH2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EZH2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EZH2 mRNA

NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:76,624,399...76,687,362

G

ezrin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EZR mRNA

NCBI chr 1:49,373,033...49,416,573
Ensembl chr 1:46,967,658...47,011,505

G

coagulation factor II (thrombin) receptor

decreases expression

Coumestrol results in decreased expression of F2R mRNA

NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:26,868,404...26,885,870

G

F2R like trypsin receptor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of F2RL1 mRNA
Coumestrol results in decreased expression of F2RL1 mRNA

NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:26,772,278...26,785,226

G

fatty acid binding protein 5

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA]

NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:91,765,056...91,853,773

G

fatty acid desaturase 1

increases expression
multiple interactions

Coumestrol results in increased expression of FADS1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of FADS1 mRNA

NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:206,827,765...206,842,734

G

fumarylacetoacetate hydrolase

increases expression

Coumestrol results in increased expression of FAH mRNA

NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505

G

family with sequence similarity 107, member B

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM107B mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of FAM107B mRNA
Coumestrol results in decreased expression of FAM107B mRNA

NCBI chr17:79,387,795...79,594,165
Ensembl chr17:74,478,608...74,684,989

G

family with sequence similarity 110, member B

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM110B mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of FAM110B mRNA
Coumestrol results in decreased expression of FAM110B mRNA

NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:18,789,389...18,929,828

G

family with sequence similarity 110, member C

decreases expression
multiple interactions

Coumestrol results in decreased expression of FAM110C mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of FAM110C mRNA

NCBI chr 6:47,638,466...47,644,723
Ensembl chr 6:47,638,276...47,644,634

G

FAM111 trypsin like peptidase A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FAM111A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FAM111A mRNA
Coumestrol results in increased expression of FAM111A mRNA

NCBI chr 1:219,065,542...219,081,213
Ensembl chr 1:209,640,953...209,656,547

G

family with sequence similarity 149, member B1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM149B1 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of FAM149B1 mRNA
Coumestrol results in decreased expression of FAM149B1 mRNA

NCBI chr15:3,929,190...3,967,140
Ensembl chr15:3,929,190...3,966,997

G

FAM161 centrosomal protein B

decreases expression
multiple interactions

Coumestrol results in decreased expression of FAM161B mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of FAM161B mRNA

NCBI chr 6:109,722,073...109,750,003
Ensembl chr 6:103,992,170...104,018,776

G

family with sequence similarity 169, member A

decreases expression

Coumestrol results in decreased expression of FAM169A mRNA

NCBI chr 2:28,384,162...28,441,361
Ensembl chr 2:28,383,784...28,438,910

G

family with sequence similarity 171, member B

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of FAM171B mRNA

NCBI chr 3:68,930,755...68,986,113
Ensembl chr 3:68,930,822...68,986,127

G

family with sequence similarity 174, member B

decreases expression

Coumestrol results in decreased expression of FAM174B mRNA

NCBI chr 1:127,515,393...127,618,591
Ensembl chr 1:127,514,041...127,596,128
Ensembl chr 1:127,514,041...127,596,128

G

family with sequence similarity 210, member B

decreases expression

Coumestrol results in decreased expression of FAM210B mRNA

NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397

G

family with sequence similarity 216, member A

increases expression

Coumestrol results in increased expression of FAM216A mRNA

NCBI chr12:34,198,526...34,207,673
Ensembl chr12:34,198,526...34,207,665

G

family with sequence similarity 222, member B

decreases expression

Coumestrol results in decreased expression of FAM222B mRNA

NCBI chr10:62,986,571...63,052,350
Ensembl chr10:62,986,571...63,052,350

G

family with sequence similarity 43, member A

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM43A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of FAM43A mRNA
Coumestrol results in decreased expression of FAM43A mRNA

NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401

G

FA complementation group A

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of FANCA mRNA

NCBI chr19:68,210,562...68,271,080
Ensembl chr19:51,304,021...51,362,527

G

FA complementation group D2

increases expression
multiple interactions

Coumestrol results in increased expression of FANCD2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCD2 mRNA

NCBI chr 4:148,234,633...148,299,035
Ensembl chr 4:146,679,179...146,743,412

G

FA complementation group G

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCG mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCG mRNA
Coumestrol results in increased expression of FANCG mRNA

NCBI chr 5:62,027,494...62,037,202
Ensembl chr 5:57,231,685...57,240,029

G

FA complementation group I

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCI mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCI mRNA
Coumestrol results in increased expression of FANCI mRNA

NCBI chr 1:142,736,636...142,792,999
Ensembl chr 1:133,327,297...133,383,640

G

FA complementation group L

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCL mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCL mRNA

NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255

G

phenylalanyl-tRNA synthetase subunit beta

increases expression

Coumestrol results in increased expression of FARSB mRNA

NCBI chr 9:87,336,321...87,395,546
Ensembl chr 9:79,887,842...79,947,045

G

filamin binding LIM protein 1

decreases expression

Coumestrol results in decreased expression of FBLIM1 mRNA

NCBI chr 5:159,167,004...159,198,578
Ensembl chr 5:153,883,960...153,913,757

G

F-box and leucine-rich repeat protein 5

decreases expression

Coumestrol results in decreased expression of FBXL5 mRNA

NCBI chr14:67,305,109...67,347,383
Ensembl chr14:67,267,801...67,347,383

G

F-box protein 38

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FBXO38 mRNA

NCBI chr18:58,227,253...58,274,320
Ensembl chr18:55,956,959...56,003,961

G

F-box protein 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FBXO5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FBXO5 mRNA
Coumestrol results in increased expression of FBXO5 mRNA

NCBI chr 1:44,601,412...44,607,781
Ensembl chr 1:42,196,068...42,202,437

G

Fcf1 rRNA-processing protein

increases expression

Coumestrol results in increased expression of FCF1 mRNA

NCBI chr 6:104,617,780...104,629,643
Ensembl chr 6:104,617,770...104,629,643

G

Fc mu receptor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FCMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA]

PMID:18310284 PMID:19167446

NCBI chr13:44,889,628...44,903,926
Ensembl chr13:42,337,414...42,351,653

G

farnesyl diphosphate farnesyl transferase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FDFT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FDFT1 mRNA
Coumestrol results in increased expression of FDFT1 mRNA

NCBI chr15:41,588,114...41,616,168
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of FDPS mRNA
Coumestrol results in increased expression of FDPS mRNA

NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:174,486,665...174,507,776

G

flap structure-specific endonuclease 1

increases expression
multiple interactions

Coumestrol results in increased expression of FEN1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FEN1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FEN1 mRNA

NCBI chr 1:216,270,016...216,274,873
Ensembl chr 1:206,844,884...206,850,003

G

FERM domain containing kindlin 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FERMT2 mRNA

NCBI chr15:21,162,603...21,257,995
Ensembl chr15:18,682,927...18,751,811

G

Fibroblast growth factor receptor 1

decreases expression

Coumestrol results in decreased expression of FGFR1 mRNA

NCBI chr16:73,194,631...73,249,855
Ensembl chr16:66,494,042...66,547,350

G

fumarate hydratase

increases expression

Coumestrol results in increased expression of FH mRNA

NCBI chr13:90,056,565...90,082,450
Ensembl chr13:87,524,337...87,550,266

G

four and a half LIM domains 1

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA]

NCBI chr X:139,592,794...139,652,290
Ensembl chr X:134,555,479...134,614,928

G

four and a half LIM domains 2

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of FHL2 mRNA
Coumestrol results in increased expression of FHL2 mRNA

NCBI chr 9:52,881,091...52,954,540
Ensembl chr 9:45,388,981...45,431,192

G

FGF1 intracellular binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIBP mRNA

NCBI chr 1:212,197,216...212,201,732
Ensembl chr 1:202,768,078...202,772,399

G

fidgetin-like 1

increases expression
multiple interactions

Coumestrol results in increased expression of FIGNL1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIGNL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FIGNL1 mRNA

NCBI chr14:90,573,090...90,595,342
Ensembl chr14:86,368,675...86,377,455

G

filamin A interacting protein 1-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FILIP1L mRNA

NCBI chr11:56,403,467...56,646,422
Ensembl chr11:42,940,467...43,177,415

G

FIGNL1 interacting regulator of recombination and mitosis

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIRRM mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of FIRRM mRNA
Coumestrol results in increased expression of FIRRM mRNA

NCBI chr13:78,835,081...78,879,022
Ensembl chr13:76,301,918...76,345,804

G

FKBP prolyl isomerase 11

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FKBP11 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of FKBP11 mRNA
Coumestrol results in increased expression of FKBP11 mRNA

NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303

G

FKBP prolyl isomerase 4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FKBP4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FKBP4 mRNA
Coumestrol results in increased expression of FKBP4 mRNA

NCBI chr 4:163,389,464...163,397,918
Ensembl chr 4:161,703,379...161,711,833

G

FKBP prolyl isomerase 5

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of FKBP5 mRNA
Coumestrol results in increased expression of FKBP5 mRNA

NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,457,216...6,541,674

G

FKBP prolyl isomerase like

increases expression

Coumestrol results in increased expression of FKBPL mRNA

NCBI chr20:4,099,845...4,101,315
Ensembl chr20:4,099,806...4,101,368

G

folliculin

decreases expression
multiple interactions

Coumestrol results in decreased expression of FLCN mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FLCN mRNA

NCBI chr10:45,088,164...45,107,581
Ensembl chr10:44,588,624...44,607,769

G

formin-like 2

decreases expression

Coumestrol results in decreased expression of FMNL2 mRNA

NCBI chr 3:37,348,791...37,624,746
Ensembl chr 3:37,348,574...37,624,754

G

formin binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FNBP1 mRNA

NCBI chr 3:34,706,814...34,826,770
Ensembl chr 3:14,309,640...14,424,881

G

formin binding protein 1-like

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FNBP1L mRNA
Coumestrol results in decreased expression of FNBP1L mRNA

NCBI chr 2:210,647,241...210,748,203
Ensembl chr 2:210,647,246...210,738,455

G

fibronectin type III domain containing 3B

decreases expression

Coumestrol results in decreased expression of FNDC3B mRNA

NCBI chr 2:112,240,108...112,546,113
Ensembl chr 2:110,312,694...110,547,830

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOS mRNA

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box D1

decreases expression

Coumestrol results in decreased expression of FOXD1 mRNA

NCBI chr 2:29,702,558...29,704,978
Ensembl chr 2:29,702,558...29,704,978

G

forkhead box M1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FOXM1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of FOXM1 mRNA
Coumestrol results in increased expression of FOXM1 mRNA

NCBI chr 4:163,325,628...163,338,100
Ensembl chr 4:161,638,816...161,650,684

G

forkhead box O3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOXO3 mRNA
Coumestrol results in decreased expression of FOXO3 mRNA

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:45,672,995...45,764,561

G

forkhead box P2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOXP2 mRNA

NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683

G

FAD-dependent oxidoreductase domain containing 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of FOXRED2 mRNA

NCBI chr 7:111,402,322...111,419,056
Ensembl chr 7:109,521,761...109,540,874

G

FERM domain containing 3

decreases expression

Coumestrol results in decreased expression of FRMD3 mRNA

NCBI chr 5:87,764,755...88,031,091
Ensembl chr 5:87,764,604...88,031,091

G

FERM domain containing 6

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FRMD6 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of FRMD6 mRNA
Coumestrol results in decreased expression of FRMD6 mRNA

NCBI chr 6:89,345,983...89,419,579
Ensembl chr 6:89,346,035...89,419,579

G

fascin actin-bundling protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FSCN1 mRNA

NCBI chr12:16,710,601...16,723,734
Ensembl chr12:11,597,048...11,610,211

G

FtsJ RNA 2'-O-methyltransferase 1

increases expression

Coumestrol results in increased expression of FTSJ1 mRNA

NCBI chr X:14,243,684...14,256,555
Ensembl chr X:14,244,050...14,252,030

G

alpha-L-fucosidase 1

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of FUCA1 mRNA
Coumestrol results in decreased expression of FUCA1 mRNA

NCBI chr 5:153,436,262...153,453,512
Ensembl chr 5:148,152,700...148,169,972

G

Friend virus susceptibility 1

increases expression

Coumestrol results in increased expression of C19ORF48P mRNA

NCBI chr 1:94,730,839...94,736,791
Ensembl chr 1:94,730,606...94,737,594

G

FYN binding protein 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of FYB2 mRNA

NCBI chr 5:124,906,005...125,029,867
Ensembl chr 5:119,677,204...119,800,910

G

FYVE and coiled-coil domain autophagy adaptor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FYCO1 mRNA
Coumestrol results in decreased expression of FYCO1 mRNA

NCBI chr 8:123,412,105...123,479,315
Ensembl chr 8:123,412,112...123,479,021

G

frizzled class receptor 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of FZD2 mRNA

NCBI chr10:88,061,988...88,063,898
Ensembl chr10:87,561,326...87,565,334

G

G2/M-phase specific E3 ubiquitin protein ligase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G2E3 mRNA
Coumestrol results in increased expression of G2E3 mRNA

NCBI chr 6:74,498,801...74,530,703
Ensembl chr 6:68,764,185...68,793,924

G

G3BP stress granule assembly factor 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G3BP2 mRNA

NCBI chr14:16,216,684...16,304,828
Ensembl chr14:15,987,417...16,020,548

G

GA binding protein transcription factor subunit beta 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GABPB2 mRNA
Coumestrol results in increased expression of GABPB2 mRNA

NCBI chr 2:182,755,304...182,795,368
Ensembl chr 2:182,761,359...182,795,109

G

growth arrest and DNA-damage-inducible, alpha

decreases expression
multiple interactions

Coumestrol results in decreased expression of GADD45A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:96,154,789...96,157,115

G

GADD45G interacting protein 1

increases expression

Coumestrol results in increased expression of GADD45GIP1 mRNA

NCBI chr19:40,225,503...40,228,052
Ensembl chr19:23,320,159...23,323,236

G

galanin and GMAP prepropeptide

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA]

NCBI chr 1:210,079,709...210,084,572
Ensembl chr 1:200,650,439...200,654,959

G

galactosamine (N-acetyl)-6-sulfatase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNS mRNA

NCBI chr19:67,537,175...67,570,900
Ensembl chr19:50,628,552...50,662,246

G

polypeptide N-acetylgalactosaminyltransferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT1 mRNA

NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,489,020...15,568,245

G

polypeptide N-acetylgalactosaminyltransferase 10

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT10 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GALNT10 mRNA
Coumestrol results in decreased expression of GALNT10 mRNA

NCBI chr10:42,321,691...42,468,087
Ensembl chr10:41,820,158...41,967,013

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT7 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GALNT7 mRNA
Coumestrol results in decreased expression of GALNT7 mRNA

NCBI chr16:37,589,368...37,713,911
Ensembl chr16:32,578,690...32,702,690

G

glucosidase II alpha subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GANAB mRNA

NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695

G

phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase

increases expression

Coumestrol results in increased expression of GART mRNA

NCBI chr11:44,351,841...44,377,086
Ensembl chr11:30,865,889...30,891,125

G

growth arrest-specific 2 like 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GAS2L3 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of GAS2L3 mRNA

NCBI chr 7:23,803,578...23,836,816
Ensembl chr 7:23,806,310...23,836,411

G

GATA binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GATA2 mRNA

NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:120,658,986...120,667,761

G

GATA binding protein 3

decreases expression

Coumestrol results in decreased expression of GATA3 mRNA

NCBI chr17:73,544,234...73,575,670
Ensembl chr17:68,643,873...68,665,391

G

GATA zinc finger domain containing 1

decreases expression

Coumestrol results in decreased expression of GATAD1 mRNA

NCBI chr 4:31,462,251...31,473,827
Ensembl chr 4:30,507,538...30,519,107

G

guanylate binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GBP2 mRNA

NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:231,332,284...231,348,571

G

GTP cyclohydrolase I feedback regulator

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GCHFR mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GCHFR mRNA
Coumestrol results in increased expression of GCHFR mRNA

NCBI chr 3:126,611,892...126,615,926
Ensembl chr 3:106,159,394...106,162,080

G

glutamate cysteine ligase, modifier subunit

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:210,347,482...210,367,535

G

growth differentiation factor 15

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GDF15 mRNA
Coumestrol results in decreased expression of GDF15 mRNA

NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,805,239...18,808,055

G

glycerophosphodiester phosphodiesterase domain containing 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GDPD3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GDPD3 mRNA
Coumestrol results in decreased expression of GDPD3 mRNA

NCBI chr 1:190,804,053...190,813,609
Ensembl chr 1:181,366,626...181,383,063

G

GTP binding protein overexpressed in skeletal muscle

increases expression

Coumestrol results in increased expression of GEM mRNA

NCBI chr 5:30,011,641...30,022,554
Ensembl chr 5:25,214,309...25,225,222

G

gem (nuclear organelle) associated protein 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GEMIN2 mRNA
Coumestrol results in increased expression of GEMIN2 mRNA

NCBI chr 6:82,442,419...82,456,050
Ensembl chr 6:76,707,523...76,721,153

G

gem (nuclear organelle) associated protein 4

increases expression

Coumestrol results in increased expression of GEMIN4 mRNA

NCBI chr10:61,560,172...61,571,765
Ensembl chr10:61,066,425...61,073,431
Ensembl chr10:61,066,425...61,073,431

G

gem (nuclear organelle) associated protein 6

increases expression

Coumestrol results in increased expression of GEMIN6 mRNA

NCBI chr 6:20,538,325...20,542,867
Ensembl chr 6:14,786,070...14,790,612

G

GDNF family receptor alpha 1

increases expression
multiple interactions

Coumestrol results in increased expression of GFRA1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GFRA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GFRA1 mRNA

NCBI chr 1:267,325,297...267,557,037
Ensembl chr 1:257,321,742...257,551,473

G

golgi associated, gamma adaptin ear containing, ARF binding protein 2

increases expression

Coumestrol results in increased expression of GGA2 mRNA

NCBI chr 1:185,983,302...186,016,582
Ensembl chr 1:176,552,046...176,585,361

G

gamma-glutamyl cyclotransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GGCT mRNA

NCBI chr 4:85,453,387...85,459,597
Ensembl chr 4:84,123,118...84,129,277

G

gamma-glutamyl hydrolase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GGH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GGH mRNA
Coumestrol results in increased expression of GGH mRNA

NCBI chr 5:38,326,747...38,349,655
Ensembl chr 5:33,529,880...33,552,787

G

GINS complex subunit 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GINS1 mRNA
Coumestrol results in increased expression of GINS1 mRNA

NCBI chr 3:160,184,920...160,206,334
Ensembl chr 3:139,724,490...139,745,936

G

GINS complex subunit 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GINS2 mRNA
Coumestrol results in increased expression of GINS2 mRNA

NCBI chr19:65,535,492...65,548,270
Ensembl chr19:48,626,770...48,639,339

G

GINS complex subunit 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GINS3 mRNA
Coumestrol results in increased expression of GINS3 mRNA

NCBI chr19:9,420,085...9,428,621
Ensembl chr19:9,420,086...9,428,687

G

GINS complex subunit 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS4 mRNA

NCBI chr16:68,787,572...68,799,938
Ensembl chr16:68,767,339...68,802,273

G

galactosidase, alpha

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of GLA mRNA
Coumestrol results in increased expression of GLA mRNA

NCBI chr X:102,062,497...102,073,915
Ensembl chr X:97,768,996...97,780,664

G

GLE1 RNA export mediator

increases expression
multiple interactions

Coumestrol results in increased expression of GLE1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GLE1 mRNA

NCBI chr 3:33,607,160...33,638,879
Ensembl chr 3:13,209,322...13,237,379

G

glomulin, FKBP associated protein

increases expression

Coumestrol results in increased expression of GLMN mRNA

NCBI chr14:2,332,052...2,375,366
Ensembl chr14:2,187,642...2,230,420

G

glycosylated lysosomal membrane protein

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of GLMP mRNA

NCBI chr 2:173,794,273...173,797,863
Ensembl chr 2:173,794,255...173,799,960

G

glutaminase

decreases expression

Coumestrol results in decreased expression of GLS mRNA

NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:49,344,781...49,416,900

G

geminin, DNA replication inhibitor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GMNN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GMNN mRNA
Coumestrol results in increased expression of GMNN mRNA

NCBI chr17:40,729,760...40,738,077
Ensembl chr17:40,301,808...40,310,054

G

guanine monophosphate synthase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GMPS mRNA

NCBI chr 2:150,587,824...150,641,564
Ensembl chr 2:148,435,643...148,485,875

G

G protein subunit alpha i1

decreases expression

Coumestrol results in decreased expression of GNAI1 mRNA

NCBI chr 4:17,706,061...17,790,176
Ensembl chr 4:16,814,001...16,896,417

G

G protein subunit alpha q

decreases expression

Coumestrol results in decreased expression of GNAQ mRNA

NCBI chr 1:222,852,453...223,098,754
Ensembl chr 1:213,424,465...213,667,672

G

G protein nucleolar 3 like

decreases expression

Coumestrol results in decreased expression of GNL3L mRNA

NCBI chr X:23,404,324...23,437,501
Ensembl chr X:19,958,603...19,994,508

G

glucosamine (N-acetyl)-6-sulfatase

decreases expression

Coumestrol results in decreased expression of GNS mRNA

NCBI chr 7:58,774,625...58,808,650
Ensembl chr 7:56,889,232...56,923,151

G

golgin A2

decreases expression
multiple interactions

Coumestrol results in decreased expression of GOLGA2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GOLGA2 mRNA

NCBI chr 3:35,981,783...36,002,023
Ensembl chr 3:15,584,039...15,604,279

G

glutamic-oxaloacetic transaminase 1

increases expression
multiple interactions

Coumestrol results in increased expression of GOT1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GOT1 mRNA

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:242,357,306...242,380,633

G

glycosylphosphatidylinositol anchor attachment 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPAA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GPAA1 mRNA

NCBI chr 7:108,051,896...108,055,479
Ensembl chr 7:108,051,861...108,055,484

G

glycerol-3-phosphate acyltransferase 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPAT4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GPAT4 mRNA

NCBI chr16:68,819,031...68,852,903
Ensembl chr16:68,819,079...68,852,901

G

G patch domain containing 11

increases expression

Coumestrol results in increased expression of GPATCH11 mRNA

NCBI chr 6:16,229,933...16,243,305
Ensembl chr 6:16,233,059...16,243,238

G

G patch domain containing 2-like

decreases expression

Coumestrol results in decreased expression of GPATCH2L mRNA

NCBI chr 6:111,614,344...111,666,603
Ensembl chr 6:105,883,460...105,934,888

G

G patch domain containing 4

increases expression

Coumestrol results in increased expression of GPATCH4 mRNA

NCBI chr 2:175,797,503...175,816,547
Ensembl chr 2:173,509,897...173,518,684

G

glycerol-3-phosphate dehydrogenase 2

increases expression

Coumestrol results in increased expression of GPD2 mRNA

NCBI chr 3:62,209,432...62,346,590
Ensembl chr 3:41,801,930...41,936,901

G

G protein-coupled estrogen receptor 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of GPER1 mRNA

NCBI chr12:20,331,073...20,336,527
Ensembl chr12:15,217,442...15,221,889

G

G protein-coupled receptor 137B

decreases expression

Coumestrol results in decreased expression of GPR137B mRNA

NCBI chr17:92,987,792...93,026,003
Ensembl chr17:85,966,921...86,041,835

G

G protein-coupled receptor 160

decreases expression

Coumestrol results in decreased expression of GPR160 mRNA

NCBI chr 2:114,414,084...114,491,590
Ensembl chr 2:112,484,935...112,563,148

G

G protein-coupled receptor, class C, group 5, member A

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GPRC5A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GPRC5A mRNA
Coumestrol results in decreased expression of GPRC5A mRNA

NCBI chr 4:169,634,896...169,653,627
Ensembl chr 4:167,903,542...167,922,260

G

G protein-coupled receptor, class C, group 5, member C

decreases expression
multiple interactions

Coumestrol results in decreased expression of GPRC5C mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GPRC5C mRNA

NCBI chr10:100,385,682...100,407,953
Ensembl chr10:99,887,077...99,908,926

G

G-protein signaling modulator 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPSM2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GPSM2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA]
Coumestrol results in increased expression of GPSM2 mRNA

PMID:18310284 PMID:19167446

NCBI chr 2:199,015,250...199,063,788
Ensembl chr 2:196,327,149...196,375,154

G

glutathione peroxidase 8

increases expression
multiple interactions

Coumestrol results in increased expression of GPX8 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of GPX8 mRNA

NCBI chr 2:46,409,646...46,413,401
Ensembl chr 2:44,676,454...44,680,195

G

GRAM domain containing 1A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GRAMD1A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GRAMD1A mRNA

NCBI chr 1:86,367,001...86,393,348
Ensembl chr 1:86,367,001...86,393,336

G

growth factor receptor bound protein 10

decreases expression

Coumestrol results in decreased expression of GRB10 mRNA

NCBI chr14:90,708,653...90,816,399
Ensembl chr14:86,495,054...86,602,806

G

growth regulating estrogen receptor binding 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GREB1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GREB1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA]
Coumestrol results in increased expression of GREB1 mRNA

PMID:18310284 PMID:19167446 PMID:35307500

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

grainyhead-like transcription factor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GRHL3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GRHL3 mRNA

NCBI chr 5:153,057,760...153,089,890
Ensembl chr 5:147,774,160...147,806,160

G

G protein-coupled receptor kinase 6

increases expression

Coumestrol results in increased expression of GRK6 mRNA

NCBI chr17:9,182,160...9,198,380
Ensembl chr17:9,177,019...9,192,644

G

granulin precursor

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of GRN mRNA

NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,387,638...87,393,775

G

GrpE-like 1, mitochondrial

increases expression

Coumestrol results in increased expression of GRPEL1 mRNA

NCBI chr14:78,517,049...78,522,868
Ensembl chr14:74,292,023...74,298,200

G

general transcription factor 2H subunit 4

increases expression

Coumestrol results in increased expression of GTF2H4 mRNA

NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984

G

GTF2I repeat domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GTF2IRD1 mRNA

NCBI chr12:22,254,113...22,361,052
Ensembl chr12:22,254,221...22,361,040

G

G-2 and S-phase expressed 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GTSE1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GTSE1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA]
Coumestrol results in increased expression of GTSE1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 7:118,829,793...118,846,662
Ensembl chr 7:116,950,053...116,966,806

G

GULP PTB domain containing engulfment adaptor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GULP1 mRNA
Coumestrol results in decreased expression of GULP1 mRNA

NCBI chr 9:54,114,823...54,391,058
Ensembl chr 9:46,622,669...46,899,005

G

H1.2 linker histone, cluster member

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H1-2 mRNA
Coumestrol results in decreased expression of H1-2 mRNA

NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,388,477...41,392,635

G

H2A clustered histone 25

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2AC25 mRNA

NCBI chr10:44,233,283...44,234,835
Ensembl chr10:43,733,668...43,744,874

G

H2A.X variant histone

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AX mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of H2AX mRNA
Coumestrol results in increased expression of H2AX mRNA; Coumestrol results in increased expression of H2AX protein modified form

PMID:19167446 PMID:28986287

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

H2A.Z variant histone 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AZ1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of H2AZ1 mRNA
Coumestrol results in increased expression of H2AZ1 mRNA

NCBI chr 2:229,026,464...229,031,411
Ensembl chr 2:226,355,708...226,358,485

G

H2A.Z variant histone 2

increases expression
multiple interactions

Coumestrol results in increased expression of H2AZ2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AZ2 mRNA

NCBI chr14:81,293,304...81,312,209
Ensembl chr14:81,293,299...81,312,144
Ensembl chr 4:81,293,299...81,312,144
Ensembl chr16:81,293,299...81,312,144

G

H2B clustered histone 12

decreases expression

Coumestrol results in decreased expression of H2BC12 mRNA

NCBI chr17:42,485,699...42,486,162

G

H2B clustered histone 6

decreases expression

Coumestrol results in decreased expression of H2BC6 mRNA

NCBI chr17:41,948,813...41,949,276

G

H2B clustered histone 8

decreases expression
multiple interactions

Coumestrol results in decreased expression of H2BC8 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC8 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of H2BC8 mRNA

NCBI chr17:47,404,405...47,405,155

G

H2B clustered histone 9

decreases expression
multiple interactions

Coumestrol results in decreased expression of H2BC9 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC9 mRNA

NCBI chr17:42,470,593...42,478,590

G

H3.3 histone B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H3-3B mRNA

NCBI chr10:101,755,404...101,764,616
Ensembl chr10:101,256,480...101,258,709
Ensembl chr13:101,256,480...101,258,709

G

hydroxyacyl-CoA dehydrogenase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HADH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HADH mRNA
Coumestrol results in increased expression of HADH mRNA

NCBI chr 2:222,462,049...222,504,446
Ensembl chr 2:219,787,927...219,830,353

G

histone H3 associated protein kinase

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of HASPIN mRNA

NCBI chr10:58,246,244...58,249,031
Ensembl chr10:57,747,573...57,750,512

G

histone acetyltransferase 1

increases expression

Coumestrol results in increased expression of HAT1 mRNA

NCBI chr 3:76,624,442...76,672,701
Ensembl chr 3:56,217,342...56,275,517

G

HAUS augmin-like complex, subunit 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HAUS1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HAUS1 mRNA
Coumestrol results in increased expression of HAUS1 mRNA

NCBI chr18:73,550,549...73,561,757
Ensembl chr18:71,273,537...71,286,660

G

HAUS augmin like complex subunit 2

decreases expression

Coumestrol results in decreased expression of HAUS2 mRNA

NCBI chr 3:128,006,894...128,019,730
Ensembl chr 3:107,553,161...107,565,157

G

HAUS augmin-like complex, subunit 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HAUS4 mRNA

NCBI chr15:31,964,555...31,976,853
Ensembl chr15:27,994,532...28,005,938

G

HAUS augmin-like complex, subunit 7

increases expression

Coumestrol results in increased expression of HAUS7 mRNA

NCBI chr X:151,154,979...151,174,441
Ensembl chr X:151,154,979...151,180,577

G

HAUS augmin-like complex, subunit 8

increases expression
multiple interactions

Coumestrol results in increased expression of HAUS8 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of HAUS8 mRNA

NCBI chr16:17,930,819...17,945,254
Ensembl chr16:17,930,820...17,945,237

G

HMG-box transcription factor 1

decreases expression

Coumestrol results in decreased expression of HBP1 mRNA

NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787

G

heme binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HEBP1 mRNA

NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854

G

HECT domain E3 ubiquitin protein ligase 3

decreases expression

Coumestrol results in decreased expression of HECTD3 mRNA

NCBI chr 5:130,469,840...130,479,802
Ensembl chr 5:130,469,840...130,478,561

G

helicase, lymphoid specific

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HELLS mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HELLS mRNA
Coumestrol results in increased expression of HELLS mRNA

NCBI chr 1:246,113,580...246,159,230
Ensembl chr 1:236,701,758...236,746,844

G

helicase with zinc finger 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of HELZ2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HELZ2 mRNA

NCBI chr 3:188,716,370...188,730,776
Ensembl chr 3:168,338,813...168,353,159

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HERC1 mRNA

NCBI chr 8:75,796,347...75,965,347
Ensembl chr 8:66,856,935...67,070,312

G

HERPUD family member 2

decreases expression

Coumestrol results in decreased expression of HERPUD2 mRNA

NCBI chr 8:31,849,216...31,894,219
Ensembl chr 8:23,573,379...23,617,874

G

hes family bHLH transcription factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HES1 mRNA

NCBI chr11:84,210,632...84,213,045
Ensembl chr11:70,705,764...70,708,192

G

homeodomain interacting protein kinase 1

decreases expression

Coumestrol results in decreased expression of HIPK1 mRNA

NCBI chr 2:191,248,817...191,299,787
Ensembl chr 2:191,248,817...191,298,902

G

homeodomain interacting protein kinase 2

decreases expression

Coumestrol results in decreased expression of HIPK2 mRNA

NCBI chr 4:68,399,358...68,586,404
Ensembl chr 4:67,440,501...67,619,223

G

HIRA interacting protein 3

increases expression
multiple interactions

Coumestrol results in increased expression of HIRIP3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HIRIP3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HIRIP3 mRNA

NCBI chr 1:190,903,065...190,905,610
Ensembl chr 1:181,472,056...181,475,079

G

histone cluster 1 H2A family member F

decreases expression
multiple interactions

Coumestrol results in decreased expression of H2AC8 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2AC8 mRNA

NCBI chr17:41,807,261...41,807,653
Ensembl chr17:41,379,404...41,379,796

G

histone cluster 1 H2A family member H

decreases expression

Coumestrol results in decreased expression of H2AC11 mRNA

NCBI chr17:41,384,521...41,385,018

G

histone cluster 1 H2A family like 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of H2AC6 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2AC6 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of H2AC6 mRNA

NCBI chr17:47,403,701...47,404,167

G

histone cluster 1, H2bc

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC21 mRNA
Coumestrol results in decreased expression of H2BC21 mRNA

NCBI chr17:42,692,335...42,696,601
Ensembl chr17:42,694,723...42,696,642

G

histone cluster 1 H2B family member D

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC5 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of H2BC5 mRNA
Coumestrol results in decreased expression of H2BC5 mRNA

NCBI chr17:42,792,887...42,793,268

G

histone cluster 1 H2B family member Q

decreases expression

Coumestrol results in decreased expression of H2BC7 mRNA

NCBI chr17:41,432,100...41,441,487
Ensembl chr17:41,429,164...41,442,153
Ensembl chr17:41,429,164...41,442,153
Ensembl chr17:41,429,164...41,442,153

G

HIVEP zinc finger 1

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of HIVEP1 mRNA
Coumestrol results in decreased expression of HIVEP1 mRNA

NCBI chr17:22,585,016...22,714,517
Ensembl chr17:22,585,016...22,711,956

G

Holliday junction recognition protein

increases expression
multiple interactions

Coumestrol results in increased expression of HJURP mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HJURP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HJURP mRNA

NCBI chr 9:88,853,379...88,867,730
Ensembl chr 9:88,853,386...88,867,728

G

high mobility group AT-hook 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMGA1 mRNA

NCBI chr20:5,612,902...5,620,596
Ensembl chr20:5,611,694...5,618,752

G

high mobility group box 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMGB1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HMGB1 mRNA
Coumestrol results in increased expression of HMGB1 mRNA

NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group box 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMGB2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HMGB2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA]
Coumestrol results in increased expression of HMGB2 mRNA

PMID:18310284 PMID:19167446

NCBI chr16:37,721,374...37,723,950
Ensembl chr16:32,710,658...32,713,140
Ensembl chr 1:32,710,658...32,713,140

G

high mobility group nucleosomal binding domain 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMGN3 mRNA

NCBI chr 8:84,022,493...84,059,329
Ensembl chr 8:84,022,495...84,062,976

G

hyaluronan-mediated motility receptor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HMMR mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA]
Coumestrol results in increased expression of HMMR mRNA

PMID:18310284 PMID:19167446

NCBI chr10:25,635,249...25,665,389
Ensembl chr10:25,132,977...25,163,060

G

heterogeneous nuclear ribonucleoprotein H1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HNRNPH1 mRNA

NCBI chr10:35,187,412...35,203,909
Ensembl chr10:34,693,555...34,702,846

G

heterogeneous nuclear ribonucleoprotein H3

increases expression

Coumestrol results in increased expression of HNRNPH3 mRNA

NCBI chr20:25,619,540...25,624,397
Ensembl chr20:25,614,733...25,625,750

G

heterogeneous nuclear ribonucleoprotein M

increases expression

Coumestrol results in increased expression of HNRPM mRNA

NCBI chr 7:15,140,877...15,178,871
Ensembl chr 7:14,438,688...14,476,762

G

heterogeneous nuclear ribonucleoprotein U

increases expression

Coumestrol results in increased expression of HNRNPU mRNA

NCBI chr13:92,609,791...92,618,580
Ensembl chr13:90,074,181...90,086,588

G

homeobox C13

decreases expression

Coumestrol results in decreased expression of HOXC13 mRNA

NCBI chr 7:134,058,640...134,065,479
Ensembl chr 7:134,058,640...134,064,800

G

homeo box C6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HOXC6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HOXC6 mRNA

NCBI chr 7:134,138,017...134,148,899
Ensembl chr 7:134,135,502...134,148,392

G

hypoxanthine phosphoribosyltransferase 1

increases expression
multiple interactions

Coumestrol results in increased expression of HPRT1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HPRT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HPRT1 mRNA

NCBI chr X:137,655,744...137,687,718
Ensembl chr X:132,736,096...132,768,154

G

heparan sulfate 6-O-sulfotransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HS6ST2 mRNA

NCBI chr X:130,966,547...131,261,629
Ensembl chr X:130,968,385...131,261,492

G

hydroxysteroid (17-beta) dehydrogenase 6

increases expression
multiple interactions

Coumestrol results in increased expression of HSD17B6 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HSD17B6 mRNA

NCBI chr 7:831,407...850,950
Ensembl chr 7:422,480...442,425

G

hydroxysteroid (17-beta) dehydrogenase 8

increases expression

Coumestrol results in increased expression of HSD17B8 mRNA

NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742

G

heat shock protein 90 alpha family class A member 1

increases expression

Coumestrol results in increased expression of HSP90AA1 protein

NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein 90 alpha family class B member 1

increases expression

Coumestrol results in increased expression of HSP90AB1 mRNA; Coumestrol results in increased expression of HSP90AB1 protein

NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein 90 beta family member 1

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of HSP90B1 mRNA
Coumestrol results in increased expression of HSP90B1 mRNA
Coumestrol results in increased expression of HSP90B1 protein

PMID:12460799 PMID:19167446

NCBI chr 7:22,997,962...23,012,293
Ensembl chr 7:21,110,457...21,124,788

G

heat shock protein family A (Hsp70) member 1A

increases expression

Coumestrol results in increased expression of HSPA1A protein

NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 4 like

increases expression
multiple interactions

Coumestrol results in increased expression of HSPA4L mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HSPA4L mRNA

NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084

G

heat shock protein family A (Hsp70) member 9

increases expression

Coumestrol results in increased expression of HSPA9 mRNA

NCBI chr18:26,810,004...26,832,958
Ensembl chr18:26,535,798...26,554,292

G

hyccin PI4KA lipid kinase complex subunit 2

decreases expression

Coumestrol results in decreased expression of HYCC2 mRNA

NCBI chr 9:60,056,883...60,129,176
Ensembl chr 9:60,056,890...60,093,007

G

HYLS1, centriolar and ciliogenesis associated

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HYLS1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of HYLS1 mRNA
Coumestrol results in increased expression of HYLS1 mRNA

NCBI chr 8:33,912,692...33,921,760
Ensembl chr 8:33,912,692...33,921,760

G

Huntingtin interacting protein K

increases expression

Coumestrol results in increased expression of HYPK mRNA

NCBI chr 3:128,888,709...128,890,089
Ensembl chr 3:108,432,539...108,436,370

G

islet cell autoantigen 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ICA1 mRNA

NCBI chr 4:37,622,759...37,771,055
Ensembl chr 4:36,656,475...36,804,298

G

interactor of little elongation complex ELL subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ICE1 mRNA

NCBI chr 1:34,468,839...34,508,346
Ensembl chr 1:32,640,407...32,679,898

G

isoprenylcysteine carboxyl methyltransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ICMT mRNA

NCBI chr 5:168,084,487...168,097,519
Ensembl chr 5:162,804,368...162,811,128

G

inhibitor of DNA binding 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ID3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ID3 mRNA
Coumestrol results in decreased expression of ID3 mRNA

NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:148,372,762...148,374,349

G

isopentenyl-diphosphate delta isomerase 1

decreases expression

Coumestrol results in decreased expression of IDI1 mRNA

NCBI chr17:66,539,761...66,547,524
Ensembl chr17:61,629,594...61,637,357

G

iduronate 2-sulfatase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IDS mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of IDS mRNA

NCBI chr X:149,025,976...149,046,641
Ensembl chr X:149,025,976...149,046,663

G

immediate early response 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IER2 mRNA

NCBI chr19:40,399,373...40,400,897
Ensembl chr19:23,494,184...23,499,211

G

immediate early response 3

increases expression

Coumestrol results in increased expression of IER3 mRNA

NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,928,378...2,929,583

G

immediate early response 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IER5 mRNA

NCBI chr13:69,820,450...69,822,542
Ensembl chr13:67,270,135...67,272,227

G

immediate early response 5-like

decreases expression

Coumestrol results in decreased expression of IER5L mRNA

NCBI chr 3:13,744,056...13,745,647
Ensembl chr 3:13,744,078...13,745,647

G

interferon-induced protein 44-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFI44L mRNA

NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359

G

interferon-induced protein with tetratricopeptide repeats 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFIT2 mRNA

NCBI chr 1:241,515,735...241,521,799
Ensembl chr 1:232,102,570...232,108,635

G

interferon-related developmental regulator 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IFRD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of IFRD2 mRNA
Coumestrol results in increased expression of IFRD2 mRNA

NCBI chr 8:117,139,612...117,144,834
Ensembl chr 8:108,260,969...108,266,194

G

intraflagellar transport 122

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFT122 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of IFT122 mRNA
Coumestrol results in decreased expression of IFT122 mRNA

NCBI chr 4:150,577,525...150,648,052
Ensembl chr 4:148,905,046...148,975,458

G

intraflagellar transport 20

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFT20 mRNA

NCBI chr10:63,930,629...63,936,174
Ensembl chr10:63,432,633...63,438,124

G

intraflagellar transport 43

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFT43 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of IFT43 mRNA

NCBI chr 6:105,729,734...105,806,257
Ensembl chr 6:105,729,792...105,806,257

G

insulin-like growth factor 1

multiple interactions

[Fulvestrant co-treated with Coumestrol] results in decreased expression of IGF1 mRNA

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IGFBP2 mRNA

NCBI chr 9:81,864,811...81,892,179
Ensembl chr 9:74,415,546...74,442,937

G

insulin-like growth factor binding protein 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IGFBP4 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA]

PMID:18310284 PMID:19167446

NCBI chr10:84,491,471...84,503,487
Ensembl chr10:83,989,591...84,007,225

G

insulin-like growth factor binding protein 5

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IGFBP5 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of IGFBP5 mRNA
Coumestrol results in decreased expression of IGFBP5 mRNA

NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:74,448,382...74,465,156

G

IGF-like family receptor 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IGFLR1 mRNA
Coumestrol results in increased expression of IGFLR1 mRNA

NCBI chr 1:85,818,428...85,821,032
Ensembl chr 1:85,816,326...85,821,030

G

interleukin 17 receptor B

multiple interactions
increases expression

[Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of IL17RB mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA]
Coumestrol results in increased expression of IL17RB mRNA

PMID:18310284 PMID:19167446

NCBI chr16:5,186,961...5,200,657
Ensembl chr16:5,180,432...5,194,125

G

interleukin 1 receptor type 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IL1R1 mRNA

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:42,504,735...42,579,937

G

interleukin 2

decreases expression

Coumestrol results in decreased expression of IL2 mRNA; Coumestrol results in decreased expression of IL2 protein

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 20

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IL20 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of IL20 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA]
Coumestrol results in increased expression of IL20 mRNA

PMID:18310284 PMID:19167446

NCBI chr13:44,933,249...44,936,893
Ensembl chr13:42,380,981...42,384,625

G

interleukin 6

multiple interactions

Coumestrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 6 cytokine family signal transducer

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of IL6ST mRNA

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:44,066,130...44,109,936

G

interleukin enhancer binding factor 2

increases expression
multiple interactions

Coumestrol results in increased expression of ILF2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ILF2 mRNA

NCBI chr 2:175,952,174...175,971,191
Ensembl chr 2:175,952,186...175,971,337

G

ilvB acetolactate synthase like

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ILVBL mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ILVBL mRNA
Coumestrol results in increased expression of ILVBL mRNA

NCBI chr 7:11,039,870...11,049,924
Ensembl chr 7:11,039,871...11,049,924

G

inner mitochondrial membrane peptidase subunit 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of IMMP1L mRNA

NCBI chr 3:112,840,015...112,904,297
Ensembl chr 3:92,385,379...92,452,313

G

IMP U3 small nucleolar ribonucleoprotein 4

increases expression

Coumestrol results in increased expression of IMP4 mRNA

NCBI chr 9:36,654,127...36,659,265
Ensembl chr 9:36,654,401...36,660,075

G

inositol monophosphatase 2

increases expression

Coumestrol results in increased expression of IMPA2 mRNA

NCBI chr18:63,104,113...63,135,232
Ensembl chr18:60,834,246...60,865,641

G

inner centromere protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of INCENP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of INCENP mRNA
Coumestrol results in increased expression of INCENP mRNA

NCBI chr 1:215,945,558...216,017,247
Ensembl chr 1:206,523,380...206,553,265

G

inhibin subunit beta B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of INHBB mRNA

NCBI chr13:33,083,671...33,089,373
Ensembl chr13:30,530,860...30,537,832

G

INO80 complex subunit E

increases expression
multiple interactions

Coumestrol results in increased expression of INO80E mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of INO80E mRNA

NCBI chr 1:190,891,315...190,902,902
Ensembl chr 1:181,461,408...181,472,469

G

inositol polyphosphate-4-phosphatase type II B

decreases expression

Coumestrol results in decreased expression of INPP4B mRNA

NCBI chr19:42,824,710...43,575,039
Ensembl chr19:25,925,358...26,280,634

G

insulin induced gene 1

increases expression
multiple interactions

Coumestrol results in increased expression of INSIG1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of INSIG1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of INSIG1 mRNA

NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:7,315,495...7,323,952

G

integrator complex subunit 7

increases expression
multiple interactions

Coumestrol results in increased expression of INTS7 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of INTS7 mRNA

NCBI chr13:105,686,208...105,739,609
Ensembl chr13:103,155,090...103,208,592

G

inositol hexakisphosphate kinase 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IP6K2 mRNA
Coumestrol results in decreased expression of IP6K2 mRNA

NCBI chr 8:118,362,154...118,388,668
Ensembl chr 8:109,484,310...109,510,166

G

importin 9

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of IPO9 mRNA
Coumestrol results in increased expression of IPO9 mRNA

NCBI chr13:49,362,244...49,414,477
Ensembl chr13:46,813,171...46,862,673

G

IQ motif containing K

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IQCK mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of IQCK mRNA
Coumestrol results in decreased expression of IQCK mRNA

NCBI chr 1:173,199,308...173,316,982
Ensembl chr 1:173,199,316...173,316,984

G

IQ motif containing GTPase activating protein 3

increases expression
multiple interactions

Coumestrol results in increased expression of IQGAP3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IQGAP3 mRNA

NCBI chr 2:175,840,001...175,881,799
Ensembl chr 2:173,542,110...173,583,956

G

interferon regulatory factor 2 binding protein 2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of IRF2BP2 mRNA
Coumestrol results in decreased expression of IRF2BP2 mRNA

NCBI chr19:71,456,689...71,462,368
Ensembl chr19:54,560,128...54,566,642

G

interferon regulatory factor 6

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IRF6 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of IRF6 mRNA
Coumestrol results in decreased expression of IRF6 mRNA

NCBI chr13:107,200,876...107,220,083
Ensembl chr13:104,672,179...104,691,386

G

interferon regulatory factor 9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IRF9 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of IRF9 mRNA

NCBI chr15:33,065,422...33,071,881
Ensembl chr15:29,095,789...29,101,236

G

insulin receptor substrate 1

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA]

NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:83,548,944...83,606,122

G

insulin receptor substrate 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IRS2 mRNA
Coumestrol results in decreased expression of IRS2 mRNA

NCBI chr16:85,190,310...85,214,543
Ensembl chr16:78,485,045...78,512,482

G

inositol-3-phosphate synthase 1

increases expression
multiple interactions

Coumestrol results in increased expression of ISYNA1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ISYNA1 mRNA

NCBI chr16:18,873,119...18,876,116
Ensembl chr16:18,839,145...18,841,979

G

integrin subunit alpha 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ITGA2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ITGA2 mRNA

NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha E

increases expression
multiple interactions

Coumestrol results in increased expression of ITGAE mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ITGAE mRNA

NCBI chr10:58,203,331...58,262,606
Ensembl chr10:57,591,753...57,764,093
Ensembl chr10:57,591,753...57,764,093

G

integrin subunit beta 3 binding protein

increases expression
multiple interactions

Coumestrol results in increased expression of ITGB3BP mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ITGB3BP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ITGB3BP mRNA

NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704

G

inositol 1,4,5-trisphosphate receptor, type 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ITPR1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ITPR1 mRNA
Coumestrol results in decreased expression of ITPR1 mRNA

NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:141,187,418...141,510,491

G

influenza virus NS1A binding protein

increases expression

Coumestrol results in increased expression of IVNS1ABP mRNA

NCBI chr13:65,977,069...65,996,685
Ensembl chr13:63,427,041...63,446,701

G

jagged canonical Notch ligand 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of JAG1 mRNA
Coumestrol results in decreased expression of JAG1 mRNA

NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:124,406,794...124,442,209

G

junction mediating and regulatory protein, p53 cofactor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of JMY mRNA

NCBI chr 2:26,401,047...26,465,959
Ensembl chr 2:24,668,854...24,731,006

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of JUN mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of JUN mRNA
Coumestrol results in decreased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of JUNB mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of JUNB mRNA
Coumestrol results in decreased expression of JUNB mRNA

NCBI chr19:40,081,126...40,082,910
Ensembl chr19:23,176,294...23,178,035

G

junction plakoglobin

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of JUP mRNA
Coumestrol results in decreased expression of JUP mRNA

NCBI chr10:85,800,812...85,827,881
Ensembl chr10:85,300,440...85,327,057

G

lysine acetyltransferase 2B

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of KAT2B mRNA
Coumestrol results in decreased expression of KAT2B mRNA

NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,562,288...6,667,064

G

lysine acetyltransferase 6A

decreases expression

Coumestrol results in decreased expression of KAT6A mRNA

NCBI chr16:75,787,411...75,868,584
Ensembl chr16:69,084,914...69,163,606

G

katanin catalytic subunit A1 like 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of KATNAL1 mRNA

NCBI chr12:6,094,663...6,156,114
Ensembl chr12:6,102,836...6,157,553

G

katanin interacting protein

decreases expression

Coumestrol results in decreased expression of KATNIP mRNA

NCBI chr 1:180,270,194...180,436,766
Ensembl chr 1:180,269,929...180,436,766

G

potassium two pore domain channel subfamily K member 5

multiple interactions
increases expression

[Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA]
Coumestrol results in increased expression of KCNK5 mRNA

PMID:18310284 PMID:19167446

NCBI chr15:4,171,625...4,213,896
Ensembl chr15:4,122,442...4,164,718

G

potassium channel tetramerization domain containing 9

increases expression

Coumestrol results in increased expression of KCTD9 mRNA

NCBI chr15:46,117,211...46,145,258
Ensembl chr15:41,942,381...41,969,862

G

lysine demethylase 1A

increases expression

Coumestrol results in increased expression of KDM1A mRNA

NCBI chr 5:154,066,436...154,121,913
Ensembl chr 5:148,782,976...148,838,319

G

lysine demethylase 1B

decreases expression

Coumestrol results in decreased expression of KDM1B mRNA

NCBI chr17:17,809,232...17,850,141
Ensembl chr17:17,602,961...17,643,800

G

lysine demethylase 3A

decreases expression

Coumestrol results in decreased expression of KDM3A mRNA

NCBI chr 4:105,189,208...105,233,526
Ensembl chr 4:103,630,908...103,675,073

G

lysine demethylase 5A

decreases expression
multiple interactions

Coumestrol results in decreased expression of KDM5A mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of KDM5A mRNA

NCBI chr 4:155,238,124...155,316,121
Ensembl chr 4:153,565,846...153,642,422

G

lysine demethylase 5B

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KDM5B mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of KDM5B mRNA
Coumestrol results in decreased expression of KDM5B mRNA

NCBI chr13:48,554,367...48,625,721
Ensembl chr13:46,002,542...46,073,872

G

KIAA0586 homolog

increases expression

Coumestrol results in increased expression of KIAA0586 mRNA

NCBI chr 6:89,622,711...89,725,951
Ensembl chr 6:89,623,699...89,725,962

G

KIAA1191 homolog

decreases expression

Coumestrol results in decreased expression of KIAA1191 mRNA

NCBI chr17:10,049,142...10,061,819
Ensembl chr17:10,049,160...10,061,819

G

kinase D-interacting substrate 220

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KIDINS220 mRNA

NCBI chr 6:47,346,790...47,435,599
Ensembl chr 6:41,618,294...41,703,256

G

kinesin family member 11

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF11 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of KIF11 mRNA
Coumestrol results in increased expression of KIF11 mRNA

NCBI chr 1:244,494,916...244,589,250
Ensembl chr 1:235,124,316...235,176,766

G

kinesin family member 14

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF14 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of KIF14 mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA]
Coumestrol results in increased expression of KIF14 mRNA

PMID:18310284 PMID:19167446

NCBI chr13:50,478,646...50,542,256
Ensembl chr13:47,927,044...47,989,164

G

kinesin family member 15

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA]

NCBI chr 8:131,479,340...131,550,209
Ensembl chr 8:122,601,897...122,672,750

G

kinesin family member 18A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF18A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of KIF18A mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA]
Coumestrol results in increased expression of KIF18A mRNA

PMID:18310284 PMID:19167446

NCBI chr 3:116,219,007...116,279,378
Ensembl chr 3:95,764,388...95,824,582

G

kinesin family member 18B

increases expression

Coumestrol results in increased expression of KIF18B mRNA

NCBI chr10:88,370,520...88,392,388
Ensembl chr10:87,870,428...87,889,850

G

kinesin family member 20A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF20A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of KIF20A mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA]
Coumestrol results in increased expression of KIF20A mRNA

PMID:18310284 PMID:19167446

NCBI chr18:26,504,422...26,512,908
Ensembl chr18:26,230,230...26,238,780

G

kinesin family member 2C

increases expression
multiple interactions

Coumestrol results in increased expression of KIF2C mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF2C mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of KIF2C mRNA

NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:130,637,347...130,662,637

G

kinesin family member 5C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KIF5C mRNA

NCBI chr 3:54,441,266...54,591,630
Ensembl chr 3:34,032,105...34,182,413

G

kinesin family member C1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIFC1 mRNA
Coumestrol results in increased expression of KIFC1 mRNA

NCBI chr20:5,000,929...5,018,967
Ensembl chr20:4,999,047...5,017,105

G

KLF transcription factor 12

decreases expression
multiple interactions

Coumestrol results in decreased expression of KLF12 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLF12 mRNA

NCBI chr15:83,037,548...83,469,998
Ensembl chr15:76,637,654...77,062,056

G

KLF transcription factor 4

decreases expression

Coumestrol results in decreased expression of KLF4 mRNA

NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:70,278,972...70,283,602

G

KLF transcription factor 6

decreases expression
multiple interactions

Coumestrol results in decreased expression of KLF6 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLF6 mRNA

NCBI chr17:69,449,483...69,458,478
Ensembl chr17:64,531,463...64,588,570

G

KLF transcription factor 9

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLF9 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of KLF9 mRNA
Coumestrol results in decreased expression of KLF9 mRNA

NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:220,700,108...220,725,037

G

kelch domain containing 10

decreases expression

Coumestrol results in decreased expression of KLHDC10 mRNA

NCBI chr 4:59,988,710...60,046,518
Ensembl chr 4:59,021,310...59,074,941

G

kelch domain containing 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KLHDC3 mRNA

NCBI chr 9:21,799,870...21,806,337
Ensembl chr 9:14,302,354...14,308,736

G

kelch-like family member 24

decreases expression
multiple interactions

Coumestrol results in decreased expression of KLHL24 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLHL24 mRNA

NCBI chr11:94,348,024...94,382,085
Ensembl chr11:80,846,755...80,877,636

G

kelch-like family member 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLHL5 mRNA

NCBI chr14:43,497,915...43,565,833
Ensembl chr14:43,144,257...43,184,238

G

killer cell lectin like receptor G2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of KLRG2 mRNA

NCBI chr 4:67,360,216...67,374,867
Ensembl chr 4:67,363,919...67,374,147

G

lysine methyltransferase 2D

decreases expression

Coumestrol results in decreased expression of KMT2D mRNA

NCBI chr 7:131,859,696...131,901,032
Ensembl chr 7:129,962,887...130,020,325

G

lysine methyltransferase 2E

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KMT2E mRNA
Coumestrol results in decreased expression of KMT2E mRNA

NCBI chr 4:12,550,570...12,655,329
Ensembl chr 4:11,658,979...11,727,373

G

lysine methyltransferase 5B

decreases expression

Coumestrol results in decreased expression of KMT5B mRNA

NCBI chr 1:210,429,672...210,479,042
Ensembl chr 1:201,000,444...201,049,819

G

kinetochore scaffold 1

multiple interactions
increases expression

[Coumestrol co-treated with Resveratrol] results in increased expression of KNL1 mRNA
Coumestrol results in increased expression of KNL1 mRNA

NCBI chr 3:126,483,498...126,545,774
Ensembl chr 3:106,029,661...106,091,915

G

kinetochore-localized astrin/SPAG5 binding protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KNSTRN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of KNSTRN mRNA
Coumestrol results in increased expression of KNSTRN mRNA

NCBI chr 3:126,254,633...126,274,412
Ensembl chr 3:105,800,954...105,820,715

G

kinetochore associated 1

increases expression
multiple interactions

Coumestrol results in increased expression of KNTC1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of KNTC1 mRNA

NCBI chr12:38,429,925...38,500,564
Ensembl chr12:32,769,020...32,839,561

G

karyopherin subunit alpha 3

decreases expression

Coumestrol results in decreased expression of KPNA3 mRNA

NCBI chr15:39,712,375...39,786,127
Ensembl chr15:35,536,316...35,610,419

G

karyopherin subunit alpha 4

decreases expression
multiple interactions

Coumestrol results in decreased expression of KPNA4 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KPNA4 mRNA

NCBI chr 2:155,635,679...155,691,056
Ensembl chr 2:153,324,273...153,381,081

G

KRAS proto-oncogene, GTPase

decreases expression

Coumestrol results in decreased expression of KRAS mRNA

NCBI chr 4:179,916,255...179,949,613

G

lysine-rich coiled-coil 1

decreases expression

Coumestrol results in decreased expression of KRCC1 mRNA

NCBI chr 4:103,261,642...103,274,672
Ensembl chr 4:103,261,536...103,277,156

G

keratin 80

decreases expression
multiple interactions

Coumestrol results in decreased expression of KRT80 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KRT80 mRNA

NCBI chr 7:134,341,951...134,363,872
Ensembl chr 7:132,463,218...132,485,508

G

kinectin 1

decreases expression

Coumestrol results in decreased expression of KTN1 mRNA

NCBI chr15:23,392,570...23,485,061
Ensembl chr15:20,914,642...21,002,578

G

L1 cell adhesion molecule

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of L1CAM mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of L1CAM mRNA
Coumestrol results in decreased expression of L1CAM mRNA

NCBI chr X:156,748,597...156,775,116
Ensembl chr X:151,597,277...151,623,857

G

L-2-hydroxyglutarate dehydrogenase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of L2HGDH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of L2HGDH mRNA
Coumestrol results in increased expression of L2HGDH mRNA

NCBI chr 6:93,900,427...93,941,534
Ensembl chr 6:88,164,440...88,205,578

G

lactamase, beta

decreases expression

Coumestrol results in decreased expression of LACTB mRNA

NCBI chr 8:67,571,504...67,587,592
Ensembl chr 8:67,571,500...67,587,539

G

L antigen family, member 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LAGE3 mRNA
Coumestrol results in increased expression of LAGE3 mRNA

NCBI chr X:152,138,209...152,139,632
Ensembl chr X:152,138,218...152,139,632

G

lysosomal-associated membrane protein 1

increases expression

Coumestrol results in increased expression of LAMP1 mRNA

NCBI chr16:83,058,131...83,082,843
Ensembl chr16:76,355,984...76,381,883

G

La ribonucleoprotein 6, translational regulator

decreases expression
multiple interactions

Coumestrol results in decreased expression of LARP6 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of LARP6 mRNA

NCBI chr 8:61,183,744...61,205,548
Ensembl chr 8:61,184,116...61,205,535

G

lamin B receptor

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of LBR mRNA
Coumestrol results in increased expression of LBR mRNA

NCBI chr13:96,071,058...96,095,709
Ensembl chr13:93,538,920...93,564,017

G

leucine carboxyl methyltransferase 2

increases expression
multiple interactions

Coumestrol results in increased expression of LCMT2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LCMT2 mRNA

NCBI chr 3:108,099,960...108,102,084
Ensembl chr 3:108,099,961...108,102,084

G

low density lipoprotein receptor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LDLR mRNA

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580

G

leptin receptor

decreases expression
multiple interactions

Coumestrol results in decreased expression of LEPR mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of LEPR mRNA

NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:116,289,823...116,475,908

G

galectin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of LGALS1 mRNA

NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:110,481,392...110,488,345

G

galectin 8

decreases expression

Coumestrol results in decreased expression of LGALS8 mRNA

NCBI chr17:62,716,368...62,744,272
Ensembl chr17:58,028,105...58,052,764

G

LIM homeobox 2

increases expression

Coumestrol results in increased expression of LHX2 mRNA

NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908

G

DNA ligase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LIG1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of LIG1 mRNA
Coumestrol results in increased expression of LIG1 mRNA

NCBI chr 1:83,243,043...83,281,707
Ensembl chr 1:74,165,842...74,204,413

G

DNA ligase 4

decreases expression

Coumestrol results in decreased expression of LIG4 mRNA

NCBI chr16:86,220,345...86,228,930
Ensembl chr16:79,518,312...79,527,040

G

LIM domain and actin binding 1

decreases expression

Coumestrol results in decreased expression of LIMA1 mRNA

NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473

G

lin-52 DREAM MuvB core complex component

increases expression

Coumestrol results in increased expression of LIN52 mRNA

NCBI chr 6:104,098,818...104,199,323
Ensembl chr 6:104,099,162...104,194,103

G

lin-7 homolog A, crumbs cell polarity complex component

decreases expression
multiple interactions

Coumestrol results in decreased expression of LIN7A mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of LIN7A mRNA

NCBI chr 7:42,586,704...42,742,609
Ensembl chr 7:42,586,719...42,730,550

G

lin-7 homolog C, crumbs cell polarity complex component

increases expression

Coumestrol results in increased expression of LIN7C mRNA

NCBI chr 3:96,406,800...96,417,779
Ensembl chr 3:96,406,813...96,417,728

G

LIM and cysteine-rich domains 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of LMCD1 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of LMCD1 mRNA

NCBI chr 4:146,948,993...147,007,878
Ensembl chr 4:145,393,145...145,452,046

G

lamin B1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LMNB1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of LMNB1 mRNA
Coumestrol results in increased expression of LMNB1 mRNA

NCBI chr18:52,373,939...52,413,284
Ensembl chr18:50,175,874...50,214,502

G

lamin B2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LMNB2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of LMNB2 mRNA

NCBI chr 7:9,443,308...9,459,468
Ensembl chr 7:8,789,314...8,808,665

G

lon peptidase 1, mitochondrial

increases expression

Coumestrol results in increased expression of LONP1 mRNA

NCBI chr 9:1,534,581...1,546,908
Ensembl chr 9:1,447,447...1,459,771

G

leucine-rich repeats and immunoglobulin-like domains 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LRIG1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of LRIG1 mRNA

NCBI chr 4:128,687,723...128,788,219
Ensembl chr 4:127,130,898...127,231,513

G

LDL receptor related protein 10

decreases expression

Coumestrol results in decreased expression of LRP10 mRNA

NCBI chr15:31,891,358...31,897,530
Ensembl chr15:27,920,259...27,927,505

G

LDL receptor related protein 8

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of LRP8 mRNA
Coumestrol results in increased expression of LRP8 mRNA

NCBI chr 5:127,792,236...127,864,207
Ensembl chr 5:122,563,453...122,631,352

G

leucine rich repeat protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LRR1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of LRR1 mRNA
Coumestrol results in increased expression of LRR1 mRNA

NCBI chr 6:93,379,159...93,387,950
Ensembl chr 6:87,643,217...87,651,894

G

leucine rich repeat containing 8 VRAC subunit E

decreases expression

Coumestrol results in decreased expression of LRRC8E mRNA

NCBI chr12:2,578,240...2,589,407
Ensembl chr12:2,578,315...2,589,412

G

LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LSM2 mRNA
Coumestrol results in increased expression of LSM2 mRNA

NCBI chr20:3,848,120...3,853,298
Ensembl chr20:3,843,466...3,847,266

G

LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated

increases expression

Coumestrol results in increased expression of LSM4 mRNA

NCBI chr16:18,789,466...18,795,164
Ensembl chr16:18,755,484...18,760,926

G

LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated

increases expression

Coumestrol results in increased expression of LSM7 mRNA

NCBI chr 7:9,507,373...9,509,787
Ensembl chr 7:8,856,489...8,859,119

G

LUC7-like

increases expression

Coumestrol results in increased expression of LUC7L mRNA

NCBI chr10:15,777,837...15,811,586
Ensembl chr10:15,273,348...15,303,112

G

Ly1 antibody reactive

increases expression

Coumestrol results in increased expression of LYAR mRNA

NCBI chr14:76,789,193...76,802,973
Ensembl chr14:72,576,879...72,590,612

G

LYN proto-oncogene, Src family tyrosine kinase

decreases expression

Coumestrol results in decreased expression of LYN mRNA

NCBI chr 5:21,437,127...21,553,097
Ensembl chr 5:16,639,466...16,756,868

G

Ly6/Plaur domain containing 6

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of LYPD6 mRNA

NCBI chr 3:34,487,425...34,632,887
Ensembl chr 3:34,496,485...34,630,308

G

mitotic arrest deficient 2 like 1

increases expression
multiple interactions

Coumestrol results in increased expression of MAD2L1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MAD2L1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MAD2L1 mRNA

NCBI chr 4:97,236,419...97,247,603
Ensembl chr 4:95,906,817...95,913,470

G

mitotic arrest deficient 2 like 2

increases expression

Coumestrol results in increased expression of MAD2L2 mRNA

NCBI chr 5:163,846,678...163,859,851
Ensembl chr 5:158,563,567...158,576,693

G

MAF bZIP transcription factor F

decreases expression
multiple interactions

Coumestrol results in decreased expression of MAFF mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAFF mRNA

NCBI chr 7:112,792,787...112,804,139
Ensembl chr 7:110,912,499...110,923,851

G

MAGE family member D2

decreases expression

Coumestrol results in decreased expression of MAGED2 mRNA

NCBI chr X:19,733,593...19,741,769
Ensembl chr X:19,733,597...19,740,477

G

membrane associated guanylate kinase, WW and PDZ domain containing 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of MAGI1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAGI1 mRNA

NCBI chr 4:127,762,590...128,368,228
Ensembl chr 4:126,206,816...126,811,691

G

mago homolog B, exon junction complex subunit

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of MAGOHB mRNA

NCBI chr 4:166,765,558...166,773,406
Ensembl chr 4:165,034,122...165,041,967

G

mannosidase, alpha, class 2A, member 1

decreases expression

Coumestrol results in decreased expression of MAN2A1 mRNA

NCBI chr 9:111,698,913...111,855,257
Ensembl chr 9:104,252,001...104,408,349

G

mannosidase, endo-alpha

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of MANEA mRNA

NCBI chr 5:40,196,373...40,218,540
Ensembl chr 5:40,196,396...40,218,459

G

microtubule-associated protein 1B

decreases expression
multiple interactions

Coumestrol results in decreased expression of MAP1B mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAP1B mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of MAP1B mRNA

NCBI chr 2:32,551,423...32,644,471
Ensembl chr 2:30,817,261...30,910,317

G

microtubule-associated protein 1 light chain 3 beta

decreases expression

Coumestrol results in decreased expression of MAP1LC3B mRNA

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase kinase 3

decreases expression

Coumestrol results in decreased expression of MAP2K3 mRNA

NCBI chr10:46,107,639...46,128,986
Ensembl chr10:45,607,163...45,629,492

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAP4K4 mRNA
Coumestrol results in decreased expression of MAP4K4 mRNA

NCBI chr 9:49,696,573...49,822,353
Ensembl chr 9:42,200,278...42,326,698

G

mitogen activated protein kinase 1

increases phosphorylation

Coumestrol results in increased phosphorylation of MAPK1 protein

PMID:15531431 PMID:17174995

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation

Coumestrol results in increased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

membrane associated ring-CH-type finger 7

decreases expression

Coumestrol results in decreased expression of MARCHF7 mRNA

NCBI chr 3:65,090,640...65,128,768
Ensembl chr 3:44,681,632...44,720,168

G

myristoylated alanine rich protein kinase C substrate

decreases expression

Coumestrol results in decreased expression of MARCKS mRNA

NCBI chr20:42,240,185...42,245,882
Ensembl chr20:40,685,315...40,691,012

G

microtubule associated serine/threonine kinase family member 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MAST4 mRNA

NCBI chr 2:33,893,241...34,483,682
Ensembl chr 2:33,894,436...34,483,723

G

microtubule associated serine/threonine kinase-like

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MASTL mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MASTL mRNA
Coumestrol results in increased expression of MASTL mRNA

NCBI chr17:90,158,592...90,195,550
Ensembl chr17:85,251,997...85,287,353

G

matrilin 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MATN3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of MATN3 mRNA
Coumestrol results in decreased expression of MATN3 mRNA

NCBI chr 6:31,748,517...31,768,564
Ensembl chr 6:31,748,474...31,768,101

G

MYC associated factor X

increases expression

Coumestrol results in increased expression of MAX mRNA

NCBI chr 6:101,369,989...101,395,333
Ensembl chr 6:95,636,858...95,662,137

G

MYC associated zinc finger protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MAZ mRNA

NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:181,629,729...181,650,408

G

Mab-21 domain containing 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MB21D2 mRNA
Coumestrol results in decreased expression of MB21D2 mRNA

NCBI chr11:71,825,748...71,924,770
Ensembl chr11:71,825,748...71,924,769

G

melanoma cell adhesion molecule

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCAM mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MCAM mRNA
Coumestrol results in increased expression of MCAM mRNA

NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571

G

minichromosome maintenance 10 replication initiation factor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM10 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MCM10 mRNA
Coumestrol results in increased expression of MCM10 mRNA

NCBI chr17:78,172,049...78,197,644
Ensembl chr17:73,266,095...73,287,364

G

minichromosome maintenance complex component 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MCM2 mRNA
Coumestrol results in increased expression of MCM2 mRNA

NCBI chr 4:122,903,679...122,918,205
Ensembl chr 4:121,346,434...121,360,847

G

minichromosome maintenance complex component 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MCM3 mRNA
Coumestrol results in increased expression of MCM3 mRNA

NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:23,219,169...23,237,314

G

minichromosome maintenance complex component 4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MCM4 mRNA
Coumestrol results in increased expression of MCM4 mRNA

NCBI chr11:98,762,599...98,776,300
Ensembl chr11:85,258,443...85,272,144

G

minichromosome maintenance complex component 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MCM5 mRNA
Coumestrol results in increased expression of MCM5 mRNA

NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,483,066...13,504,389

G

minichromosome maintenance complex component 6

increases expression
multiple interactions

Coumestrol results in increased expression of MCM6 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MCM6 mRNA

NCBI chr13:42,379,161...42,404,352
Ensembl chr13:39,826,763...39,851,960

G

minichromosome maintenance complex component 7

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM7 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MCM7 mRNA
Coumestrol results in increased expression of MCM7 mRNA

NCBI chr12:22,155,921...22,163,320
Ensembl chr12:17,042,212...17,050,063

G

minichromosome maintenance 8 homologous recombination repair factor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM8 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MCM8 mRNA
Coumestrol results in increased expression of MCM8 mRNA

NCBI chr 3:140,539,590...140,569,891
Ensembl chr 3:120,086,763...120,117,008

G

mitochondrial calcium uniporter dominant negative subunit beta

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCUB mRNA
Coumestrol results in increased expression of MCUB mRNA

NCBI chr 2:221,153,525...221,223,814
Ensembl chr 2:218,479,301...218,549,593

G

mediator of DNA damage checkpoint 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MDC1 mRNA
Coumestrol results in increased expression of MDC1 mRNA

NCBI chr20:2,898,496...2,914,960
Ensembl chr20:2,895,505...2,910,240

G

male-enhanced antigen 1

increases expression
multiple interactions

Coumestrol results in increased expression of MEA1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MEA1 mRNA

NCBI chr 9:14,300,283...14,304,130
Ensembl chr 9:14,293,446...14,302,060

G

MYST/Esa1-associated factor 6

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MEAF6 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of MEAF6 mRNA
Coumestrol results in decreased expression of MEAF6 mRNA

NCBI chr 5:142,628,281...142,653,076
Ensembl chr 5:137,344,380...137,370,014

G

myocyte enhancer factor 2a

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MEF2A mRNA
Coumestrol results in decreased expression of MEF2A mRNA

NCBI chr 1:130,258,083...130,392,819
Ensembl chr 1:120,850,080...120,981,948

G

maternal embryonic leucine zipper kinase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MELK mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MELK mRNA
Coumestrol results in increased expression of MELK mRNA

NCBI chr 5:63,336,151...63,396,254
Ensembl chr 5:58,540,449...58,600,937

G

methylphosphate capping enzyme

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MEPCE mRNA
Coumestrol results in increased expression of MEPCE mRNA

NCBI chr12:24,548,596...24,553,315
Ensembl chr12:18,911,796...18,916,514

G

methionyl aminopeptidase 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of METAP2 mRNA
Coumestrol results in decreased expression of METAP2 mRNA

NCBI chr 7:30,299,433...30,327,477
Ensembl chr 7:28,411,608...28,440,434

G

methyltransferase 1, tRNA methylguanosine

increases expression

Coumestrol results in increased expression of METTL1 mRNA

NCBI chr 7:64,750,189...64,754,531
Ensembl chr 7:62,864,853...62,869,202

G

microfibrillar-associated protein 1A

increases expression

Coumestrol results in increased expression of MFAP1 mRNA

NCBI chr 3:108,440,163...108,456,744
Ensembl chr 3:108,438,845...108,456,750

G

MAX dimerization protein MGA

decreases expression

Coumestrol results in decreased expression of MGA mRNA

NCBI chr 3:127,300,558...127,396,694
Ensembl chr 3:106,851,140...106,941,043

G

alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MGAT4B mRNA

NCBI chr10:35,049,421...35,060,307
Ensembl chr10:34,549,433...34,559,229

G

alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase

increases expression

Coumestrol results in increased expression of MGAT5 mRNA

NCBI chr13:41,228,327...41,516,462
Ensembl chr13:38,676,119...38,959,513

G

monoglyceride lipase

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MGLL mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of MGLL mRNA
Coumestrol results in decreased expression of MGLL mRNA

NCBI chr 4:122,749,436...122,851,440
Ensembl chr 4:121,192,195...121,294,179

G

matrix Gla protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MGP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MGP mRNA

NCBI chr 4:171,497,472...171,500,888
Ensembl chr 4:169,766,279...169,769,667

G

MICAL-like 1

decreases expression

Coumestrol results in decreased expression of MICALL1 mRNA

NCBI chr 7:112,557,192...112,587,618
Ensembl chr 7:110,676,775...110,707,177

G

MICAL-like 2

decreases expression

Coumestrol results in decreased expression of MICALL2 mRNA

NCBI chr12:14,899,188...14,927,949
Ensembl chr12:14,899,157...14,927,946

G

MHC class I polypeptide-related sequence B

multiple interactions

[Coumestrol co-treated with Resveratrol] results in increased expression of MICB mRNA

NCBI chr 1:87,623,826...87,641,075
Ensembl chr 1:78,495,779...78,512,827

G

microRNA 21

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MIR21 mRNA

NCBI chr10:71,902,600...71,902,691
Ensembl chr10:71,405,257...71,405,348

G

MIS18 binding protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MIS18BP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MIS18BP1 mRNA
Coumestrol results in increased expression of MIS18BP1 mRNA

NCBI chr 6:88,918,743...88,968,225
Ensembl chr 6:83,182,499...83,231,383

G

mitochondrial matrix import factor 23

increases expression

Coumestrol results in increased expression of MIX23 mRNA

NCBI chr11:78,166,038...78,186,323
Ensembl chr11:64,660,711...64,681,000

G

marker of proliferation Ki-67

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MKI67 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MKI67 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA]
Coumestrol results in increased expression of MKI67 mRNA

PMID:18310284 PMID:19167446

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762

G

MAPK interacting serine/threonine kinase 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of MKNK2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MKNK2 mRNA

NCBI chr 7:9,690,385...9,701,527
Ensembl chr 7:9,039,728...9,050,827

G

myeloid leukemia factor 1

decreases expression

Coumestrol results in decreased expression of MLF1 mRNA

NCBI chr 2:153,958,060...153,991,705
Ensembl chr 2:151,648,511...151,681,652

G

mutL homolog 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MLH1 mRNA
Coumestrol results in increased expression of MLH1 mRNA

NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:111,196,468...111,233,617

G

mixed lineage kinase domain like pseudokinase

increases expression

Coumestrol results in increased expression of MLKL mRNA

NCBI chr19:56,186,860...56,213,886
Ensembl chr19:39,276,785...39,304,502

G

metabolism of cobalamin associated B

increases expression

Coumestrol results in increased expression of MMAB mRNA

NCBI chr12:47,819,757...47,833,127
Ensembl chr12:42,159,089...42,172,490

G

matrix metallopeptidase 16

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of MMP16 mRNA

NCBI chr 5:36,109,265...36,353,252
Ensembl chr 5:31,312,280...31,548,388

G

meiosis-specific nuclear structural 1

increases expression

Coumestrol results in increased expression of MNS1 mRNA

NCBI chr 8:82,029,587...82,050,276
Ensembl chr 8:73,148,877...73,176,925

G

modulator of apoptosis 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MOAP1 mRNA
Coumestrol results in decreased expression of MOAP1 mRNA

NCBI chr 6:121,882,565...121,884,500
Ensembl chr 6:121,882,366...121,898,643
Ensembl chr17:121,882,366...121,898,643

G

mortality factor 4 like 2

decreases expression

Coumestrol results in decreased expression of MORF4L2 mRNA

NCBI chr X:104,874,850...104,885,946
Ensembl chr X:100,082,404...100,093,728

G

motile sperm domain containing 1

decreases expression

Coumestrol results in decreased expression of MOSPD1 mRNA

NCBI chr X:133,100,200...133,127,960
Ensembl chr X:133,100,422...133,127,908
Ensembl chr 1:133,100,422...133,127,908
Ensembl chr14:133,100,422...133,127,908

G

M-phase phosphoprotein 9

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MPHOSPH9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MPHOSPH9 mRNA
Coumestrol results in increased expression of MPHOSPH9 mRNA

NCBI chr12:37,936,442...38,007,053
Ensembl chr12:32,275,558...32,342,392

G

metallophosphoesterase domain containing 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of MPPED2 mRNA

NCBI chr 3:93,180,895...93,355,605
Ensembl chr 3:93,181,167...93,355,618

G

MRE11 homolog, double strand break repair nuclease

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRE11 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MRE11 mRNA

NCBI chr 8:19,900,211...19,961,906
Ensembl chr 8:11,632,354...11,678,279

G

mitochondrial rRNA methyltransferase 2

increases expression
multiple interactions

Coumestrol results in increased expression of MRM2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRM2 mRNA

NCBI chr12:14,309,556...14,314,759
Ensembl chr12:14,251,941...14,314,118

G

mitochondrial ribosomal protein L37

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRPL37 mRNA
Coumestrol results in increased expression of MRPL37 mRNA

NCBI chr 5:121,827,892...121,846,187
Ensembl chr 5:121,829,111...121,846,176

G

mitochondrial ribosomal protein L57

increases expression

Coumestrol results in increased expression of MRPL57 mRNA

NCBI chr15:31,970,904...31,971,766
Ensembl chr15:31,970,860...31,973,993

G

mitochondrial ribosomal protein S26

increases expression
multiple interactions

Coumestrol results in increased expression of MRPS26 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRPS26 mRNA

NCBI chr 3:117,769,220...117,770,883
Ensembl chr 3:117,769,100...117,770,885

G

mitochondrial ribosomal protein S27

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRPS27 mRNA

NCBI chr 2:32,474,178...32,542,741
Ensembl chr 2:30,740,033...30,808,577

G

mitochondrial ribosomal protein S6

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of MRPS6 mRNA

NCBI chr11:44,778,667...44,834,420
Ensembl chr11:31,295,614...31,348,484

G

MRT4 homolog, ribosome maturation factor

increases expression

Coumestrol results in increased expression of MRT4 mRNA

NCBI chr 5:156,884,985...156,891,738
Ensembl chr 5:151,601,780...151,608,287

G

mutS homolog 2

increases expression

Coumestrol results in increased expression of MSH2 mRNA

NCBI chr 6:12,567,368...12,626,534
Ensembl chr 6:6,813,795...6,872,938

G

mutS homolog 3

decreases expression

Coumestrol results in decreased expression of MSH3 mRNA

NCBI chr 2:25,179,400...25,320,857

G

mutS homolog 6

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MSH6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MSH6 mRNA
Coumestrol results in increased expression of MSH6 mRNA

NCBI chr 6:12,316,190...12,333,505
Ensembl chr 6:6,562,632...6,579,956

G

msh homeobox 2

decreases expression

Coumestrol results in decreased expression of MSX2 mRNA

NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,097,103...11,102,879

G

mature T-cell proliferation 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MTCP1 mRNA
Coumestrol results in increased expression of MTCP1 mRNA

NCBI chr18:126,189...130,123

G

mitochondrial fission process 1

increases expression
multiple interactions

Coumestrol results in increased expression of MTFP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MTFP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MTFP1 mRNA

NCBI chr14:83,192,013...83,195,853
Ensembl chr14:78,968,442...78,972,274

G

mitochondrial fission regulator 2

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of MTFR2 mRNA
Coumestrol results in increased expression of MTFR2 mRNA

NCBI chr 1:16,942,814...16,958,218
Ensembl chr 1:15,070,894...15,148,832

G

mitochondrial ribosome-associated GTPase 1

increases expression

Coumestrol results in increased expression of MTG1 mRNA

NCBI chr 1:194,931,543...194,944,278
Ensembl chr 1:194,931,531...194,944,277

G

methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1

increases expression
multiple interactions

Coumestrol results in increased expression of MTHFD1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MTHFD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MTHFD1 mRNA

NCBI chr 6:100,713,510...100,781,013
Ensembl chr 6:94,977,862...95,045,372

G

myotubularin related protein 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MTMR4 mRNA

NCBI chr10:72,890,665...72,913,598
Ensembl chr10:72,392,551...72,416,342

G

microtubule associated scaffold protein 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of MTUS1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MTUS1 mRNA

NCBI chr16:57,905,991...58,051,466
Ensembl chr16:51,253,562...51,347,793

G

major vault protein

decreases expression
multiple interactions

Coumestrol results in decreased expression of MVP mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MVP mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of MVP mRNA

NCBI chr 1:191,025,259...191,052,866
Ensembl chr 1:181,594,734...181,622,380

G

Max dimerization protein 4

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MXD4 mRNA
Coumestrol results in decreased expression of MXD4 mRNA

NCBI chr14:76,562,105...76,576,224
Ensembl chr14:76,561,774...76,576,221

G

MAX interactor 1, dimerization protein

decreases expression

Coumestrol results in decreased expression of MXI1 mRNA

NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681

G

matrix remodeling associated 7

decreases expression

Coumestrol results in decreased expression of MXRA7 mRNA

NCBI chr10:102,003,034...102,031,428
Ensembl chr10:102,003,319...102,031,409

G

MYB proto-oncogene, transcription factor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MYB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA]
Coumestrol results in increased expression of MYB mRNA

PMID:18310284 PMID:19167446

NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:15,939,761...15,973,057

G

MYB proto-oncogene like 2

increases expression
multiple interactions

Coumestrol results in increased expression of MYBL2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MYBL2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of MYBL2 mRNA

NCBI chr 3:172,124,765...172,153,221
Ensembl chr 3:151,705,288...151,733,708

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA]

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630

G

Myc binding protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MYCBP mRNA
Coumestrol results in increased expression of MYCBP mRNA

NCBI chr 5:141,420,727...141,427,938
Ensembl chr 5:136,135,931...136,145,616

G

MYC binding protein 2

decreases expression

Coumestrol results in decreased expression of MYCBP2 mRNA

NCBI chr15:86,352,061...86,590,126
Ensembl chr15:79,937,354...80,175,498

G

myosin heavy chain 14

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of MYH14 mRNA
Coumestrol results in decreased expression of MYH14 mRNA

NCBI chr 1:104,232,778...104,295,369
Ensembl chr 1:95,096,266...95,158,836

G

myosin regulatory light chain interacting protein

decreases expression
multiple interactions

Coumestrol results in decreased expression of MYLIP mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYLIP mRNA

NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,286,650...19,308,295

G

myosin XIX

increases expression

Coumestrol results in increased expression of MYO19 mRNA

NCBI chr10:70,250,500...70,279,867
Ensembl chr10:69,753,068...69,782,450

G

myosin Ib

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYO1B mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of MYO1B mRNA
Coumestrol results in decreased expression of MYO1B mRNA

NCBI chr 9:57,182,059...57,344,335
Ensembl chr 9:49,690,086...49,850,798

G

myosin VA

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYO5A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of MYO5A mRNA
Coumestrol results in decreased expression of MYO5A mRNA

NCBI chr 8:84,692,524...84,860,564
Ensembl chr 8:75,812,412...75,975,918

G

myosin Vb

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYO5B mRNA

NCBI chr18:70,313,717...70,613,918
Ensembl chr18:68,038,759...68,338,745

G

myosin VI

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYO6 mRNA
Coumestrol results in decreased expression of MYO6 mRNA

NCBI chr 8:89,967,351...90,122,219
Ensembl chr 8:81,087,139...81,239,292

G

myoferlin

increases expression

Coumestrol results in increased expression of MYOF mRNA

NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:235,673,666...235,822,334

G

mitotic spindle organizing protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MZT1 mRNA
Coumestrol results in increased expression of MZT1 mRNA

NCBI chr15:82,195,128...82,205,436
Ensembl chr15:75,786,994...75,797,589

G

Nedd4 binding protein 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of N4BP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of N4BP1 mRNA

NCBI chr19:36,396,082...36,446,835
Ensembl chr19:20,222,776...20,273,570

G

NEDD4 binding protein 2-like 1

decreases expression

Coumestrol results in decreased expression of N4BP2L1 mRNA

NCBI chr12:4,938,199...4,965,003
Ensembl chr12:102,573...127,257

G

N(alpha)-acetyltransferase 15, NatA auxiliary subunit

increases expression

Coumestrol results in increased expression of NAA15 mRNA

NCBI chr 2:137,608,883...137,671,618
Ensembl chr 2:135,457,948...135,520,756

G

N(alpha)-acetyltransferase 50, NatE catalytic subunit

increases expression
multiple interactions

Coumestrol results in increased expression of NAA50 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NAA50 mRNA

NCBI chr11:70,044,281...70,066,754
Ensembl chr11:56,538,366...56,560,842

G

Ngfi-A binding protein 1

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of NAB1 mRNA
Coumestrol results in increased expression of NAB1 mRNA

NCBI chr 9:56,545,547...56,585,045
Ensembl chr 9:49,053,758...49,092,098

G

NAD kinase 2, mitochondrial

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of NADK2 mRNA
Coumestrol results in increased expression of NADK2 mRNA

NCBI chr 2:58,117,674...58,159,815
Ensembl chr 2:58,117,674...58,159,808

G

nanos C2HC-type zinc finger 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NANOS1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of NANOS1 mRNA
Coumestrol results in decreased expression of NANOS1 mRNA

NCBI chr 1:269,883,713...269,887,611
Ensembl chr 1:259,897,939...259,898,730

G

N-acetylneuraminic acid phosphatase

increases expression

Coumestrol results in increased expression of NANP mRNA

NCBI chr 3:139,826,549...139,841,655
Ensembl chr 3:139,826,549...139,841,648

G

nucleosome assembly protein 1-like 4

increases expression

Coumestrol results in increased expression of NAP1L4 mRNA

NCBI chr 1:198,709,697...198,746,093
Ensembl chr 1:198,709,701...198,746,020

G

nuclear autoantigenic sperm protein

increases expression
multiple interactions

Coumestrol results in increased expression of NASP mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NASP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NASP mRNA

NCBI chr 5:135,294,599...135,319,992
Ensembl chr 5:130,057,363...130,082,928

G

N-acetyltransferase domain containing 1

decreases expression

Coumestrol results in decreased expression of NATD1 mRNA

NCBI chr10:45,580,154...45,590,333

G

neurobeachin

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NBEA mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of NBEA mRNA
Coumestrol results in decreased expression of NBEA mRNA

NCBI chr 2:141,930,147...142,489,172
Ensembl chr 2:139,780,021...140,340,584

G

neurobeachin-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NBEAL1 mRNA

NCBI chr 9:69,069,326...69,237,932
Ensembl chr 9:61,575,356...61,736,750

G

non-SMC condensin I complex, subunit D2

increases expression

Coumestrol results in increased expression of NCAPD2 mRNA

NCBI chr 4:159,655,051...159,677,938
Ensembl chr 4:157,968,815...157,992,020

G

non-SMC condensin II complex, subunit D3

increases expression

Coumestrol results in increased expression of NCAPD3 mRNA

NCBI chr 8:33,696,214...33,765,520
Ensembl chr 8:25,437,123...25,506,373

G

non-SMC condensin I complex, subunit G

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NCAPG mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NCAPG mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA]
Coumestrol results in increased expression of NCAPG mRNA

PMID:18310284 PMID:19167446

NCBI chr14:69,616,473...69,645,445
Ensembl chr14:65,404,163...65,432,902

G

non-SMC condensin II complex, subunit G2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NCAPG2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NCAPG2 mRNA
Coumestrol results in increased expression of NCAPG2 mRNA

NCBI chr 6:143,484,651...143,561,850
Ensembl chr 6:137,342,943...137,415,159

G

non-SMC condensin I complex, subunit H

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of NCAPH mRNA
Coumestrol results in increased expression of NCAPH mRNA

NCBI chr 3:134,825,271...134,852,502
Ensembl chr 3:114,371,941...114,399,180

G

non-SMC condensin II complex, subunit H2

increases expression

Coumestrol results in increased expression of NCAPH2 mRNA

NCBI chr 7:122,302,550...122,319,570
Ensembl chr 7:120,422,956...120,439,938

G

nuclear cap binding protein subunit 1

increases expression

Coumestrol results in increased expression of NCBP1 mRNA

NCBI chr 5:65,211,632...65,244,532
Ensembl chr 5:60,415,982...60,449,089

G

nuclear receptor coactivator 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NCOA1 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of NCOA1 mRNA
Coumestrol results in decreased expression of NCOA1 mRNA

NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:27,232,611...27,475,664

G

nuclear receptor coactivator 2

multiple interactions

Coumestrol promotes the reaction [NCOA2 protein binds to ESR1 protein]

NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:5,835,706...6,067,451

G

nuclear receptor coactivator 3

decreases expression

Coumestrol results in decreased expression of NCOA3 mRNA

NCBI chr 3:175,157,824...175,237,831
Ensembl chr 3:154,738,581...154,818,594

G

nuclear receptor coactivator 7

decreases expression
multiple interactions

Coumestrol results in decreased expression of NCOA7 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NCOA7 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of NCOA7 mRNA

NCBI chr 1:28,674,614...28,835,891
Ensembl chr 1:26,856,530...27,015,871

G

NDC1 transmembrane nucleoporin

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NDC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NDC1 mRNA
Coumestrol results in increased expression of NDC1 mRNA

NCBI chr 5:127,384,172...127,431,093
Ensembl chr 5:122,155,967...122,202,291

G

NDC80 kinetochore complex component

increases expression
multiple interactions

Coumestrol results in increased expression of NDC80 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NDC80 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of NDC80 mRNA

NCBI chr 9:118,853,806...118,887,582
Ensembl chr 9:111,407,191...111,440,924

G

nudE neurodevelopment protein 1

increases expression
multiple interactions

Coumestrol results in increased expression of NDE1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NDE1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NDE1 mRNA

NCBI chr10:1,347,010...1,391,167
Ensembl chr10:839,788...883,869

G

Nedd4 family interacting protein 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of NDFIP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NDFIP1 mRNA

NCBI chr18:30,516,931...30,567,199
Ensembl chr18:30,250,613...30,322,311

G

NADH:ubiquinone oxidoreductase core subunit S8

decreases expression

Coumestrol results in decreased expression of NDUFS8 mRNA

NCBI chr 1:210,569,823...210,573,707
Ensembl chr 1:201,140,585...201,144,511

G

NADH:ubiquinone oxidoreductase core subunit V1

increases expression

Coumestrol results in increased expression of NDUFV1 mRNA

NCBI chr 1:210,729,856...210,735,103
Ensembl chr 1:201,299,985...201,305,466

G

nebulette

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NEBL mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of NEBL mRNA
Coumestrol results in decreased expression of NEBL mRNA

NCBI chr17:85,022,953...85,374,848
Ensembl chr17:80,118,543...80,466,210

G

nectin cell adhesion molecule 2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of NECTIN2 mRNA
Coumestrol results in decreased expression of NECTIN2 mRNA

NCBI chr 1:88,500,086...88,535,474
Ensembl chr 1:79,372,119...79,407,360

G

NEDD4 like E3 ubiquitin protein ligase

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NEDD4L mRNA
Coumestrol results in decreased expression of NEDD4L mRNA

NCBI chr18:60,663,918...60,996,824
Ensembl chr18:58,393,509...58,723,137

G

neural precursor cell expressed, developmentally down-regulated 9

decreases expression
multiple interactions

Coumestrol results in decreased expression of NEDD9 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NEDD9 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of NEDD9 mRNA

NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,282,326...23,468,019

G

nei-like DNA glycosylase 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NEIL3 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of NEIL3 mRNA
Coumestrol results in increased expression of NEIL3 mRNA

NCBI chr16:45,091,401...45,151,419
Ensembl chr16:38,359,371...38,418,527

G

NIMA-related kinase 2

increases expression
multiple interactions

Coumestrol results in increased expression of NEK2 mRNA
[Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NEK2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA]

PMID:18310284 PMID:19167446

NCBI chr13:105,936,809...105,950,054
Ensembl chr13:103,405,819...103,419,051

G

neural EGFL like 2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of NELL2 mRNA
Coumestrol results in decreased expression of NELL2 mRNA

NCBI chr 7:126,343,089...126,662,903
Ensembl chr 7:126,198,851...126,733,503

G

nuclear envelope integral membrane protein 1

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of NEMP1 mRNA
Coumestrol results in increased expression of NEMP1 mRNA

NCBI chr 7:65,399,297...65,424,054
Ensembl chr 7:63,479,951...63,534,602

G

neuropilin and tolloid like 2

increases expression

Coumestrol results in increased expression of NETO2 mRNA

NCBI chr19:37,517,518...37,588,961
Ensembl chr19:21,344,289...21,417,023

G

neuraminidase 1

decreases expression

Coumestrol results in decreased expression of NEU1 mRNA

NCBI chr20:3,897,480...3,901,745
Ensembl chr20:3,897,480...3,901,745

G

neuralized E3 ubiquitin protein ligase 1B

increases expression
multiple interactions

Coumestrol results in increased expression of NEURL1B mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NEURL1B mRNA

NCBI chr10:16,754,002...16,785,049
Ensembl chr10:16,757,208...16,785,119

G

nuclear factor of activated T-cells 2 interacting protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NFATC2IP mRNA
Coumestrol results in increased expression of NFATC2IP mRNA

NCBI chr 1:190,385,416...190,403,309
Ensembl chr 1:180,955,043...180,971,747

G

nuclear factor, interleukin 3 regulated

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NFIL3 mRNA

NCBI chr17:12,432,376...12,447,605
Ensembl chr17:12,280,484...12,295,858

G

nuclear factor kappa B subunit 1

decreases expression

Coumestrol results in decreased expression of NFKB1 protein

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

decreases expression

Coumestrol results in decreased expression of NFKBIA mRNA

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941

G

NHERF family PDZ scaffold protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NHERF1 mRNA

NCBI chr10:100,902,165...100,919,265
Ensembl chr10:100,403,069...100,420,598

G

ninein-like

decreases expression
multiple interactions

Coumestrol results in decreased expression of NINL mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NINL mRNA

NCBI chr 3:139,748,353...139,814,683
Ensembl chr 3:139,748,355...139,814,622

G

Sodium/potassium transporting ATPase interacting 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of NKAIN1 mRNA

NCBI chr 5:142,747,702...142,792,665
Ensembl chr 5:142,747,505...142,791,863

G

N-myristoyltransferase 1

increases expression

Coumestrol results in increased expression of NMT1 mRNA

NCBI chr10:88,488,918...88,525,496
Ensembl chr10:87,988,826...88,022,648

G

N-myristoyltransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NMT2 mRNA

NCBI chr17:79,826,999...79,874,088
Ensembl chr17:74,917,833...74,961,080

G

neuromedin U

increases expression
multiple interactions

Coumestrol results in increased expression of NMU mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NMU mRNA

NCBI chr14:32,198,789...32,226,397
Ensembl chr14:31,844,728...31,872,192

G

nicotinamide nucleotide transhydrogenase

increases expression

Coumestrol results in increased expression of NNT mRNA

NCBI chr 2:53,144,157...53,237,857
Ensembl chr 2:51,411,413...51,504,823

G

NOC3-like DNA replication regulator

increases expression

Coumestrol results in increased expression of NOC3L mRNA

NCBI chr 1:236,556,037...236,585,372
Ensembl chr 1:236,556,789...236,585,318

G

nucleolar and coiled-body phosphoprotein 1

increases expression

Coumestrol results in increased expression of NOLC1 mRNA

NCBI chr 1:254,870,195...254,881,070
Ensembl chr 1:244,921,377...244,932,088

G

nucleolar protein with MIF4G domain 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NOM1 mRNA
Coumestrol results in increased expression of NOM1 mRNA

NCBI chr 4:6,562,931...6,586,093
Ensembl chr 4:5,892,909...5,909,709

G

notch receptor 3

decreases expression

Coumestrol results in decreased expression of NOTCH3 mRNA

NCBI chr 7:11,783,550...11,834,585
Ensembl chr 7:11,133,706...11,184,025

G

neuronal PAS domain protein 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NPAS3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of NPAS3 mRNA
Coumestrol results in decreased expression of NPAS3 mRNA

NCBI chr 6:76,438,064...77,263,185
Ensembl chr 6:70,703,170...71,524,884

G

aminopeptidase puromycin sensitive

increases expression
multiple interactions

Coumestrol results in increased expression of NPEPPS mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NPEPPS mRNA

NCBI chr10:82,191,454...82,273,967
Ensembl chr10:82,191,456...82,273,967

G

nephrocystin 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NPHP3 mRNA
Coumestrol results in decreased expression of NPHP3 mRNA

NCBI chr 8:113,500,708...113,541,179
Ensembl chr 8:104,621,864...104,662,383

G

nucleophosmin/nucleoplasmin, 3

increases expression

Coumestrol results in increased expression of NPM3 mRNA

NCBI chr 1:254,544,664...254,546,649
Ensembl chr 1:244,595,644...244,597,591

G

nephronectin

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NPNT mRNA
Coumestrol results in decreased expression of NPNT mRNA

NCBI chr 2:224,065,191...224,133,567
Ensembl chr 2:221,391,153...221,459,401

G

neuropeptide Y receptor Y1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NPY1R mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of NPY1R mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA]
Coumestrol results in increased expression of NPY1R mRNA

PMID:18310284 PMID:19167446

NCBI chr16:27,804,416...27,814,070
Ensembl chr16:23,037,789...23,046,759

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

increases expression
multiple interactions

Coumestrol results in increased expression of NQO2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NQO2 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of NQO2 mRNA

NCBI chr17:31,114,825...31,144,062
Ensembl chr17:30,909,187...30,938,320

G

nuclear receptor subfamily 1, group I, member 2

increases expression
increases activity

Coumestrol results in increased expression of NR1I2 mRNA
Coumestrol results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 2, group C, member 1

decreases expression

Coumestrol results in decreased expression of NR2C1 mRNA

NCBI chr 7:28,715,347...28,768,624
Ensembl chr 7:28,715,562...28,767,160

G

nuclear receptor 2C2-associated protein

increases expression

Coumestrol results in increased expression of NR2C2AP mRNA

NCBI chr16:19,288,454...19,290,940
Ensembl chr16:19,288,454...19,290,719

G

nuclear receptor subfamily 2, group F, member 2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of NR2F2 mRNA
Coumestrol results in decreased expression of NR2F2 mRNA

NCBI chr 1:133,419,161...133,434,290
Ensembl chr 1:124,009,181...124,022,031

G

nuclear receptor subfamily 2, group F, member 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NR2F6 mRNA

NCBI chr16:18,080,003...18,087,449
Ensembl chr16:18,046,013...18,053,459

G

nuclear receptor subfamily 3, group C, member 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of NR3C1 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of NR3C1 mRNA

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NR4A2 mRNA

NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:41,689,851...41,697,877

G

neuronal cell adhesion molecule

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NRCAM mRNA

NCBI chr 6:67,129,723...67,425,510
Ensembl chr 6:61,329,863...61,702,992

G

nurim

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NRM mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NRM mRNA
Coumestrol results in increased expression of NRM mRNA

NCBI chr20:2,888,321...2,892,804
Ensembl chr20:2,877,567...2,891,802

G

nuclear receptor binding SET domain protein 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NSD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NSD2 mRNA
Coumestrol results in increased expression of NSD2 mRNA

NCBI chr14:81,057,727...81,135,866
Ensembl chr14:76,835,637...76,913,641

G

5' nucleotidase, ecto

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NT5E mRNA
Coumestrol results in decreased expression of NT5E mRNA

NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:89,270,696...89,314,881

G

netrin 4

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NTN4 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of NTN4 mRNA
Coumestrol results in decreased expression of NTN4 mRNA

NCBI chr 7:30,073,637...30,187,407
Ensembl chr 7:28,186,611...28,300,390

G

NUAK family kinase 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NUAK1 mRNA
Coumestrol results in decreased expression of NUAK1 mRNA

NCBI chr 7:19,330,034...19,401,918
Ensembl chr 7:19,329,933...19,401,913

G

nudix hydrolase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUDT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NUDT1 mRNA
Coumestrol results in increased expression of NUDT1 mRNA

NCBI chr12:19,416,411...19,423,448
Ensembl chr12:14,302,694...14,305,826

G

nudix hydrolase 16

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of NUDT16 mRNA

NCBI chr 8:114,618,706...114,620,761
Ensembl chr 8:105,739,623...105,741,998

G

nudix hydrolase 21

increases expression

Coumestrol results in increased expression of NUDT21 mRNA

NCBI chr19:10,980,797...10,996,903
Ensembl chr19:10,974,241...10,991,682

G

nucleoporin 107

increases expression
multiple interactions

Coumestrol results in increased expression of NUP107 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUP107 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of NUP107 mRNA

NCBI chr 7:55,239,610...55,285,050
Ensembl chr 7:53,353,743...53,398,370

G

nucleoporin 155

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUP155 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NUP155 mRNA
Coumestrol results in increased expression of NUP155 mRNA

NCBI chr 2:58,927,171...58,980,162
Ensembl chr 2:57,201,272...57,254,148

G

nucleoporin 205

increases expression

Coumestrol results in increased expression of NUP205 mRNA

NCBI chr 4:64,822,051...64,887,996
Ensembl chr 4:63,854,783...63,920,844

G

nucleoporin 210

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUP210 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NUP210 mRNA
Coumestrol results in increased expression of NUP210 mRNA

NCBI chr 4:123,511,558...123,609,874
Ensembl chr 4:123,511,559...123,609,874

G

nucleoporin 35

increases expression

Coumestrol results in increased expression of NUP35 mRNA

NCBI chr 3:85,965,907...85,991,659
Ensembl chr 3:65,558,968...65,585,130

G

nucleoporin 37

increases expression

Coumestrol results in increased expression of NUP37 mRNA

NCBI chr 7:24,443,998...24,497,088
Ensembl chr 7:22,573,764...22,609,616

G

nucleoporin 50

increases expression

Coumestrol results in increased expression of NUP50 mRNA

NCBI chr 7:117,927,882...117,945,155
Ensembl chr 7:116,048,021...116,066,905

G

nucleoporin 62 C-terminal like

increases expression
multiple interactions

Coumestrol results in increased expression of NUP62CL mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUP62CL mRNA

NCBI chr X:108,457,043...108,513,525
Ensembl chr X:103,668,455...103,724,081

G

nucleoporin 85

increases expression

Coumestrol results in increased expression of NUP85 mRNA

NCBI chr10:101,305,241...101,323,980
Ensembl chr10:100,806,437...100,825,043

G

nucleolar and spindle associated protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUSAP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of NUSAP1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA]
Coumestrol results in increased expression of NUSAP1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 3:127,057,220...127,092,779
Ensembl chr 3:106,603,289...106,633,624

G

neurexophilin and PC-esterase domain family, member 3

decreases expression

Coumestrol results in decreased expression of NXPE3 mRNA

NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694

G

O-acyl-ADP-ribose deacylase 1

increases expression

Coumestrol results in increased expression of OARD1 mRNA

NCBI chr 9:20,074,507...20,084,946
Ensembl chr 9:12,578,970...12,587,249

G

ornithine decarboxylase antizyme 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of OAZ2 mRNA

NCBI chr 8:75,094,817...75,108,634
Ensembl chr 8:66,199,706...66,231,453

G

obscurin like cytoskeletal adaptor 1

decreases expression

Coumestrol results in decreased expression of OBSL1 mRNA

NCBI chr 9:84,416,447...84,442,415
Ensembl chr 9:76,974,253...76,993,560

G

outer dense fiber of sperm tails 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ODF2 mRNA

NCBI chr 3:33,557,738...33,605,076
Ensembl chr 3:13,161,494...13,206,985

G

O-GlcNAcase

decreases expression

Coumestrol results in decreased expression of OGA mRNA

NCBI chr 1:254,547,311...254,589,596
Ensembl chr 1:244,598,292...244,634,359

G

2-oxoglutarate and iron-dependent oxygenase domain containing 1

increases expression

Coumestrol results in increased expression of OGFOD1 mRNA

NCBI chr19:10,945,031...10,974,602
Ensembl chr19:10,946,018...10,975,119

G

Opa interacting protein 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of OIP5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of OIP5 mRNA
Coumestrol results in increased expression of OIP5 mRNA

NCBI chr 3:127,047,559...127,057,043
Ensembl chr 3:106,593,760...106,603,250

G

olfactomedin 1

increases expression
multiple interactions

Coumestrol results in increased expression of OLFM1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of OLFM1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of OLFM1 mRNA

NCBI chr 3:11,520,522...11,558,240
Ensembl chr 3:11,520,729...11,558,239

G

optineurin

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OPTN mRNA
Coumestrol results in decreased expression of OPTN mRNA

NCBI chr17:78,118,847...78,169,543
Ensembl chr17:73,209,575...73,260,251

G

origin recognition complex, subunit 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ORC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ORC1 mRNA
Coumestrol results in increased expression of ORC1 mRNA

NCBI chr 5:128,552,975...128,581,943
Ensembl chr 5:123,324,315...123,348,375

G

origin recognition complex, subunit 6

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ORC6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ORC6 mRNA
Coumestrol results in increased expression of ORC6 mRNA

NCBI chr19:37,931,085...37,938,856
Ensembl chr19:21,757,866...21,765,662

G

oxysterol binding protein-like 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OSBPL2 mRNA

NCBI chr 3:167,210,945...167,256,219
Ensembl chr 3:167,210,832...167,256,219

G

oxidative stress responsive serine-rich 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OSER1 mRNA

NCBI chr 3:152,066,975...152,085,180
Ensembl chr 3:152,066,975...152,085,149

G

osteoclastogenesis associated transmembrane protein 1

decreases expression

Coumestrol results in decreased expression of OSTM1 mRNA

NCBI chr20:47,653,696...47,769,248
Ensembl chr20:46,153,075...46,187,023

G

OTU deubiquitinase 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of OTUD1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OTUD1 mRNA

NCBI chr17:87,168,248...87,171,098
Ensembl chr17:82,259,840...82,262,995

G

3-oxoacid CoA transferase 1

increases expression
multiple interactions

Coumestrol results in increased expression of OXCT1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of OXCT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of OXCT1 mRNA

NCBI chr 2:54,963,964...55,112,303
Ensembl chr 2:53,236,368...53,384,714

G

oxytocin receptor

decreases expression
multiple interactions

Coumestrol results in decreased expression of OXTR mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OXTR mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of OXTR mRNA

NCBI chr 4:147,154,374...147,171,723
Ensembl chr 4:145,599,561...145,614,674

G

prolyl 4-hydroxylase subunit beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of P4HB mRNA

NCBI chr10:106,335,300...106,346,911
Ensembl chr10:105,836,982...105,848,500

G

PABIR family member 2

increases expression

Coumestrol results in increased expression of PABIR2 mRNA

NCBI chr X:137,908,653...137,935,153
Ensembl chr X:132,989,124...133,015,580

G

Paxip1-associated glutamate-rich protein 1

increases expression

Coumestrol results in increased expression of PAGR1 mRNA

NCBI chr 1:191,053,228...191,055,554

G

phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PAICS mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of PAICS mRNA
Coumestrol results in increased expression of PAICS mRNA

NCBI chr14:31,553,355...31,586,843
Ensembl chr14:31,173,541...31,232,635

G

poly(A) binding protein interacting protein 1

decreases expression

Coumestrol results in decreased expression of PAIP1 mRNA

NCBI chr 2:51,523,190...51,550,241
Ensembl chr 2:51,522,921...51,550,241

G

poly(A) specific ribonuclease subunit PAN2

increases expression

Coumestrol results in increased expression of PAN2 mRNA

NCBI chr 7:729,146...747,744
Ensembl chr 7:729,562...747,744

G

poly (A) polymerase alpha

decreases expression

Coumestrol results in decreased expression of PAPOLA mRNA

NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468

G

3'-phosphoadenosine 5'-phosphosulfate synthase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PAPSS2 mRNA

NCBI chr 1:239,867,597...239,952,614
Ensembl chr 1:230,454,426...230,539,331

G

progestin and adipoQ receptor family member 5

decreases expression
multiple interactions

Coumestrol results in decreased expression of PAQR5 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of PAQR5 mRNA

NCBI chr 8:71,327,397...71,409,201
Ensembl chr 8:62,431,867...62,513,688

G

par-3 family cell polarity regulator

decreases expression

Coumestrol results in decreased expression of PARD3 mRNA

NCBI chr19:71,977,420...72,527,273
Ensembl chr19:55,080,282...55,629,778

G

poly (ADP-ribose) polymerase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PARP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PARP1 mRNA

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase 2

increases expression
multiple interactions

Coumestrol results in increased expression of PARP2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PARP2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PARP2 mRNA

NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338

G

PARP1 binding protein

increases expression
multiple interactions

Coumestrol results in increased expression of PARPBP mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PARPBP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PARPBP mRNA

NCBI chr 7:24,398,897...24,468,330
Ensembl chr 7:22,511,427...22,573,695

G

parvin, alpha

decreases expression
multiple interactions

Coumestrol results in decreased expression of PARVA mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PARVA mRNA

NCBI chr 1:175,981,725...176,139,523
Ensembl chr 1:166,547,132...166,704,950

G

PATJ, crumbs cell polarity complex component

decreases expression

Coumestrol results in decreased expression of PATJ mRNA

NCBI chr 5:118,177,557...118,480,301
Ensembl chr 5:113,062,118...113,364,807

G

pro-apoptotic WT1 regulator

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PAWR mRNA
Coumestrol results in decreased expression of PAWR mRNA

NCBI chr 7:45,531,480...45,611,492
Ensembl chr 7:43,645,084...43,725,028

G

PAXX, non-homologous end joining factor

increases expression

Coumestrol results in increased expression of PAXX mRNA

NCBI chr 3:28,672,906...28,676,252
Ensembl chr 3:8,274,762...8,276,521

G

PDZ binding kinase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PBK mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PBK mRNA
Coumestrol results in increased expression of PBK mRNA

NCBI chr15:44,198,506...44,209,572
Ensembl chr15:40,023,002...40,034,014

G

PBX homeobox 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of PBX1 mRNA

NCBI chr13:82,811,664...83,121,447
Ensembl chr13:80,278,770...80,588,594

G

poly(rC) binding protein 2

decreases expression

Coumestrol results in decreased expression of PCBP2 mRNA

NCBI chr 7:135,483,702...135,508,254
Ensembl chr 7:133,605,573...133,629,863

G

protocadherin 10

decreases expression

Coumestrol results in decreased expression of PCDH10 mRNA

NCBI chr 2:128,617,212...128,683,354
Ensembl chr 2:128,617,174...128,677,190

G

protocadherin gamma subfamily C, 3

increases expression

Coumestrol results in increased expression of PCDHGC3 mRNA

NCBI chr18:29,633,016...29,667,865
Ensembl chr18:29,493,954...29,667,868

G

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

increases expression
multiple interactions

Coumestrol results in increased expression of PCK2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PCK2 mRNA

NCBI chr15:32,997,853...33,006,691
Ensembl chr15:29,027,894...29,037,283

G

PCNA clamp associated factor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PCLAF mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PCLAF mRNA
Coumestrol results in increased expression of PCLAF mRNA

NCBI chr 8:75,311,028...75,328,108
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994

G

protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of PCMTD1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PCMTD1 mRNA

NCBI chr 5:17,071,629...17,143,803
Ensembl chr 5:12,284,711...12,354,899

G

proliferating cell nuclear antigen

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PCNA mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PCNA mRNA
Coumestrol results in increased expression of PCNA mRNA

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995

G

pericentrin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PCNT mRNA

NCBI chr20:12,189,767...12,278,179
Ensembl chr20:12,191,648...12,278,710

G

Purkinje cell protein 4

increases expression
multiple interactions

Coumestrol results in increased expression of PCP4 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of PCP4 mRNA

NCBI chr11:49,229,185...49,331,186
Ensembl chr11:35,800,713...35,861,725

G

proprotein convertase subtilisin/kexin type 6

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PCSK6 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of PCSK6 mRNA
Coumestrol results in decreased expression of PCSK6 mRNA

NCBI chr 1:119,428,978...119,627,626
Ensembl chr 1:119,429,265...119,627,596

G

phosphatidylcholine transfer protein

decreases expression

Coumestrol results in decreased expression of PCTP mRNA

NCBI chr10:75,305,999...75,351,919
Ensembl chr10:74,808,887...74,849,867

G

programmed cell death 4

increases expression

Coumestrol results in increased expression of PDCD4 mRNA

NCBI chr 1:262,912,659...262,949,581
Ensembl chr 1:252,921,392...252,944,275

G

programmed cell death 6 interacting protein

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PDCD6IP mRNA
Coumestrol results in decreased expression of PDCD6IP mRNA

NCBI chr 8:122,469,223...122,524,993
Ensembl chr 8:113,590,998...113,646,773

G

platelet derived growth factor receptor alpha

increases expression

Coumestrol results in increased expression of PDGFRA mRNA; Coumestrol results in increased expression of PDGFRA protein

NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,005,839...33,054,335

G

platelet derived growth factor receptor beta

increases expression

Coumestrol results in increased expression of PDGFRB mRNA; Coumestrol results in increased expression of PDGFRB protein

NCBI chr18:56,770,348...56,809,228
Ensembl chr18:54,499,964...54,538,843

G

protein disulfide isomerase family A, member 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PDIA3 mRNA

NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:108,388,245...108,413,236

G

protein disulfide isomerase family A, member 6

increases expression
multiple interactions

Coumestrol results in increased expression of PDIA6 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PDIA6 mRNA

NCBI chr 6:45,791,704...45,808,947
Ensembl chr 6:40,062,926...40,080,613

G

PDZ and LIM domain 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PDLIM1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of PDLIM1 mRNA
Coumestrol results in decreased expression of PDLIM1 mRNA

NCBI chr 1:248,991,818...249,040,409
Ensembl chr 1:239,042,385...239,091,076

G

PDZ and LIM domain 3

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA]

NCBI chr16:53,085,020...53,116,495
Ensembl chr16:46,352,467...46,383,657

G

pyruvate dehydrogenase phosphatase catalytic subunit 1

decreases expression

Coumestrol results in decreased expression of PDP1 mRNA

NCBI chr 5:30,245,699...30,252,494
Ensembl chr 5:25,446,272...25,455,217

G

decaprenyl diphosphate synthase subunit 1

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of PDSS1 mRNA
Coumestrol results in increased expression of PDSS1 mRNA

NCBI chr17:89,964,768...90,006,819
Ensembl chr17:85,060,106...85,098,730

G

PDZ domain containing 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PDZK1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PDZK1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA]
Coumestrol results in increased expression of PDZK1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 2:187,064,995...187,096,348
Ensembl chr 2:184,376,161...184,407,514

G

p53 apoptosis effector related to PMP22

decreases expression

Coumestrol results in decreased expression of PERP mRNA

NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511

G

phosphofructokinase, liver type

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PFKL mRNA

NCBI chr20:10,663,907...10,685,967
Ensembl chr20:10,664,272...10,686,315

G

placental growth factor

decreases expression

Coumestrol results in decreased expression of PGF mRNA

NCBI chr 6:110,547,165...110,557,747
Ensembl chr 6:104,816,104...104,826,685

G

protein geranylgeranyltransferase type I subunit beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PGGT1B mRNA

NCBI chr18:38,952,147...38,995,656
Ensembl chr18:38,952,914...38,995,503

G

phosphoglycerate kinase 1

increases expression

Coumestrol results in increased expression of PGK1 mRNA

NCBI chr X:75,336,988...75,352,962
Ensembl chr X:71,271,440...71,287,418

G

phosphoglucomutase 2-like 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PGM2L1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of PGM2L1 mRNA
Coumestrol results in decreased expression of PGM2L1 mRNA

NCBI chr 1:154,571,410...154,620,901
Ensembl chr 1:154,571,766...154,620,902

G

phosphoglucomutase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PGM3 mRNA

NCBI chr 8:96,398,331...96,416,045
Ensembl chr 8:87,517,701...87,536,022

G

progesterone receptor

increases expression
multiple interactions

Coumestrol results in increased expression of PGR mRNA
[Fulvestrant co-treated with Coumestrol] results in decreased expression of PGR mRNA
Coumestrol inhibits the reaction [Estradiol results in increased expression of PGR protein]
ESR1 protein inhibits the reaction [Coumestrol results in increased expression of PGR mRNA]

PMID:10397250 PMID:11368421 PMID:11867264 PMID:23384675 PMID:34848279 More...

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344

G

progesterone receptor membrane component 1

increases expression
multiple interactions

Coumestrol results in increased expression of PGRMC1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PGRMC1 mRNA

NCBI chr X:120,698,610...120,706,805
Ensembl chr X:115,832,884...115,888,682

G

progesterone receptor membrane component 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PGRMC2 mRNA
Coumestrol results in decreased expression of PGRMC2 mRNA

NCBI chr 2:125,996,190...126,012,090
Ensembl chr 2:124,068,260...124,084,155

G

phosphatase and actin regulator 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PHACTR2 mRNA
Coumestrol results in decreased expression of PHACTR2 mRNA

NCBI chr 1:7,591,254...7,860,431
Ensembl chr 1:7,597,927...7,860,289

G

PHD finger protein 10

increases expression

Coumestrol results in increased expression of PHF10 mRNA

NCBI chr 1:64,625,373...64,642,110
Ensembl chr 1:55,952,253...55,969,038

G

PHD finger protein 19

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PHF19 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PHF19 mRNA
Coumestrol results in increased expression of PHF19 mRNA

NCBI chr 3:38,572,766...38,604,950
Ensembl chr 3:18,175,282...18,196,405

G

PHD finger protein 20-like 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PHF20L1 mRNA
Coumestrol results in decreased expression of PHF20L1 mRNA

NCBI chr 7:98,330,580...98,396,526
Ensembl chr 7:98,330,580...98,396,526

G

phosphoglycerate dehydrogenase

increases expression

Coumestrol results in increased expression of PHGDH mRNA

NCBI chr 2:188,595,700...188,624,789
Ensembl chr 2:185,906,966...185,935,944

G

pleckstrin homology-like domain, family A, member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PHLDA2 mRNA

NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:198,696,897...198,697,836

G

pleckstrin homology-like domain, family B, member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PHLDB2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of PHLDB2 mRNA

NCBI chr11:68,321,738...68,540,724
Ensembl chr11:54,859,135...55,078,467

G

phosphatase, orphan 2

decreases expression

Coumestrol results in decreased expression of PHOSPHO2 mRNA

NCBI chr 3:54,554,829...54,561,990
Ensembl chr 3:54,554,733...54,562,238

G

putative homeodomain transcription factor 1

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of PHTF1 mRNA
Coumestrol results in increased expression of PHTF1 mRNA

NCBI chr 2:194,161,343...194,249,925
Ensembl chr 2:191,473,130...191,512,078

G

putative homeodomain transcription factor 2

increases expression

Coumestrol results in increased expression of PHTF2 mRNA

NCBI chr 4:14,215,190...14,330,549
Ensembl chr 4:14,215,263...14,330,513

G

5-phosphohydroxy-L-lysine phospho-lyase

decreases expression

Coumestrol results in decreased expression of PHYKPL mRNA

NCBI chr10:35,839,965...35,863,631
Ensembl chr10:35,839,983...35,859,508

G

phosphatidylinositol binding clathrin assembly protein

decreases expression

Coumestrol results in decreased expression of PICALM mRNA

NCBI chr 1:153,468,982...153,550,086
Ensembl chr 1:144,056,721...144,137,557

G

PIF1 5'-to-3' DNA helicase

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA]

NCBI chr 8:66,110,641...66,120,202
Ensembl chr 8:66,111,072...66,120,200

G

PIH1 domain containing 1

increases expression

Coumestrol results in increased expression of PIH1D1 mRNA

NCBI chr 1:104,774,562...104,781,757
Ensembl chr 1:95,639,592...95,645,290

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha

decreases expression

Coumestrol results in decreased expression of PIK3C2A mRNA

NCBI chr 1:180,012,248...180,117,786
Ensembl chr 1:170,577,942...170,683,472

G

phosphatidylinositol 3-kinase, catalytic subunit type 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PIK3C3 mRNA

NCBI chr18:22,119,677...22,203,546
Ensembl chr18:21,845,295...21,929,048

G

PICALM interacting mitotic regulator

increases expression
multiple interactions

Coumestrol results in increased expression of PIMREG mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PIMREG mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PIMREG mRNA

NCBI chr10:57,168,136...57,173,713
Ensembl chr10:56,669,675...56,674,791

G

PTEN induced kinase 1

decreases expression

Coumestrol results in decreased expression of PINK1 mRNA

NCBI chr 5:155,813,838...155,825,950
Ensembl chr 5:150,530,523...150,542,635

G

phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha

increases expression

Coumestrol results in increased expression of PIP5K1A mRNA

NCBI chr 2:185,317,319...185,361,859
Ensembl chr 2:182,628,300...182,671,598

G

cAMP-dependent protein kinase inhibitor beta

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PKIB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of PKIB mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA]
Coumestrol results in increased expression of PKIB mRNA

PMID:18310284 PMID:19167446

NCBI chr20:37,511,564...37,608,607
Ensembl chr20:36,905,340...37,062,187

G

pyruvate kinase M1/2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PKM mRNA

NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:60,057,402...60,079,599

G

protein kinase, membrane associated tyrosine/threonine 1

increases expression
multiple interactions

Coumestrol results in increased expression of PKMYT1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PKMYT1 mRNA

NCBI chr10:13,252,805...13,263,584
Ensembl chr10:12,748,237...12,758,995

G

phosphatidylinositol-specific phospholipase C, X domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PLCXD1 mRNA

NCBI chr12:46,578,917...46,582,181
Ensembl chr12:46,579,225...46,582,392

G

pleckstrin homology domain containing A5

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PLEKHA5 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of PLEKHA5 mRNA
Coumestrol results in decreased expression of PLEKHA5 mRNA

NCBI chr 4:173,333,891...173,503,546
Ensembl chr 4:173,334,055...173,503,546

G

pleckstrin homology domain containing B2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PLEKHB2 mRNA
Coumestrol results in decreased expression of PLEKHB2 mRNA

NCBI chr 9:44,545,473...44,578,122
Ensembl chr 9:37,038,751...37,082,231

G

pleckstrin homology and FYVE domain containing 2

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of PLEKHF2 mRNA
Coumestrol results in decreased expression of PLEKHF2 mRNA

NCBI chr 5:24,091,077...24,106,758
Ensembl chr 5:24,090,688...24,106,601

G

polo-like kinase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PLK1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PLK1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA]
Coumestrol results in increased expression of PLK1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 1:186,147,658...186,157,637
Ensembl chr 1:176,716,420...176,726,400

G

polo-like kinase 4

increases expression
multiple interactions

Coumestrol results in increased expression of PLK4 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PLK4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PLK4 mRNA

NCBI chr 2:125,730,480...125,748,894
Ensembl chr 2:123,802,512...123,820,942

G

plasmolipin

decreases expression

Coumestrol results in decreased expression of PLLP mRNA

NCBI chr19:10,315,104...10,335,892
Ensembl chr19:10,315,104...10,335,892

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PLOD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PLOD2 mRNA

NCBI chr 8:101,964,318...102,047,022
Ensembl chr 8:93,084,513...93,167,255

G

phospholipid phosphatase 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of PLPP2 mRNA

NCBI chr 7:10,175,918...10,184,032
Ensembl chr 7:10,175,948...10,184,071

G

phospholipid phosphatase 6

decreases expression

Coumestrol results in decreased expression of PLPP6 mRNA

NCBI chr 1:226,679,100...226,681,952
Ensembl chr 1:226,679,100...226,681,949

G

plexin B2

decreases expression

Coumestrol results in decreased expression of PLXNB2 mRNA

NCBI chr 7:120,232,276...120,258,385
Ensembl chr 7:120,232,331...120,258,330

G

plexin D1

decreases expression

Coumestrol results in decreased expression of PLXND1 mRNA

NCBI chr 4:150,675,377...150,715,706
Ensembl chr 4:149,002,784...149,043,244

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of PMAIP1 mRNA

NCBI chr18:62,255,970...62,262,384
Ensembl chr18:59,986,017...59,992,429

G

prostate transmembrane protein, androgen induced 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of PMEPA1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PMEPA1 mRNA

NCBI chr 3:182,430,193...182,478,649
Ensembl chr 3:162,012,751...162,060,454

G

peripheral myelin protein 22

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of PMP22 mRNA

NCBI chr10:48,294,932...48,324,941
Ensembl chr10:47,795,709...47,825,714

G

peptidase, mitochondrial processing subunit beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PMPCB mRNA

NCBI chr 4:14,189,807...14,202,584
Ensembl chr 4:13,297,559...13,310,367

G

PMS1 homolog 1, mismatch repair system component

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of PMS1 mRNA
Coumestrol results in increased expression of PMS1 mRNA

NCBI chr 9:55,721,393...55,832,225
Ensembl chr 9:48,253,410...48,340,237

G

purine nucleoside phosphorylase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PNP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PNP mRNA
Coumestrol results in increased expression of PNP mRNA

NCBI chr15:26,644,147...26,651,808
Ensembl chr15:24,170,602...24,203,986

G

patatin-like phospholipase domain containing 8

decreases expression

Coumestrol results in decreased expression of PNPLA8 mRNA

NCBI chr 6:67,056,783...67,118,714
Ensembl chr 6:61,329,810...61,391,734

G

proline-rich nuclear receptor coactivator 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of PNRC1 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of PNRC1 mRNA

NCBI chr 5:47,647,070...47,657,832
Ensembl chr 5:47,647,071...47,650,161

G

POC1 centriolar protein A

increases expression

Coumestrol results in increased expression of POC1A mRNA

NCBI chr 8:115,801,335...115,869,812
Ensembl chr 8:106,922,978...106,991,089

G

DNA polymerase alpha 1, catalytic subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of POLA1 mRNA
Coumestrol results in increased expression of POLA1 mRNA

NCBI chr X:62,028,475...62,342,455
Ensembl chr X:58,034,619...58,348,536

G

DNA polymerase alpha 2, accessory subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLA2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of POLA2 mRNA
Coumestrol results in increased expression of POLA2 mRNA

NCBI chr 1:212,656,500...212,680,667
Ensembl chr 1:203,203,388...203,251,348

G

DNA polymerase delta 1, catalytic subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of POLD1 mRNA
Coumestrol results in increased expression of POLD1 mRNA

NCBI chr 1:104,161,984...104,178,074
Ensembl chr 1:95,025,499...95,036,465

G

DNA polymerase delta 2, accessory subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of POLD2 mRNA
Coumestrol results in increased expression of POLD2 mRNA

NCBI chr14:84,962,933...84,969,148
Ensembl chr14:80,748,974...80,755,160

G

DNA polymerase delta 3, accessory subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLD3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of POLD3 mRNA
Coumestrol results in increased expression of POLD3 mRNA

NCBI chr 1:163,830,217...163,870,015
Ensembl chr 1:154,418,084...154,456,665

G

DNA polymerase delta interacting protein 2

increases expression

Coumestrol results in increased expression of POLDIP2 mRNA

NCBI chr10:63,905,287...63,915,655
Ensembl chr10:63,407,213...63,417,605

G

DNA polymerase epsilon, catalytic subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLE mRNA
Coumestrol results in increased expression of POLE mRNA

NCBI chr12:52,005,155...52,053,761
Ensembl chr12:46,345,420...46,393,939

G

DNA polymerase epsilon 2, accessory subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLE2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of POLE2 mRNA
Coumestrol results in increased expression of POLE2 mRNA

NCBI chr 6:93,410,713...93,448,782
Ensembl chr 6:87,674,702...87,699,305

G

DNA polymerase epsilon 3, accessory subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLE3 mRNA

NCBI chr 5:80,989,508...80,992,742
Ensembl chr 5:75,974,717...75,977,231
Ensembl chr 7:75,974,717...75,977,231

G

DNA polymerase iota

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of POLI mRNA

NCBI chr18:64,116,774...64,134,373
Ensembl chr18:64,116,774...64,163,418

G

DNA polymerase theta

increases expression

Coumestrol results in increased expression of POLQ mRNA

NCBI chr11:77,179,190...77,281,270
Ensembl chr11:63,673,816...63,775,878

G

RNA polymerase I subunit B

increases expression

Coumestrol results in increased expression of POLR1B mRNA

NCBI chr 3:136,787,130...136,811,608
Ensembl chr 3:116,333,889...116,358,379

G

RNA polymerase I subunit H

increases expression

Coumestrol results in increased expression of POLR1H mRNA

NCBI chr20:1,600,170...1,604,088
Ensembl chr20:1,594,936...1,598,854

G

RNA polymerase II subunit D

increases expression

Coumestrol results in increased expression of POLR2D mRNA

NCBI chr18:23,418,097...23,425,228
Ensembl chr18:23,418,097...23,425,228

G

RNA polymerase II, I and III subunit E

increases expression

Coumestrol results in increased expression of POLR2E mRNA

NCBI chr 7:10,317,332...10,321,280
Ensembl chr 7:9,666,716...9,670,643

G

RNA polymerase II subunit G

increases expression

Coumestrol results in increased expression of POLR2G mRNA

NCBI chr 1:205,689,160...205,692,537
Ensembl chr 1:205,689,160...205,692,686

G

RNA polymerase II, I and III subunit H

increases expression

Coumestrol results in increased expression of POLR2H mRNA

NCBI chr11:93,696,423...93,701,902
Ensembl chr11:80,192,032...80,197,515
Ensembl chr10:80,192,032...80,197,515

G

phosphoribosyl pyrophosphate amidotransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PPAT mRNA

NCBI chr14:31,570,010...31,604,410
Ensembl chr14:31,216,165...31,250,144

G

phosphopantothenoylcysteine decarboxylase

increases expression

Coumestrol results in increased expression of PPCDC mRNA

NCBI chr 8:66,711,115...66,738,782
Ensembl chr 8:57,815,195...58,000,570

G

peptidylprolyl isomerase B

increases expression

Coumestrol results in increased expression of PPIB mRNA

NCBI chr 8:75,498,966...75,504,823
Ensembl chr 8:66,603,861...66,630,428

G

peptidylprolyl isomerase F

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PPIF mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PPIF mRNA
Coumestrol results in increased expression of PPIF mRNA

NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,257,106...1,263,913

G

periplakin

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PPL mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of PPL mRNA
Coumestrol results in decreased expression of PPL mRNA

NCBI chr10:10,957,388...11,003,035
Ensembl chr10:10,450,919...10,496,575

G

protein phosphatase, Mg2+/Mn2+ dependent, 1A

decreases expression

Coumestrol results in decreased expression of PPM1A mRNA

NCBI chr 6:97,174,955...97,216,585
Ensembl chr 6:91,438,834...91,480,697

G

protein phosphatase, Mg2+/Mn2+ dependent, 1E

increases expression
multiple interactions

Coumestrol results in increased expression of PPM1E mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of PPM1E mRNA

NCBI chr10:72,548,906...72,684,702
Ensembl chr10:72,055,208...72,187,282

G

protein phosphatase 1, regulatory subunit 10

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PPP1R10 mRNA

NCBI chr20:2,827,802...2,842,418
Ensembl chr20:2,822,995...2,837,611

G

protein phosphatase 1, regulatory subunit 12A

decreases expression

Coumestrol results in decreased expression of PPP1R12A mRNA

NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:43,482,803...43,593,425

G

protein phosphatase 1, regulatory subunit 13 like

decreases expression

Coumestrol results in decreased expression of PPP1R13L mRNA

NCBI chr 1:88,139,000...88,158,714
Ensembl chr 1:79,011,745...79,030,712

G

protein phosphatase 1, regulatory subunit 15A

decreases expression

Coumestrol results in decreased expression of PPP1R15A mRNA

NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:96,000,058...96,003,171

G

protein phosphatase 1, regulatory (inhibitor) subunit 2

decreases expression

Coumestrol results in decreased expression of PPP1R2 mRNA

NCBI chr11:82,977,634...82,999,426
Ensembl chr11:69,472,555...69,494,463

G

protein phosphatase 2, regulatory subunit B, alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PPP2R2A mRNA

NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924

G

protein phosphatase 2, regulatory subunit B'', alpha

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PPP2R3A mRNA
Coumestrol results in decreased expression of PPP2R3A mRNA

NCBI chr 8:110,582,479...110,720,516
Ensembl chr 8:101,704,778...101,841,502

G

protein phosphatase 2 regulatory subunit B', epsilon

decreases expression

Coumestrol results in decreased expression of PPP2R5E mRNA

NCBI chr 6:99,904,569...100,053,672
Ensembl chr 6:94,168,846...94,317,872

G

protein phosphatase 3 catalytic subunit gamma

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PPP3CC mRNA

NCBI chr15:51,699,586...51,771,763
Ensembl chr15:45,290,373...45,361,832

G

protein phosphatase 5, catalytic subunit

increases expression

Coumestrol results in increased expression of PPP5C mRNA

NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:77,690,208...77,714,456

G

peroxiredoxin 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRDX4 mRNA

NCBI chr X:40,026,762...40,044,066
Ensembl chr X:40,026,651...40,044,066

G

phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PREX1 mRNA

NCBI chr 3:175,724,939...175,875,764
Ensembl chr 3:155,306,950...155,456,688

G

DNA primase subunit 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRIM1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PRIM1 mRNA
Coumestrol results in increased expression of PRIM1 mRNA

NCBI chr 7:1,031,436...1,047,134
Ensembl chr 7:431,805...462,526

G

DNA primase subunit 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRIM2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PRIM2 mRNA
Coumestrol results in increased expression of PRIM2 mRNA

NCBI chr 9:35,692,376...35,904,521
Ensembl chr 9:35,692,376...35,903,030

G

protein kinase cAMP-activated catalytic subunit beta

decreases expression

Coumestrol results in decreased expression of PRKACB mRNA

NCBI chr 2:238,297,140...238,389,317
Ensembl chr 2:235,636,885...235,726,198

G

protein kinase C, eta

decreases expression

Coumestrol results in decreased expression of PRKCH mRNA

NCBI chr 6:98,027,830...98,226,486
Ensembl chr 6:92,292,000...92,490,654

G

protein kinase, DNA-activated, catalytic subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRKDC mRNA
Coumestrol results in increased expression of PRKDC mRNA

NCBI chr11:98,544,952...98,762,499
Ensembl chr11:85,040,792...85,257,952

G

prolactin

increases secretion
multiple interactions

Coumestrol results in increased secretion of PRL protein
Nifedipine inhibits the reaction [Coumestrol results in increased secretion of PRL protein]

PMID:15811834 PMID:17174995 PMID:19400946

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:37,860,007...37,870,062

G

protein arginine methyltransferase 5

increases expression

Coumestrol results in increased expression of PRMT5 mRNA

NCBI chr15:31,938,927...31,948,318
Ensembl chr15:27,968,910...27,978,296

G

prominin 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of PROM2 mRNA

NCBI chr 3:135,200,944...135,215,130
Ensembl chr 3:114,747,654...114,761,787

G

pre-mRNA splicing tri-snRNP complex factor PRPF4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRPF4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PRPF4 mRNA
Coumestrol results in increased expression of PRPF4 mRNA

NCBI chr 5:80,875,511...80,889,501
Ensembl chr 5:75,859,924...75,873,919

G

phosphoribosyl pyrophosphate synthetase 2

increases expression
multiple interactions

Coumestrol results in increased expression of PRPS2 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of PRPS2 mRNA

NCBI chr X:30,592,845...30,630,127
Ensembl chr X:26,976,061...27,013,181

G

proline rich 14

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRR14 mRNA

NCBI chr 1:182,083,838...182,089,330
Ensembl chr 1:182,084,126...182,089,317

G

proline rich 15

decreases expression

Coumestrol results in decreased expression of PRR15 mRNA

NCBI chr 4:83,432,002...83,435,582
Ensembl chr 4:83,431,758...83,437,436

G

proline-rich coiled-coil 2A

increases expression
multiple interactions

Coumestrol results in increased expression of PRRC2A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRRC2A mRNA

NCBI chr20:3,658,391...3,674,143
Ensembl chr20:3,658,695...3,674,130

G

proline-rich coiled-coil 2C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PRRC2C mRNA

NCBI chr13:77,537,226...77,606,926
Ensembl chr13:75,004,010...75,073,643

G

proline-rich transmembrane protein 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PRRT3 mRNA

NCBI chr 4:146,641,173...146,650,487
Ensembl chr 4:146,641,173...146,650,317

G

serine protease 23

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PRSS23 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of PRSS23 mRNA
Coumestrol results in decreased expression of PRSS23 mRNA

NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:143,401,396...143,422,091

G

serine protease 8

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of PRSS8 mRNA
Coumestrol results in decreased expression of PRSS8 mRNA

NCBI chr 1:182,536,229...182,540,745
Ensembl chr 1:182,536,229...182,540,815

G

pleckstrin and Sec7 domain containing 3

decreases expression

Coumestrol results in decreased expression of PSD3 mRNA

NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547

G

PC4 and SRSF1 interacting protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PSIP1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of PSIP1 mRNA
Coumestrol results in increased expression of PSIP1 mRNA

NCBI chr 5:102,892,929...102,925,191
Ensembl chr 5:97,847,015...97,879,257

G

proteasome 26S subunit, ATPase 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PSMC3 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of PSMC3 mRNA
Coumestrol results in increased expression of PSMC3 mRNA

NCBI chr 3:77,031,825...77,037,207
Ensembl chr 3:77,031,825...77,043,358

G

PSMC3 interacting protein

increases expression
multiple interactions

Coumestrol results in increased expression of PSMC3IP mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of PSMC3IP mRNA

NCBI chr10:86,524,546...86,527,764
Ensembl chr10:86,023,950...86,027,423

G

proteasome activator subunit 2

increases expression

Coumestrol results in increased expression of PSME2 mRNA

NCBI chr15:33,048,452...33,053,055
Ensembl chr15:29,078,500...29,082,946

G

proteasome assembly chaperone 3

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of PSMG3 mRNA
Coumestrol results in increased expression of PSMG3 mRNA

NCBI chr12:14,809,440...14,812,357
Ensembl chr12:14,809,450...14,812,342

G

proline and serine rich coiled-coil 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PSRC1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of PSRC1 mRNA
Coumestrol results in increased expression of PSRC1 mRNA

NCBI chr 2:198,710,427...198,715,001
Ensembl chr 2:196,022,361...196,026,874

G

polypyrimidine tract binding protein 1

increases expression
multiple interactions

Coumestrol results in increased expression of PTBP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PTBP1 mRNA

NCBI chr 7:10,493,199...10,502,957
Ensembl chr 7:9,842,574...9,852,397

G

Pentatricopeptide repeat domain 3

increases expression

Coumestrol results in increased expression of PTCD3 mRNA

NCBI chr 4:103,922,440...103,957,445
Ensembl chr 4:103,920,566...103,957,538

G

phosphatase and tensin homolog

decreases expression

Coumestrol results in decreased expression of PTEN mRNA

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin E synthase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PTGES mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of PTGES mRNA

NCBI chr 3:34,575,643...34,586,987

G

prothymosin alpha

decreases expression

Coumestrol results in decreased expression of PTMA protein alternative form

NCBI chr 9:94,624,194...94,628,276
Ensembl chr 9:87,176,230...87,180,333

G

protein tyrosine phosphatase 4A1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PTP4A1 mRNA
Coumestrol results in increased expression of PTP4A1 mRNA

NCBI chr 9:40,710,250...40,718,176
Ensembl chr 9:33,214,208...33,221,964

G

protein tyrosine phosphatase, non-receptor type 1

decreases expression

Coumestrol results in decreased expression of PTPN1 mRNA

NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:156,638,769...156,687,504

G

protein tyrosine phosphatase, non-receptor type 12

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PTPN12 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of PTPN12 mRNA
Coumestrol results in decreased expression of PTPN12 mRNA

NCBI chr 4:14,913,071...14,985,084
Ensembl chr 4:14,021,052...14,092,927

G

protein tyrosine phosphatase, non-receptor type 21

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PTPN21 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of PTPN21 mRNA
Coumestrol results in decreased expression of PTPN21 mRNA

NCBI chr 6:117,933,066...117,998,095
Ensembl chr 6:117,933,066...117,998,095

G

protein tyrosine phosphatase, receptor type, F

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of PTPRF mRNA
Coumestrol results in decreased expression of PTPRF mRNA

NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:131,742,754...131,810,023

G

protein tyrosine phosphatase, receptor type, K

decreases expression

Coumestrol results in decreased expression of PTPRK mRNA

NCBI chr 1:18,557,091...19,056,297
Ensembl chr 1:16,850,576...17,103,605

G

PTTG1 regulator of sister chromatid separation, securin

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PTTG1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of PTTG1 mRNA
Coumestrol results in increased expression of PTTG1 mRNA

NCBI chr10:28,394,940...28,406,410
Ensembl chr10:27,893,689...27,904,837

G

pseudouridine synthase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PUS3 mRNA

NCBI chr 8:33,910,461...33,918,716
Ensembl chr 8:33,911,357...33,918,714

G

pyridine nucleotide-disulphide oxidoreductase domain 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PYROXD1 mRNA

NCBI chr 4:175,292,124...175,311,143
Ensembl chr 4:175,292,177...175,308,689

G

glutamine and serine rich 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of QSER1 mRNA

NCBI chr 3:91,137,516...91,202,426
Ensembl chr 3:91,140,967...91,202,052

G

R3H domain containing 2

decreases expression

Coumestrol results in decreased expression of R3HDM2 mRNA

NCBI chr 7:65,097,685...65,225,863
Ensembl chr 7:63,232,346...63,340,540

G

RAB11 family interacting protein 1

decreases expression

Coumestrol results in decreased expression of RAB11FIP1 mRNA

NCBI chr16:64,886,902...64,917,491
Ensembl chr16:64,884,676...64,917,491

G

RAB14, member RAS oncogene family

decreases expression

Coumestrol results in decreased expression of RAB14 mRNA

NCBI chr 3:38,899,430...38,920,572
Ensembl chr 3:18,501,963...18,523,172

G

RAB24, member RAS oncogene family

decreases expression

Coumestrol results in decreased expression of RAB24 mRNA

NCBI chr17:9,313,593...9,315,675
Ensembl chr17:9,308,525...9,310,553

G

RAB29, member RAS oncogene family

decreases expression

Coumestrol results in decreased expression of RAB29 mRNA

NCBI chr13:45,859,930...45,865,468
Ensembl chr13:43,307,775...43,313,417

G

RAB2A, member RAS oncogene family

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RAB2 mRNA

NCBI chr 5:26,473,424...26,537,441
Ensembl chr 5:21,676,129...21,739,899

G

RAB31, member RAS oncogene family

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAB31 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RAB31 mRNA
Coumestrol results in increased expression of RAB31 mRNA

NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:105,246,709...105,381,253

G

RAB32, member RAS oncogene family

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RAB32 mRNA

NCBI chr 1:6,766,448...6,781,258
Ensembl chr 1:4,945,036...4,960,934

G

RAB33B, member RAS oncogene family

decreases expression

Coumestrol results in decreased expression of RAB33B mRNA

NCBI chr 2:137,678,953...137,689,581
Ensembl chr 2:135,528,116...135,538,719

G

Rab40b, member RAS oncogene family

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RAB40B mRNA
Coumestrol results in decreased expression of RAB40B mRNA

NCBI chr10:106,631,514...106,659,090
Ensembl chr10:106,631,514...106,659,090

G

RAB6A, member RAS oncogene family

decreases expression

Coumestrol results in decreased expression of RAB6A mRNA

NCBI chr 1:164,370,033...164,422,324
Ensembl chr 1:154,958,189...154,996,715

G

RAB8A, member RAS oncogene family

increases expression
multiple interactions

Coumestrol results in increased expression of RAB8A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAB8A mRNA

NCBI chr16:17,688,049...17,709,412
Ensembl chr16:17,654,034...17,675,678

G

Rac GTPase-activating protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RACGAP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RACGAP1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA]
Coumestrol results in increased expression of RACGAP1 mRNA

PMID:18310284 PMID:19167446

NCBI chr 7:132,629,789...132,659,738
Ensembl chr 7:130,750,936...130,780,831

G

RAD1 checkpoint DNA exonuclease

increases expression

Coumestrol results in increased expression of RAD1 mRNA

NCBI chr 2:61,188,755...61,196,868
Ensembl chr 2:59,461,607...59,469,689

G

RAD18 E3 ubiquitin protein ligase

increases expression

Coumestrol results in increased expression of RAD18 mRNA

NCBI chr 4:147,291,463...147,376,904
Ensembl chr 4:145,735,654...145,821,069

G

RAD21 cohesin complex component

increases expression
multiple interactions

Coumestrol results in increased expression of RAD21 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD21 mRNA

NCBI chr 7:85,177,715...85,204,657
Ensembl chr 7:83,287,870...83,314,817

G

RAD51 recombinase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD51 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RAD51 mRNA
Coumestrol results in increased expression of RAD51 mRNA

NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:106,100,381...106,125,035

G

RAD51 associated protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD51AP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RAD51AP1 mRNA
Coumestrol results in increased expression of RAD51AP1 mRNA

NCBI chr 4:161,445,610...161,458,661
Ensembl chr 4:159,759,459...159,772,524

G

RAD51 paralog C

increases expression
multiple interactions

Coumestrol results in increased expression of RAD51C mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD51C mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RAD51C mRNA

NCBI chr10:72,702,299...72,728,980
Ensembl chr10:72,205,032...72,231,248

G

RAD54 homolog B

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD54B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RAD54B mRNA
Coumestrol results in increased expression of RAD54B mRNA

NCBI chr 5:29,829,465...29,901,967
Ensembl chr 5:25,032,066...25,104,616

G

RAD54 like

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD54L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RAD54L mRNA
Coumestrol results in increased expression of RAD54L mRNA

NCBI chr 5:134,812,158...134,841,821
Ensembl chr 5:129,575,378...129,605,070

G

ribonucleic acid export 1

increases expression

Coumestrol results in increased expression of RAE1 mRNA

NCBI chr 3:161,779,096...161,794,048
Ensembl chr 3:161,779,088...161,794,038

G

retinoic acid induced 1

decreases expression

Coumestrol results in decreased expression of RAI1 mRNA

NCBI chr10:44,913,231...45,008,232
Ensembl chr10:44,947,909...45,008,232

G

Ral GTPase activating protein catalytic subunit alpha 1

decreases expression

Coumestrol results in decreased expression of RALGAPA1 mRNA

NCBI chr 6:78,712,554...78,987,486
Ensembl chr 6:72,977,432...73,252,378

G

RAN binding protein 1

increases expression
multiple interactions

Coumestrol results in increased expression of RANBP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RANBP1 mRNA

NCBI chr11:96,246,912...96,255,145
Ensembl chr11:82,742,600...82,750,838

G

RAN GTPase activating protein 1

increases expression
multiple interactions

Coumestrol results in increased expression of RANGAP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RANGAP1 mRNA

NCBI chr 7:115,104,820...115,130,564
Ensembl chr 7:113,224,703...113,250,438

G

Rap guanine nucleotide exchange factor 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RAPGEF2 mRNA

NCBI chr 2:166,505,868...166,728,139
Ensembl chr 2:164,207,513...164,244,247

G

Rap guanine nucleotide exchange factor like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAPGEFL1 mRNA

NCBI chr10:83,793,711...83,810,373
Ensembl chr10:83,793,694...83,810,371

G

RAS p21 protein activator 1

decreases expression

Coumestrol results in decreased expression of RASA1 mRNA

NCBI chr 2:17,593,136...17,676,707
Ensembl chr 2:15,857,980...15,940,854

G

ras related dexamethasone induced 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RASD1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of RASD1 mRNA

NCBI chr10:45,265,975...45,275,279
Ensembl chr10:44,766,455...44,768,186

G

RAS and EF hand domain containing

decreases expression
multiple interactions

Coumestrol results in decreased expression of RASEF mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RASEF mRNA

NCBI chr 5:87,548,908...87,619,286
Ensembl chr 5:87,548,908...87,619,031

G

RAS guanyl releasing protein 1

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA]

NCBI chr 3:124,624,039...124,684,079
Ensembl chr 3:104,170,013...104,230,056

G

RAS-like family 11 member B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RASL11B mRNA

NCBI chr14:34,369,029...34,373,250
Ensembl chr14:34,014,509...34,019,152

G

Ras association domain family member 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RASSF3 mRNA

NCBI chr 7:56,935,888...57,000,554
Ensembl chr 7:56,935,973...57,000,553

G

ribonucleoprotein, PTB-binding 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAVER1 mRNA

NCBI chr 8:19,610,464...19,629,188
Ensembl chr 8:19,610,466...19,629,152

G

RB1-inducible coiled-coil 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of RB1CC1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RB1CC1 mRNA

NCBI chr 5:17,948,522...18,012,434
Ensembl chr 5:13,161,648...13,225,560

G

RB binding protein 4, chromatin remodeling factor

increases expression
multiple interactions

Coumestrol results in increased expression of RBBP4 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBBP4 mRNA

NCBI chr 5:141,655,863...141,675,157
Ensembl chr 5:141,638,421...141,675,284
Ensembl chr 2:141,638,421...141,675,284

G

RB binding protein 8, endonuclease

increases expression
multiple interactions

Coumestrol results in increased expression of RBBP8 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBBP8 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RBBP8 mRNA

NCBI chr18:3,198,188...3,263,643
Ensembl chr18:2,921,286...2,988,846

G

RB binding protein 9, serine hydrolase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBBP9 mRNA
Coumestrol results in increased expression of RBBP9 mRNA

NCBI chr 3:152,378,426...152,392,370
Ensembl chr 3:131,925,341...131,932,156

G

RNA binding fox-1 homolog 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RBFOX2 mRNA

NCBI chr 7:110,691,230...110,934,901
Ensembl chr 7:108,810,628...109,054,691

G

RB transcriptional corepressor like 2

decreases expression

Coumestrol results in decreased expression of RBL2 mRNA

NCBI chr19:32,049,690...32,096,467
Ensembl chr19:15,876,853...15,923,572

G

RNA binding motif protein 10

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBM10 mRNA

NCBI chr X:4,093,914...4,126,060
Ensembl chr X:1,540,398...1,572,575

G

RNA binding motif protein 15

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBM15 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RBM15 mRNA
Coumestrol results in increased expression of RBM15 mRNA

NCBI chr 2:197,634,174...197,642,697
Ensembl chr 2:194,945,974...194,954,703

G

RNA binding motif protein 24

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of RBM24 mRNA

NCBI chr17:18,275,681...18,288,231
Ensembl chr17:18,275,688...18,288,102

G

RNA binding motif protein 41

decreases expression

Coumestrol results in decreased expression of RBM41 mRNA

NCBI chr X:103,605,732...103,660,381
Ensembl chr X:103,608,585...103,660,381

G

RNA binding motif, single stranded interacting protein 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of RBMS1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RBMS1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of RBMS1 mRNA

NCBI chr 3:45,195,828...45,420,406
Ensembl chr 3:45,197,972...45,420,376

G

RNA binding motif protein, X-linked

increases expression

Coumestrol results in increased expression of RBMX mRNA

NCBI chr X:140,342,544...140,352,121
Ensembl chr X:135,305,325...135,314,743

G

regulator of calcineurin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RCAN1 mRNA

NCBI chr11:45,108,123...45,188,065
Ensembl chr11:31,622,210...31,702,045

G

RCC1 and BTB domain containing protein 1

decreases expression

Coumestrol results in decreased expression of RCBTB1 mRNA

NCBI chr15:37,430,453...37,477,920
Ensembl chr15:33,319,586...33,365,302

G

RCC1 domain containing 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RCCD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RCCD1 mRNA
Coumestrol results in increased expression of RCCD1 mRNA

NCBI chr 1:134,271,870...134,281,556
Ensembl chr 1:134,271,857...134,280,781

G

REST corepressor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RCOR3 mRNA

NCBI chr13:106,156,166...106,196,542
Ensembl chr13:103,624,971...103,665,565

G

retinol dehydrogenase 13

decreases expression

Coumestrol results in decreased expression of RDH13 mRNA

NCBI chr 1:69,373,014...69,401,454
Ensembl chr 1:69,373,113...69,400,908

G

RAD52 motif containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RDM1 mRNA

NCBI chr10:87,062,322...87,073,273
Ensembl chr10:86,539,553...86,573,034

G

RecQ like helicase 4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RECQL4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RECQL4 mRNA
Coumestrol results in increased expression of RECQL4 mRNA

NCBI chr 7:110,304,092...110,311,426
Ensembl chr 7:108,423,455...108,430,619

G

receptor accessory protein 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of REEP3 mRNA

NCBI chr20:21,492,695...21,575,138
Ensembl chr20:21,493,954...21,578,697

G

receptor accessory protein 4

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of REEP4 mRNA

NCBI chr15:52,030,022...52,033,229
Ensembl chr15:45,619,941...45,623,526

G

receptor accessory protein 5

decreases expression
multiple interactions

Coumestrol results in decreased expression of REEP5 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of REEP5 mRNA

NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509

G

RAS-like, estrogen-regulated, growth-inhibitor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RERG mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of RERG mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA]
Coumestrol results in increased expression of RERG mRNA

PMID:18310284 PMID:19167446

NCBI chr 4:171,712,794...171,821,268
Ensembl chr 4:169,982,279...170,089,715

G

ret proto-oncogene

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RET mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RET mRNA

NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:151,326,431...151,368,176

G

replication factor C subunit 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RFC2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RFC2 mRNA
Coumestrol results in increased expression of RFC2 mRNA

NCBI chr12:27,756,920...27,770,049
Ensembl chr12:22,120,010...22,133,557

G

replication factor C subunit 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RFC3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RFC3 mRNA
Coumestrol results in increased expression of RFC3 mRNA

NCBI chr12:5,836,546...5,847,331
Ensembl chr12:1,000,994...1,011,778

G

replication factor C subunit 4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RFC4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RFC4 mRNA
Coumestrol results in increased expression of RFC4 mRNA

NCBI chr11:91,254,273...91,268,727
Ensembl chr11:77,749,638...77,764,122

G

replication factor C subunit 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RFC5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RFC5 mRNA
Coumestrol results in increased expression of RFC5 mRNA

NCBI chr12:44,868,322...44,877,879
Ensembl chr12:39,207,484...39,217,312

G

raftlin lipid raft linker 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RFTN1 mRNA
Coumestrol results in decreased expression of RFTN1 mRNA

NCBI chr 9:18,302,143...18,499,819
Ensembl chr 9:10,804,611...11,002,084

G

regulator of G-protein signaling 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RGS2 mRNA

NCBI chr13:58,350,063...58,352,666
Ensembl chr13:55,798,829...55,802,385

G

rhomboid 5 homolog 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RHBDF1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of RHBDF1 mRNA
Coumestrol results in decreased expression of RHBDF1 mRNA

NCBI chr10:15,406,832...15,419,765
Ensembl chr10:15,406,859...15,419,763

G

RAD9-HUS1-RAD1 interacting nuclear orphan 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RHNO1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RHNO1 mRNA
Coumestrol results in increased expression of RHNO1 mRNA

NCBI chr 4:163,320,141...163,325,527
Ensembl chr 4:161,634,048...161,639,371

G

Rho-related BTB domain containing 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of RHOBTB1 mRNA

NCBI chr20:19,326,197...19,455,182
Ensembl chr20:19,327,155...19,403,012

G

ras homolog family member Q

decreases expression
multiple interactions

Coumestrol results in decreased expression of RHOQ mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RHOQ mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of RHOQ mRNA

NCBI chr 6:13,368,499...13,403,929
Ensembl chr 1:106,622,141...106,623,699

G

ras homolog family member T1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RHOT1 mRNA

NCBI chr10:65,685,687...65,760,682
Ensembl chr10:65,170,560...65,262,804

G

RIB43A domain with coiled-coils 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of RIBC2 mRNA

NCBI chr 7:116,242,863...116,257,868
Ensembl chr 7:116,242,863...116,257,863

G

RPTOR independent companion of MTOR, complex 2

decreases expression

Coumestrol results in decreased expression of RICTOR mRNA

NCBI chr 2:57,539,279...57,631,291
Ensembl chr 2:55,811,322...55,901,426

G

ribosomal oxygenase 2

decreases expression

Coumestrol results in decreased expression of RIOX2 mRNA

NCBI chr11:54,327,311...54,353,989
Ensembl chr11:40,860,774...40,884,574

G

regulator of microtubule dynamics 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of RMDN2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RMDN2 mRNA

NCBI chr 6:15,372,569...15,443,000
Ensembl chr 6:15,375,496...15,441,480

G

RecQ mediated genome instability 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RMI1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RMI1 mRNA
Coumestrol results in increased expression of RMI1 mRNA

NCBI chr17:6,261,961...6,269,947
Ensembl chr17:6,256,450...6,264,695

G

RecQ mediated genome instability 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RMI2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RMI2 mRNA
Coumestrol results in increased expression of RMI2 mRNA

NCBI chr10:5,336,269...5,344,202
Ensembl chr10:4,830,553...4,837,235

G

ribonuclease H2, subunit A

increases expression
multiple interactions

Coumestrol results in increased expression of RNASEH2A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RNASEH2A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RNASEH2A mRNA

NCBI chr19:40,091,206...40,100,904
Ensembl chr19:23,186,383...23,196,041

G

Rho family GTPase 3

decreases expression

Coumestrol results in decreased expression of RND3 mRNA

NCBI chr 3:55,981,142...55,998,494
Ensembl chr 3:35,571,143...35,589,327

G

ring finger protein 144B

decreases expression

Coumestrol results in decreased expression of RNF144B mRNA

NCBI chr17:17,637,564...17,786,685
Ensembl chr17:17,432,786...17,562,760

G

ring finger protein 187

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RNF187 mRNA

NCBI chr10:43,709,493...43,715,392
Ensembl chr10:43,702,357...43,716,157

G

ring finger protein 19A, RBR E3 ubiquitin protein ligase

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RNF19A mRNA
Coumestrol results in decreased expression of RNF19A mRNA

NCBI chr 7:67,425,833...67,465,214
Ensembl chr 7:67,425,837...67,465,222

G

ring finger protein 26

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RNF26 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RNF26 mRNA
Coumestrol results in increased expression of RNF26 mRNA

NCBI chr 8:53,351,388...53,353,586
Ensembl chr 8:44,454,292...44,457,331

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ROCK2 mRNA

NCBI chr 6:45,407,823...45,502,773
Ensembl chr 6:39,679,082...39,774,031

G

replication protein A1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RPA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RPA1 mRNA
Coumestrol results in increased expression of RPA1 mRNA

NCBI chr10:60,647,185...60,698,279
Ensembl chr10:60,148,793...60,199,949

G

replication protein A3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RPA3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RPA3 mRNA
Coumestrol results in increased expression of RPA3 mRNA

NCBI chr 4:37,270,966...37,273,997
Ensembl chr 4:36,304,651...36,307,709

G

ribosome production factor 2 homolog

increases expression

Coumestrol results in increased expression of RPF2 mRNA

NCBI chr20:45,184,511...45,205,983
Ensembl chr20:43,629,951...43,651,509

G

ribosomal protein L31

decreases expression

Coumestrol results in decreased expression of RPL31 mRNA

NCBI chr 9:49,143,044...49,147,155
Ensembl chr 9:41,647,426...41,662,129
Ensembl chr 8:41,647,426...41,662,129

G

ribosomal protein L37A

decreases expression

Coumestrol results in decreased expression of RPL37A mRNA

NCBI chr 9:74,298,843...74,300,926

G

ribosomal protein L39 like 1

increases expression
multiple interactions

Coumestrol results in increased expression of RPL39L mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RPL39L mRNA

NCBI chr10:5,962,506...5,966,621
Ensembl chr10:5,454,559...5,462,029

G

ribophorin I

increases expression

Coumestrol results in increased expression of RPN1 mRNA

NCBI chr 4:122,100,976...122,122,382
Ensembl chr 4:120,543,667...120,565,069

G

reprimo, TP53 dependent G2 arrest mediator homolog

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of RPRM mRNA

NCBI chr 3:58,948,618...58,950,035
Ensembl chr 3:38,539,581...38,540,998

G

Ras-related GTP binding C

decreases expression
multiple interactions

Coumestrol results in decreased expression of RRAGC mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RRAGC mRNA

NCBI chr 5:136,148,239...136,167,773
Ensembl chr 5:136,148,276...136,167,767

G

ribonucleotide reductase catalytic subunit M1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RRM1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RRM1 mRNA
Coumestrol results in increased expression of RRM1 mRNA

NCBI chr 1:166,235,904...166,260,206
Ensembl chr 1:156,823,960...156,848,261

G

ribonucleotide reductase regulatory subunit M2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RRM2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RRM2 mRNA
Coumestrol results in increased expression of RRM2 mRNA

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:41,340,557...41,346,773

G

ribosomal RNA processing 15 homolog

decreases expression

Coumestrol results in decreased expression of RRP15 mRNA

NCBI chr13:98,276,276...98,299,357
Ensembl chr13:98,276,134...98,299,370

G

remodeling and spacing factor 1

decreases expression

Coumestrol results in decreased expression of RSF1 mRNA

NCBI chr 1:151,892,055...152,015,089
Ensembl chr 1:151,892,434...152,009,051

G

arginine and serine rich coiled-coil 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RSRC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of RSRC1 mRNA

NCBI chr 2:151,226,821...151,632,771
Ensembl chr 2:151,231,156...151,632,765

G

Ras suppressor protein 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of RSU1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RSU1 mRNA

NCBI chr17:81,037,848...81,286,127
Ensembl chr17:76,188,812...76,377,454

G

reticulon 2

decreases expression

Coumestrol results in decreased expression of RTN2 mRNA

NCBI chr 1:88,063,124...88,076,082
Ensembl chr 1:78,935,104...78,948,069

G

RUN domain containing 3A

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of RUNDC3A mRNA
Coumestrol results in decreased expression of RUNDC3A mRNA

NCBI chr10:87,852,746...87,861,903
Ensembl chr10:87,352,646...87,361,765

G

RUN domain containing 3B

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RUNDC3B mRNA
Coumestrol results in decreased expression of RUNDC3B mRNA

NCBI chr 4:26,417,501...26,554,404
Ensembl chr 4:25,462,752...25,599,471

G

RuvB-like AAA ATPase 2

increases expression

Coumestrol results in increased expression of RUVBL2 mRNA

NCBI chr 1:105,038,487...105,051,851
Ensembl chr 1:95,901,701...95,915,342

G

ribitol xylosyltransferase 1

decreases expression

Coumestrol results in decreased expression of RXYLT1 mRNA

NCBI chr 7:57,770,841...57,782,695
Ensembl chr 7:57,770,842...57,782,657

G

receptor-like tyrosine kinase

decreases expression

Coumestrol results in decreased expression of RYK mRNA

NCBI chr 8:112,298,158...112,370,912
Ensembl chr 8:103,419,275...103,491,698

G

S100 calcium binding protein A10

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of S100A10 mRNA

NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:179,220,887...179,229,661

G

S100 calcium binding protein A6

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of S100A6 mRNA

NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:176,100,899...176,102,180

G

sphingosine-1-phosphate receptor 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of S1PR3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of S1PR3 mRNA
Coumestrol results in decreased expression of S1PR3 mRNA

NCBI chr17:13,932,773...13,946,213
Ensembl chr17:13,781,050...13,794,505

G

serum amyloid A-like 1

increases expression

Coumestrol results in increased expression of SAAL1 mRNA

NCBI chr 1:97,198,685...97,218,131
Ensembl chr 1:97,198,800...97,222,156

G

SAC3 domain containing 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of SAC3D1 mRNA

NCBI chr 1:212,843,463...212,845,842
Ensembl chr 1:203,414,187...203,416,604

G

sacsin molecular chaperone

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of SACS mRNA
Coumestrol results in increased expression of SACS mRNA

NCBI chr15:39,461,853...39,546,419
Ensembl chr15:35,285,782...35,370,335

G

SUMO1 activating enzyme subunit 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SAE1 mRNA
Coumestrol results in increased expression of SAE1 mRNA

NCBI chr 1:86,159,114...86,215,089
Ensembl chr 1:77,030,965...77,086,986

G

scaffold attachment factor B

increases expression

Coumestrol results in increased expression of SAFB mRNA

NCBI chr 9:1,504,657...1,525,545
Ensembl chr 9:1,417,525...1,438,644

G

spalt-like transcription factor 4

decreases expression
multiple interactions

Coumestrol results in decreased expression of SALL4 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SALL4 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SALL4 mRNA

NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822

G

sterile alpha motif domain containing 4A

decreases expression
multiple interactions

Coumestrol results in decreased expression of SAMD4A mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of SAMD4A mRNA

NCBI chr15:20,135,994...20,352,131
Ensembl chr15:20,134,377...20,348,380

G

SAM and SH3 domain containing 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of SASH1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SASH1 mRNA

NCBI chr 1:4,940,207...5,238,777
Ensembl chr 1:3,121,332...3,439,870

G

spermidine/spermine N1-acetyl transferase 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of SAT1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SAT1 mRNA

NCBI chr X:44,008,089...44,011,376
Ensembl chr X:40,157,046...40,196,813

G

SATB homeobox 2

decreases expression

Coumestrol results in decreased expression of SATB2 mRNA

NCBI chr 9:58,348,027...58,534,256
Ensembl chr 9:58,350,246...58,530,707

G

scavenger receptor class B, member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SCARB1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SCARB1 mRNA

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:31,296,156...31,362,647

G

scavenger receptor class B, member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SCARB2 mRNA

NCBI chr14:15,842,583...15,894,123
Ensembl chr14:15,558,236...15,609,813

G

saccharopine dehydrogenase (putative)

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SCCPDH mRNA

NCBI chr13:91,400,120...91,421,875
Ensembl chr13:91,400,190...91,422,222

G

stearoyl-CoA desaturase

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of SCD mRNA
Coumestrol results in increased expression of SCD mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

syndecan 2

increases expression
multiple interactions

Coumestrol results in increased expression of SDC2 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of SDC2 mRNA

NCBI chr 7:66,012,405...66,125,101
Ensembl chr 7:64,127,110...64,241,081

G

Sec23 homolog B, COPII coat complex component

increases expression

Coumestrol results in increased expression of SEC23B mRNA

NCBI chr 3:152,392,340...152,434,813
Ensembl chr 3:131,939,337...131,981,489

G

SEC24 homolog D, COPII coat complex component

decreases expression

Coumestrol results in decreased expression of SEC24D mRNA

NCBI chr 2:214,103,138...214,211,155
Ensembl chr 2:211,418,623...211,526,587

G

SEC61 translocon subunit alpha 1

increases expression

Coumestrol results in increased expression of SEC61A1 mRNA

NCBI chr 4:122,530,785...122,545,141
Ensembl chr 4:120,960,626...120,987,925

G

selenium binding protein 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of SELENBP1 mRNA

NCBI chr 2:185,183,022...185,193,612
Ensembl chr 2:182,493,978...182,504,594

G

selenoprotein I

increases expression

Coumestrol results in increased expression of SELENOI mRNA

NCBI chr 6:26,073,127...26,111,326
Ensembl chr 6:26,072,648...26,111,314

G

selenoprotein P

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SELENOP mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SELENOP mRNA
Coumestrol results in decreased expression of SELENOP mRNA

NCBI chr 2:54,225,736...54,236,022
Ensembl chr 2:52,498,339...52,508,852

G

selenoprotein T

increases expression

Coumestrol results in increased expression of SELENOT mRNA

NCBI chr 2:144,954,324...144,971,375
Ensembl chr 2:142,804,405...142,821,427

G

semaphorin 3C

increases expression

Coumestrol results in increased expression of SEMA3C mRNA

NCBI chr 4:18,538,452...18,702,453
Ensembl chr 4:17,583,212...17,746,534

G

SUMO specific peptidase 1

increases expression

Coumestrol results in increased expression of SENP1 mRNA

NCBI chr 7:131,042,237...131,105,826
Ensembl chr 7:129,165,774...129,221,598

G

selenophosphate synthetase 1

increases expression
multiple interactions

Coumestrol results in increased expression of SEPHS1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SEPHS1 mRNA

NCBI chr17:73,354,435...73,382,803
Ensembl chr17:73,356,530...73,382,593

G

septin 8

increases expression

Coumestrol results in increased expression of SEPTIN8 mRNA

NCBI chr10:38,185,454...38,214,502
Ensembl chr10:37,684,639...37,713,174

G

septin 9

increases expression

Coumestrol results in increased expression of SEPTIN9 mRNA

NCBI chr10:102,908,557...103,077,789
Ensembl chr10:102,409,711...102,579,055

G

serine incorporator 1

decreases expression

Coumestrol results in decreased expression of SERINC1 mRNA

NCBI chr20:37,396,497...37,415,433
Ensembl chr20:36,850,076...36,896,691

G

serine incorporator 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SERINC5 mRNA

NCBI chr 2:23,846,899...23,950,346
Ensembl chr 2:23,846,900...23,950,346

G

serpin family B member 1A

decreases expression

Coumestrol results in decreased expression of SERPINB1 mRNA

NCBI chr17:31,799,446...31,807,853
Ensembl chr17:31,590,677...31,599,102

G

sestrin 2

decreases expression

Coumestrol results in decreased expression of SESN2 mRNA

NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:144,701,530...144,721,260

G

splicing factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SF1 mRNA

NCBI chr 1:213,090,256...213,112,688
Ensembl chr 1:203,670,018...203,684,330

G

splicing factor 3b, subunit 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SF3B3 mRNA

NCBI chr19:55,692,124...55,729,640
Ensembl chr19:38,783,040...38,820,245

G

stratifin

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SFN mRNA
Coumestrol results in increased expression of SFN mRNA

NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:145,826,201...145,831,314

G

SWI5-dependent homologous recombination repair protein 1

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of SFR1 mRNA
Coumestrol results in increased expression of SFR1 mRNA

NCBI chr 1:256,560,533...256,564,547
Ensembl chr 1:246,597,044...246,623,250

G

sideroflexin 1

decreases expression

Coumestrol results in decreased expression of SFXN1 mRNA

NCBI chr17:10,491,315...10,527,793
Ensembl chr17:10,486,271...10,522,529

G

sideroflexin 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SFXN2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SFXN2 mRNA
Coumestrol results in increased expression of SFXN2 mRNA

NCBI chr 1:245,447,014...245,459,312
Ensembl chr 1:245,447,015...245,468,411
Ensembl chr 1:245,447,015...245,468,411

G

sarcoglycan, gamma

decreases expression
multiple interactions

Coumestrol results in decreased expression of SGCG mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SGCG mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SGCG mRNA

NCBI chr15:39,564,920...39,611,149
Ensembl chr15:35,386,534...35,435,148

G

SAGA complex associated factor 29

increases expression

Coumestrol results in increased expression of SGF29 mRNA

NCBI chr 1:190,668,803...190,702,500
Ensembl chr 1:181,238,468...181,274,781

G

serum/glucocorticoid regulated kinase family, member 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SGK3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SGK3 mRNA
Coumestrol results in increased expression of SGK3 mRNA

NCBI chr 5:9,345,761...9,472,243
Ensembl chr 5:9,346,040...9,415,476

G

shugoshin 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SGO1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SGO1 mRNA
Coumestrol results in increased expression of SGO1 mRNA

NCBI chr 9:6,908,661...6,943,483
Ensembl chr 9:6,672,123...6,687,805

G

shugoshin 2

increases expression
multiple interactions

Coumestrol results in increased expression of SGO2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SGO2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SGO2 mRNA

NCBI chr 9:67,032,083...67,067,439
Ensembl chr 9:59,548,683...59,573,229

G

SH3 domain binding glutamate rich protein like 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of SH3BGRL mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SH3BGRL mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SH3BGRL mRNA

NCBI chr X:78,242,704...78,343,633
Ensembl chr X:74,166,871...74,263,783

G

SH3-domain binding protein 4

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SH3BP4 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SH3BP4 mRNA
Coumestrol results in decreased expression of SH3BP4 mRNA

NCBI chr 9:89,660,156...89,739,163
Ensembl chr 9:89,660,156...89,739,163

G

SH3 domain containing 19

decreases expression

Coumestrol results in decreased expression of SH3D19 mRNA

NCBI chr 2:171,356,244...171,516,042
Ensembl chr 2:171,356,251...171,515,561

G

SH3 domain-containing kinase-binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SH3KBP1 mRNA

NCBI chr X:38,686,530...39,031,658
Ensembl chr X:34,877,866...35,222,747

G

SH3 domain containing ring finger 1

decreases expression

Coumestrol results in decreased expression of SH3RF1 mRNA

NCBI chr16:33,746,396...33,912,127
Ensembl chr16:28,735,440...28,901,644

G

SH3 and SYLF domain containing 1

decreases expression

Coumestrol results in decreased expression of SH3YL1 mRNA

NCBI chr 6:47,522,098...47,565,858
Ensembl chr 6:47,522,091...47,565,858

G

sex hormone binding globulin

affects binding

Coumestrol binds to SHBG protein

NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,332,941...54,351,057

G

SHC binding and spindle associated 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SHCBP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SHCBP1 mRNA
Coumestrol results in increased expression of SHCBP1 mRNA

NCBI chr16:91,373,843...91,405,409
Ensembl chr16:84,672,321...84,703,844

G

shisa family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SHISA2 mRNA

NCBI chr15:33,806,715...33,811,013
Ensembl chr15:33,805,958...33,811,013

G

serine hydroxymethyltransferase 1

increases expression
multiple interactions

Coumestrol results in increased expression of SHMT1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SHMT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SHMT1 mRNA

NCBI chr10:45,968,959...45,990,341
Ensembl chr10:45,468,700...45,497,820

G

serine hydroxymethyltransferase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SHMT2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SHMT2 mRNA
Coumestrol results in increased expression of SHMT2 mRNA

NCBI chr 7:65,244,247...65,249,580
Ensembl chr 7:63,358,961...63,364,236

G

shroom family member 3

decreases expression

Coumestrol results in decreased expression of SHROOM3 mRNA

NCBI chr14:15,099,415...15,396,832
Ensembl chr14:15,099,423...15,396,915

G

sirtuin 1

decreases expression

Coumestrol results in decreased expression of SIRT1 mRNA

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260

G

spindle and kinetochore associated complex subunit 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SKA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SKA1 mRNA
Coumestrol results in increased expression of SKA1 mRNA

NCBI chr18:70,069,957...70,080,303
Ensembl chr18:67,794,725...67,805,037

G

spindle and kinetochore associated complex subunit 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SKA2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SKA2 mRNA
Coumestrol results in increased expression of SKA2 mRNA

NCBI chr10:72,418,707...72,436,721
Ensembl chr10:71,921,582...71,939,458

G

spindle and kinetochore associated complex subunit 3

increases expression
multiple interactions

Coumestrol results in increased expression of SKA3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SKA3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SKA3 mRNA

NCBI chr15:36,067,372...36,086,563
Ensembl chr15:31,951,825...31,971,010

G

src kinase associated phosphoprotein 2

increases expression
multiple interactions

Coumestrol results in increased expression of SKAP2 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of SKAP2 mRNA

NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891

G

SKI-like proto-oncogene

decreases expression

Coumestrol results in decreased expression of SKIL mRNA

NCBI chr 2:114,175,534...114,203,663
Ensembl chr 2:112,247,051...112,275,080

G

S-phase kinase associated protein 2

increases expression
multiple interactions

Coumestrol results in increased expression of SKP2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SKP2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SKP2 mRNA

NCBI chr 2:59,888,406...59,916,471
Ensembl chr 2:58,161,229...58,189,338

G

stem-loop histone mRNA binding protein

increases expression
multiple interactions

Coumestrol results in increased expression of SLBP mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLBP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SLBP mRNA

NCBI chr14:81,295,479...81,306,446
Ensembl chr14:77,071,632...77,081,906

G

solute carrier family 12 member 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of SLC12A2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC12A2 mRNA

NCBI chr18:53,546,263...53,614,478
Ensembl chr18:51,348,302...51,416,440

G

solute carrier family 12 member 4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC12A4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SLC12A4 mRNA
Coumestrol results in increased expression of SLC12A4 mRNA

NCBI chr19:50,748,268...50,770,217
Ensembl chr19:33,838,419...33,860,331

G

solute carrier family 12, member 8

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC12A8 mRNA
Coumestrol results in decreased expression of SLC12A8 mRNA

NCBI chr11:80,622,000...80,771,674
Ensembl chr11:67,116,877...67,266,834

G

solute carrier family 17 member 5

decreases expression
multiple interactions

Coumestrol results in decreased expression of SLC17A5 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of SLC17A5 mRNA

NCBI chr 8:88,274,497...88,309,734

G

solute carrier family 1 member 4

increases expression
multiple interactions

Coumestrol results in increased expression of SLC1A4 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC1A4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SLC1A4 mRNA

NCBI chr14:98,718,646...98,761,672
Ensembl chr14:94,529,084...94,560,418

G

solute carrier family 22, member 23

decreases expression

Coumestrol results in decreased expression of SLC22A23 mRNA

NCBI chr17:30,544,106...30,709,790
Ensembl chr17:30,544,106...30,709,790

G

solute carrier family 25 member 11

increases expression
multiple interactions

Coumestrol results in increased expression of SLC25A11 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC25A11 mRNA

NCBI chr10:55,856,209...55,859,060
Ensembl chr10:55,357,597...55,360,410

G

solute carrier family 25 member 15

increases expression

Coumestrol results in increased expression of SLC25A15 mRNA

NCBI chr16:76,334,037...76,357,325
Ensembl chr16:69,634,414...69,653,010

G

solute carrier family 25 member 29

decreases expression

Coumestrol results in decreased expression of SLC25A29 mRNA

NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940

G

solute carrier family 25 member 37

decreases expression

Coumestrol results in decreased expression of SLC25A37 mRNA

NCBI chr15:50,944,085...50,986,506
Ensembl chr15:44,536,727...44,577,199

G

solute carrier family 25, member 39

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC25A39 mRNA
Coumestrol results in increased expression of SLC25A39 mRNA

NCBI chr10:87,862,630...87,867,626
Ensembl chr10:87,362,490...87,367,260

G

solute carrier family 26 member 11

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC26A11 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SLC26A11 mRNA

NCBI chr10:105,112,020...105,134,393
Ensembl chr10:104,613,564...104,635,970

G

solute carrier family 26 member 2

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SLC26A2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA]

PMID:18310284 PMID:19167446

NCBI chr18:56,918,662...56,937,032
Ensembl chr18:54,652,951...54,666,626

G

solute carrier family 27 member 2

increases expression
multiple interactions

Coumestrol results in increased expression of SLC27A2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC27A2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SLC27A2 mRNA

NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:113,804,728...113,842,208

G

solute carrier family 27 member 3

increases expression
multiple interactions

Coumestrol results in increased expression of SLC27A3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC27A3 mRNA

NCBI chr 2:175,853,241...175,857,909
Ensembl chr 2:175,853,241...175,857,909

G

solute carrier family 29 member 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC29A1 mRNA
Coumestrol results in increased expression of SLC29A1 mRNA

NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:15,399,612...15,414,203

G

SLC2A4 regulator

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC2A4RG mRNA
Coumestrol results in increased expression of SLC2A4RG mRNA

NCBI chr 3:168,493,975...168,497,616

G

solute carrier family 30 member 1

decreases expression

Coumestrol results in decreased expression of SLC30A1 mRNA

NCBI chr13:106,022,019...106,025,892
Ensembl chr13:103,491,037...103,494,910

G

solute carrier family 31 member 1

increases expression

Coumestrol results in increased expression of SLC31A1 mRNA

NCBI chr 5:80,830,574...80,859,810
Ensembl chr 5:75,814,743...75,844,228

G

solute carrier family 35 member A3

decreases expression

Coumestrol results in decreased expression of SLC35A3 mRNA

NCBI chr 2:207,305,008...207,344,225
Ensembl chr 2:204,579,174...204,659,319

G

solute carrier family 35 member D2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC35D2 mRNA
Coumestrol results in decreased expression of SLC35D2 mRNA

NCBI chr17:992,153...1,025,476
Ensembl chr17:988,157...1,019,743

G

solute carrier family 35, member E1

decreases expression

Coumestrol results in decreased expression of SLC35E1 mRNA

NCBI chr16:17,384,980...17,398,227
Ensembl chr16:17,350,988...17,363,268

G

solute carrier family 37 member 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC37A4 mRNA

NCBI chr 8:53,619,952...53,626,110
Ensembl chr 8:44,723,339...44,729,301

G

solute carrier family 39 member 4

increases expression

Coumestrol results in increased expression of SLC39A4 mRNA

NCBI chr 7:110,214,017...110,218,202
Ensembl chr 7:108,333,381...108,337,553

G

solute carrier family 39 member 8

increases expression
multiple interactions

Coumestrol results in increased expression of SLC39A8 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC39A8 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SLC39A8 mRNA

NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:224,256,654...224,319,129

G

solute carrier family 5 member 3

increases expression

Coumestrol results in increased expression of SLC5A3 mRNA

NCBI chr11:44,799,787...44,802,233
Ensembl chr11:31,295,476...31,318,883

G

solute carrier family 6 member 14

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC6A14 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SLC6A14 mRNA
Coumestrol results in increased expression of SLC6A14 mRNA

NCBI chr X:117,109,063...117,169,522
Ensembl chr X:112,314,691...112,375,096

G

solute carrier family 7 member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC7A1 mRNA

NCBI chr12:11,664,488...11,740,030
Ensembl chr12:6,628,007...6,703,849

G

solute carrier family 7 member 11

decreases expression
multiple interactions

Coumestrol results in decreased expression of SLC7A11 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC7A11 mRNA

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier family 7 member 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC7A5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SLC7A5 mRNA
Coumestrol results in increased expression of SLC7A5 mRNA

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:49,935,220...49,963,823

G

SMC5-SMC6 complex localization factor 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLF1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SLF1 mRNA
Coumestrol results in increased expression of SLF1 mRNA

NCBI chr 2:8,498,776...8,606,251
Ensembl chr 2:6,767,015...6,867,149

G

SMC5-SMC6 complex localization factor 2

increases expression

Coumestrol results in increased expression of SLF2 mRNA

NCBI chr 1:253,731,979...253,794,577
Ensembl chr 1:243,782,246...243,845,250

G

SMAD family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SMAD2 mRNA

NCBI chr18:72,124,792...72,193,345
Ensembl chr18:69,850,377...69,912,323

G

SMAD family member 3

decreases expression
multiple interactions

Coumestrol results in decreased expression of SMAD3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SMAD3 mRNA

NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:64,110,039...64,236,960

G

structural maintenance of chromosomes 1A

increases expression
multiple interactions

Coumestrol results in increased expression of SMC1A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SMC1A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SMC1A mRNA

NCBI chr X:24,582,732...24,627,462
Ensembl chr X:21,103,282...21,148,056

G

structural maintenance of chromosomes 2

increases expression
multiple interactions

Coumestrol results in increased expression of SMC2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SMC2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SMC2 mRNA

NCBI chr 5:71,592,428...71,648,636
Ensembl chr 5:66,807,011...66,853,242

G

structural maintenance of chromosomes 4

increases expression
multiple interactions

Coumestrol results in increased expression of SMC4 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SMC4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SMC4 mRNA

NCBI chr 2:155,550,262...155,578,695
Ensembl chr 2:153,240,283...153,271,571

G

structural maintenance of chromosomes 5

decreases expression

Coumestrol results in decreased expression of SMC5 mRNA

NCBI chr 1:230,195,894...230,265,677
Ensembl chr 1:220,769,366...220,839,096

G

small integral membrane protein 14

decreases expression

Coumestrol results in decreased expression of SMIM14 mRNA

NCBI chr14:42,783,361...42,829,762
Ensembl chr14:42,783,332...42,829,760

G

SET and MYND domain containing 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SMYD2 mRNA

NCBI chr13:103,956,470...103,997,774
Ensembl chr13:101,425,273...101,466,576

G

synaptosome associated protein 23

decreases expression

Coumestrol results in decreased expression of SNAP23 mRNA

NCBI chr 3:127,966,184...127,999,929
Ensembl chr 3:107,514,131...107,544,320

G

small nuclear RNA activating complex, polypeptide 3

decreases expression

Coumestrol results in decreased expression of SNAPC3 mRNA

NCBI chr 5:97,817,827...97,868,494
Ensembl chr 5:97,817,947...97,844,650

G

stannin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNN mRNA

NCBI chr10:4,572,933...4,581,606
Ensembl chr10:4,572,376...4,584,021
Ensembl chr 1:4,572,376...4,584,021

G

small nucleolar RNA, H/ACA box 24

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNORA24 mRNA

NCBI chr 2:82,490,770...82,490,892
Ensembl chr 2:82,490,770...82,490,892
Ensembl chr 2:82,490,770...82,490,892

G

small nucleolar RNA, C/D box 52

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNORD52 mRNA

NCBI chr20:3,878,412...3,878,477
Ensembl chr20:3,878,412...3,878,477

G

small nuclear ribonucleoprotein U11/U12 subunit 25

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNRNP25 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of SNRNP25 mRNA
Coumestrol results in increased expression of SNRNP25 mRNA

NCBI chr10:15,420,482...15,423,806
Ensembl chr10:15,420,486...15,423,804

G

small nuclear ribonucleoprotein polypeptide A

increases expression

Coumestrol results in increased expression of SNRPA mRNA

NCBI chr 1:91,609,419...91,618,119
Ensembl chr 1:82,481,770...82,490,538

G

small nuclear ribonucleoprotein polypeptide A'

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNRPA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SNRPA1 mRNA
Coumestrol results in increased expression of SNRPA1 mRNA

NCBI chr 1:129,051,492...129,065,114
Ensembl chr 1:119,638,481...119,654,653

G

small nuclear ribonucleoprotein polypeptides B and B1

increases expression
multiple interactions

Coumestrol results in increased expression of SNRPB mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNRPB mRNA

NCBI chr 3:137,824,870...137,832,479
Ensembl chr 3:117,370,100...117,379,339

G

small nuclear ribonucleoprotein D1 polypeptide

increases expression

Coumestrol results in increased expression of SNRPD1 mRNA

NCBI chr18:1,969,351...1,980,207
Ensembl chr18:1,696,852...1,708,256

G

sorting nexin 10

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNX10 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SNX10 mRNA

NCBI chr 4:81,943,262...82,007,667
Ensembl chr 4:80,612,669...80,676,996

G

sorting nexin 13

decreases expression

Coumestrol results in decreased expression of SNX13 mRNA

NCBI chr 6:57,478,139...57,589,624
Ensembl chr 6:51,753,036...51,860,224

G

sorting nexin 24

increases expression
multiple interactions

Coumestrol results in increased expression of SNX24 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNX24 mRNA

NCBI chr18:46,670,987...46,826,070
Ensembl chr18:46,671,443...46,826,068

G

sorting nexin 25

decreases expression

Coumestrol results in decreased expression of SNX25 mRNA

NCBI chr16:52,867,102...52,971,028
Ensembl chr16:46,125,804...46,238,440

G

sorting nexin 29

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNX29 mRNA

NCBI chr10:4,391,866...4,805,682
Ensembl chr10:3,888,301...4,298,655

G

sorting nexin 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNX6 mRNA

NCBI chr 6:77,966,141...78,009,343
Ensembl chr 6:72,229,870...72,315,911

G

sorting nexin 9

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNX9 mRNA
Coumestrol results in decreased expression of SNX9 mRNA

NCBI chr 1:48,827,061...48,915,215
Ensembl chr 1:46,423,553...46,509,036

G

suppressor of cytokine signaling 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SOCS2 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of SOCS2 mRNA

NCBI chr 7:31,890,564...31,932,092
Ensembl chr 7:30,008,578...30,043,548

G

suppressor of cytokine signaling 5

decreases expression

Coumestrol results in decreased expression of SOCS5 mRNA

NCBI chr 6:13,235,157...13,266,161
Ensembl chr 6:7,481,095...7,514,834

G

superoxide dismutase 2

increases expression
affects response to substance
multiple interactions

Coumestrol results in increased expression of SOD2 protein
SOD2 protein affects the susceptibility to Coumestrol
ESR2 protein affects the reaction [Coumestrol results in increased expression of SOD2 protein]; fulvestrant inhibits the reaction [Coumestrol results in increased expression of SOD2 protein]

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

G

SRY-box transcription factor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SOX3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SOX3 mRNA

NCBI chr X:144,344,892...144,346,971
Ensembl chr X:139,309,329...139,310,678

G

SRY-box transcription factor 4

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SOX4 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SOX4 mRNA
Coumestrol results in decreased expression of SOX4 mRNA

NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,667,537...35,673,665

G

SRY-box transcription factor 9

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SOX9 mRNA
Coumestrol results in decreased expression of SOX9 mRNA

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:97,806,485...97,811,994

G

sperm associated antigen 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPAG5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SPAG5 mRNA
Coumestrol results in increased expression of SPAG5 mRNA

NCBI chr10:63,693,300...63,714,813
Ensembl chr10:63,198,768...63,216,745

G

spartin

decreases expression

Coumestrol results in decreased expression of SPART mRNA

NCBI chr 2:141,442,770...141,469,388
Ensembl chr 2:139,292,355...139,319,248

G

spermatogenesis associated 20

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of SPATA20 mRNA
Coumestrol results in decreased expression of SPATA20 mRNA

NCBI chr10:79,427,525...79,435,472
Ensembl chr10:79,427,528...79,434,368

G

spermatogenesis associated 2-like

decreases expression

Coumestrol results in decreased expression of SPATA2L mRNA

NCBI chr19:51,269,078...51,273,605
Ensembl chr19:51,269,078...51,273,510

G

spermatogenesis associated 7

decreases expression
multiple interactions

Coumestrol results in decreased expression of SPATA7 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SPATA7 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SPATA7 mRNA

NCBI chr 6:123,609,519...123,655,001
Ensembl chr 6:117,879,823...117,925,284

G

SPC24 component of NDC80 kinetochore complex

increases expression
multiple interactions

Coumestrol results in increased expression of SPC24 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPC24 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SPC24 mRNA

NCBI chr 8:28,576,409...28,581,481
Ensembl chr 8:20,300,319...20,305,310

G

SPC25 component of NDC80 kinetochore complex

increases expression
multiple interactions

Coumestrol results in increased expression of SPC25 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPC25 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SPC25 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA]

PMID:18310284 PMID:19167446

NCBI chr 3:74,337,872...74,396,825
Ensembl chr 3:53,975,704...53,988,959

G

SAM pointed domain containing ets transcription factor

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of SPDEF mRNA

NCBI chr20:5,771,440...5,785,893
Ensembl chr20:5,771,441...5,785,893

G

spindle apparatus coiled-coil protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPDL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SPDL1 mRNA
Coumestrol results in increased expression of SPDL1 mRNA

NCBI chr10:19,773,456...19,798,341
Ensembl chr10:19,269,127...19,294,127

G

spindlin family, member 4

increases expression
multiple interactions

Coumestrol results in increased expression of SPIN4 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPIN4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SPIN4 mRNA

NCBI chr X:63,898,338...63,902,427
Ensembl chr X:59,891,581...59,892,330

G

spire-type actin nucleation factor 2

decreases expression

Coumestrol results in decreased expression of SPIRE2 mRNA

NCBI chr19:68,281,878...68,320,427
Ensembl chr19:51,373,228...51,411,920

G

sprouty-related, EVH1 domain containing 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of SPRED2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SPRED2 mRNA

NCBI chr14:98,350,577...98,452,143
Ensembl chr14:94,148,837...94,249,162

G

serine palmitoyltransferase, long chain base subunit 1

increases expression

Coumestrol results in increased expression of SPTLC1 mRNA

NCBI chr17:12,029,189...12,068,234
Ensembl chr17:11,877,249...11,916,295

G

sulfide quinone oxidoreductase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SQOR mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SQOR mRNA

NCBI chr 3:109,841,225...109,886,724
Ensembl chr 3:109,841,250...109,960,778

G

sequestosome 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SQSTM1 mRNA
Coumestrol results in decreased expression of SQSTM1 mRNA

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673

G

steroid receptor associated and regulated protein

decreases expression

Coumestrol results in decreased expression of SRARP mRNA

NCBI chr 5:159,023,949...159,028,053
Ensembl chr 5:153,740,975...153,744,998

G

steroid 5 alpha-reductase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRD5A3 mRNA

NCBI chr14:32,400,603...32,414,987
Ensembl chr14:32,046,408...32,060,747

G

sorcin

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SRI mRNA
Coumestrol results in decreased expression of SRI mRNA

NCBI chr 4:26,928,338...26,952,980
Ensembl chr 4:25,966,750...25,998,077

G

spermidine synthase

increases expression
multiple interactions

Coumestrol results in increased expression of SRM mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRM mRNA

NCBI chr 5:164,309,002...164,312,203
Ensembl chr 5:159,025,873...159,029,405

G

SRP receptor subunit beta

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRPRB mRNA
Coumestrol results in increased expression of SRPRB mRNA

NCBI chr 8:103,768,685...103,782,632

G

serine racemase

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of SRR mRNA

NCBI chr10:60,267,936...60,285,094
Ensembl chr10:59,769,571...59,787,011

G

serine/arginine repetitive matrix 2

increases expression

Coumestrol results in increased expression of SRRM2 mRNA

NCBI chr10:13,320,059...13,353,337
Ensembl chr10:12,815,471...12,848,751

G

serrate, RNA effector molecule

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRRT mRNA
Coumestrol results in increased expression of SRRT mRNA

NCBI chr12:19,392,578...19,406,098
Ensembl chr12:19,392,625...19,406,095

G

serine and arginine rich splicing factor 1

increases expression
multiple interactions

Coumestrol results in increased expression of SRSF1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRSF1 mRNA

NCBI chr10:73,335,519...73,342,549
Ensembl chr10:72,839,274...72,845,336

G

serine and arginine rich splicing factor 10

increases expression
multiple interactions

Coumestrol results in increased expression of SRSF10 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of SRSF10 mRNA

NCBI chr 5:153,372,307...153,386,520
Ensembl chr 5:148,088,823...148,101,768

G

serine and arginine rich splicing factor 2

increases expression

Coumestrol results in increased expression of SRSF2 mRNA

NCBI chr10:102,550,962...102,554,200
Ensembl chr10:102,052,314...102,055,338

G

serine and arginine rich splicing factor 3

increases expression

Coumestrol results in increased expression of SFRS3 mRNA

NCBI chr20:7,093,529...7,103,517
Ensembl chr20:7,091,910...7,101,078

G

single-stranded DNA binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SSBP2 mRNA

NCBI chr 2:24,385,494...24,673,768
Ensembl chr 2:22,651,258...22,933,696

G

structure specific recognition protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SSRP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SSRP1 mRNA

NCBI chr 3:90,531,024...90,541,132
Ensembl chr 3:70,118,655...70,134,482

G

SSX family member 2 interacting protein

increases expression
multiple interactions

Coumestrol results in increased expression of SSX2IP mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of SSX2IP mRNA

NCBI chr 2:235,298,012...235,330,750
Ensembl chr 2:235,298,088...235,330,745

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of ST3GAL1 mRNA

NCBI chr 7:100,734,300...100,802,443
Ensembl chr 7:98,845,270...98,913,236

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ST8SIA4 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ST8SIA4 mRNA
Coumestrol results in decreased expression of ST8SIA4 mRNA

NCBI chr 9:95,990,131...96,084,661
Ensembl chr 9:95,993,503...96,084,653

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA]

NCBI chr17:76,740,755...76,884,178
Ensembl chr17:76,745,224...76,884,299

G

STAG1 cohesin complex component

increases expression

Coumestrol results in increased expression of STAG1 mRNA

NCBI chr 8:110,057,981...110,443,666
Ensembl chr 8:101,179,039...101,564,677

G

signal transducer and activator of transcription 3

decreases expression

Coumestrol results in decreased expression of STAT3 mRNA

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057

G

stanniocalcin 1

decreases expression

Coumestrol results in decreased expression of STC1 mRNA

NCBI chr15:50,709,439...50,720,093
Ensembl chr15:44,299,621...44,310,264

G

stanniocalcin 2

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA]

NCBI chr10:16,755,508...16,765,275
Ensembl chr10:16,250,853...16,262,973

G

STIL, centriolar assembly protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of STIL mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of STIL mRNA
Coumestrol results in increased expression of STIL mRNA

NCBI chr 5:133,757,598...133,810,493
Ensembl chr 5:128,520,953...128,573,730

G

stress-induced phosphoprotein 1

increases expression

Coumestrol results in increased expression of STIP1 mRNA

NCBI chr 1:213,638,641...213,657,654
Ensembl chr 1:204,178,932...204,228,476

G

serine/threonine kinase 38 like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STK38L mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of STK38L mRNA

NCBI chr 4:179,616,288...179,693,177
Ensembl chr 4:179,634,275...179,690,983

G

serine/threonine kinase 4

decreases expression

Coumestrol results in decreased expression of STK4 mRNA

NCBI chr 3:173,165,238...173,247,135
Ensembl chr 3:152,745,681...152,827,744

G

stathmin 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of STMN1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of STMN1 mRNA
Coumestrol results in increased expression of STMN1 mRNA

NCBI chr 5:151,964,308...151,970,843
Ensembl chr 5:146,681,436...146,687,154

G

stonin 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of STON2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STON2 mRNA

NCBI chr 6:116,291,898...116,441,391
Ensembl chr 6:110,567,485...110,676,376

G

STE20 related adaptor alpha

increases expression

Coumestrol results in increased expression of STRADA mRNA

NCBI chr10:91,594,648...91,623,710
Ensembl chr10:91,094,687...91,123,830

G

striatin 3

decreases expression
multiple interactions

Coumestrol results in decreased expression of STRN3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STRN3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of STRN3 mRNA

NCBI chr 6:74,783,156...74,869,473
Ensembl chr 6:69,047,776...69,134,102

G

syntaxin 17

decreases expression

Coumestrol results in decreased expression of STX17 mRNA

NCBI chr 5:67,241,673...67,302,228
Ensembl chr 5:62,446,187...62,504,451

G

syntaxin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STX3 mRNA

NCBI chr 1:217,940,697...218,114,865
Ensembl chr 1:208,639,115...208,685,805

G

syntaxin 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STX7 mRNA

NCBI chr 1:23,016,330...23,056,579
Ensembl chr 1:21,197,075...21,237,279

G

sulfatase 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of SULF1 mRNA

NCBI chr 5:11,145,950...11,308,622
Ensembl chr 5:6,362,911...6,525,584

G

sulfatase 2

increases expression
multiple interactions

Coumestrol results in increased expression of SULF2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SULF2 mRNA

NCBI chr 3:175,241,322...175,323,808
Ensembl chr 3:154,822,085...154,904,415

G

sulfotransferase family 2B member 1

increases expression

Coumestrol results in increased expression of SULT2B1 mRNA

NCBI chr 1:105,336,614...105,397,744
Ensembl chr 1:96,200,156...96,261,295

G

SPT16 homolog, facilitates chromatin remodeling subunit

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SUPT16H mRNA
Coumestrol results in increased expression of SUPT16H mRNA

NCBI chr15:27,341,196...27,378,314
Ensembl chr15:24,866,489...24,904,846

G

SUV39H1 histone lysine methyltransferase

multiple interactions
increases expression

[Coumestrol co-treated with Resveratrol] results in increased expression of SUV39H1 mRNA
Coumestrol results in increased expression of SUV39H1 mRNA

NCBI chr X:17,093,059...17,105,942
Ensembl chr X:14,421,109...14,433,982

G

SUV39H1 histone lysine methyltransferase, pseudogene 1

multiple interactions
increases expression

[Coumestrol co-treated with resveratrol] results in increased expression of SUV39H1 mRNA
Coumestrol results in increased expression of SUV39H1 mRNA

NCBI chr X:146,828,818...146,831,485

G

SUV39H2 histone lysine methyltransferase

increases expression
multiple interactions

Coumestrol results in increased expression of SUV39H2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SUV39H2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SUV39H2 mRNA

NCBI chr17:79,665,467...79,684,492
Ensembl chr17:74,756,306...74,775,332

G

small vasohibin binding protein

decreases expression

Coumestrol results in decreased expression of SVBP mRNA

NCBI chr 5:138,091,773...138,099,048
Ensembl chr 5:132,808,204...132,813,735

G

switching B-cell complex subunit SWAP70

decreases expression
multiple interactions

Coumestrol results in decreased expression of SWAP70 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SWAP70 mRNA

NCBI chr 1:164,267,588...164,328,796
Ensembl chr 1:164,267,609...164,328,794

G

syntabulin

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of SYBU mRNA

NCBI chr 7:77,731,662...77,833,413
Ensembl chr 7:75,847,003...75,948,828

G

synaptonemal complex central element protein 2

increases expression
multiple interactions

Coumestrol results in increased expression of SYCE2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SYCE2 mRNA

NCBI chr19:40,173,713...40,195,959
Ensembl chr19:23,268,869...23,300,980

G

synapse defective Rho GTPase homolog 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SYDE2 mRNA

NCBI chr 2:237,557,395...237,591,290
Ensembl chr 2:234,897,717...234,930,994

G

synaptotagmin binding, cytoplasmic RNA interacting protein

increases expression

Coumestrol results in increased expression of SYNCRIP mRNA

NCBI chr 8:98,282,358...98,315,412
Ensembl chr 8:89,402,866...89,435,515

G

spectrin repeat containing nuclear envelope protein 2

increases expression

Coumestrol results in increased expression of SYNE2 mRNA

NCBI chr 6:100,272,729...100,586,364
Ensembl chr 6:94,537,088...94,848,064

G

synaptogyrin 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SYNGR3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SYNGR3 mRNA
Coumestrol results in decreased expression of SYNGR3 mRNA

NCBI chr10:13,710,553...13,715,309
Ensembl chr10:13,704,998...13,715,669

G

synaptojanin 2 binding protein

decreases expression

Coumestrol results in decreased expression of SYNJ2BP mRNA

NCBI chr 6:106,920,970...106,958,653
Ensembl chr 6:101,189,714...101,227,406

G

synaptotagmin 17

decreases expression

Coumestrol results in decreased expression of SYT17 mRNA

NCBI chr 1:172,695,275...172,761,906
Ensembl chr 1:172,696,120...172,761,960

G

synaptotagmin-like 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of SYTL2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SYTL2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of SYTL2 mRNA

NCBI chr 1:153,685,403...153,791,758
Ensembl chr 1:144,273,360...144,379,222

G

synaptotagmin-like 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SYTL4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SYTL4 mRNA

NCBI chr X:101,428,785...101,479,207
Ensembl chr X:97,135,500...97,185,854

G

synaptotagmin-like 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SYTL5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of SYTL5 mRNA
Coumestrol results in increased expression of SYTL5 mRNA

NCBI chr X:15,461,215...15,702,660
Ensembl chr X:12,788,698...13,030,175

G

TGF-beta activated kinase 1/MAP3K7 binding protein 2

decreases expression

Coumestrol results in decreased expression of TAB2 mRNA

NCBI chr 1:4,195,400...4,245,485
Ensembl chr 1:2,375,490...2,424,756

G

transforming, acidic coiled-coil containing protein 3

increases expression
multiple interactions

Coumestrol results in increased expression of TACC3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TACC3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TACC3 mRNA

NCBI chr14:81,275,755...81,289,894
Ensembl chr14:77,051,215...77,065,219

G

tumor-associated calcium signal transducer 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TACSTD2 mRNA

NCBI chr 4:98,037,620...98,039,320
Ensembl chr 4:96,707,951...96,709,650

G

TATA-box binding protein associated factor 12

increases expression

Coumestrol results in increased expression of TAF12 mRNA

NCBI chr 5:149,756,826...149,772,886
Ensembl chr 5:144,472,841...144,488,849

G

TATA-box binding protein associated factor 5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TAF5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TAF5 mRNA
Coumestrol results in increased expression of TAF5 mRNA

NCBI chr 1:245,958,428...245,973,914
Ensembl chr 1:245,958,428...245,973,914

G

tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TANC2 mRNA

NCBI chr10:91,052,860...91,373,291
Ensembl chr10:90,553,002...90,868,756

G

TAO kinase 1

decreases expression

Coumestrol results in decreased expression of TAOK1 mRNA

NCBI chr10:62,871,198...62,989,049
Ensembl chr10:62,381,404...62,465,766

G

TAO kinase 3

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TAOK3 mRNA
Coumestrol results in decreased expression of TAOK3 mRNA

NCBI chr12:44,973,180...45,134,439
Ensembl chr12:39,314,027...39,461,244

G

threonyl-tRNA synthetase 2, mitochondrial

increases expression
multiple interactions

Coumestrol results in increased expression of TARS2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TARS2 mRNA

NCBI chr 2:183,293,095...183,310,210
Ensembl chr 2:183,293,097...183,310,184

G

TatD DNase domain containing 2

increases expression

Coumestrol results in increased expression of TATDN2 mRNA

NCBI chr 4:146,845,156...146,865,708
Ensembl chr 4:146,845,156...146,860,897

G

TBC1 domain family, member 24

decreases expression

Coumestrol results in decreased expression of TBC1D24 mRNA

NCBI chr10:13,711,930...13,740,902
Ensembl chr10:13,209,895...13,236,050

G

tubulin folding cofactor D

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TBCD mRNA

NCBI chr10:107,215,626...107,372,398
Ensembl chr10:106,717,367...106,874,122

G

transducin (beta)-like 1 X-linked

decreases expression

Coumestrol results in decreased expression of TBL1X mRNA

NCBI chr X:45,452,983...45,609,532
Ensembl chr X:41,576,047...41,731,101

G

tandem C2 domains, nuclear

decreases expression

Coumestrol results in decreased expression of TC2N mRNA

NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:120,761,119...120,849,326

G

transcription factor 19

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TCF19 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TCF19 mRNA
Coumestrol results in increased expression of TCF19 mRNA

NCBI chr20:3,223,464...3,227,569
Ensembl chr20:3,218,693...3,223,271

G

transcription factor 7 like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TCF7L1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of TCF7L1 mRNA

NCBI chr 4:106,238,892...106,404,012
Ensembl chr 4:104,680,739...104,845,287

G

tyrosyl-DNA phosphodiesterase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TDP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TDP1 mRNA
Coumestrol results in increased expression of TDP1 mRNA

NCBI chr 6:124,892,821...124,960,646
Ensembl chr 6:119,163,166...119,231,021

G

trans-2,3-enoyl-CoA reductase

increases expression
multiple interactions

Coumestrol results in increased expression of TECR mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TECR mRNA

NCBI chr19:41,431,422...41,472,880
Ensembl chr19:24,541,615...24,568,168

G

tubulin epsilon and delta complex 1

increases expression

Coumestrol results in increased expression of TEDC1 mRNA

NCBI chr 6:132,234,764...132,245,164
Ensembl chr 6:132,236,925...132,244,928

G

terminal nucleotidyltransferase 4A

increases expression

Coumestrol results in increased expression of TENT4A mRNA

NCBI chr 1:33,765,949...33,799,405
Ensembl chr 1:33,765,672...33,799,433

G

terminal nucleotidyltransferase 5C

increases expression
multiple interactions

Coumestrol results in increased expression of TENT5C mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of TENT5C mRNA

NCBI chr 2:187,853,026...187,875,260
Ensembl chr 2:187,853,024...187,894,744

G

testin LIM domain protein

decreases expression

Coumestrol results in decreased expression of TES mRNA

NCBI chr 4:46,331,257...46,369,782
Ensembl chr 4:45,365,285...45,403,829

G

testis expressed 30

increases expression
multiple interactions

Coumestrol results in increased expression of TEX30 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TEX30 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TEX30 mRNA

NCBI chr 9:46,243,416...46,252,273
Ensembl chr 9:46,242,748...46,252,249

G

transcription factor AP-2 gamma

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TFAP2C mRNA

NCBI chr 3:161,315,114...161,322,998
Ensembl chr 3:161,315,031...161,322,995

G

transcription factor Dp-1

increases expression
multiple interactions

Coumestrol results in increased expression of TFDP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TFDP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TFDP1 mRNA

NCBI chr16:82,864,220...82,903,166
Ensembl chr16:76,162,043...76,200,817

G

trefoil factor 1

increases expression
multiple interactions

Coumestrol results in increased expression of TFF1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TFF1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA]; fulvestrant inhibits the reaction [Coumestrol results in increased expression of TFF1 mRNA]

PMID:18310284 PMID:19167446 PMID:22562034 PMID:35307500

NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,235,736...9,239,597

G

trefoil factor 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TFF3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TFF3 mRNA
Coumestrol results in increased expression of TFF3 mRNA

NCBI chr20:9,194,623...9,199,333
Ensembl chr20:9,193,262...9,198,054

G

tissue factor pathway inhibitor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TFPI mRNA

NCBI chr 3:89,939,862...89,989,253
Ensembl chr 3:69,533,156...69,576,880

G

transferrin receptor

increases expression

Coumestrol results in increased expression of TFRC mRNA

NCBI chr11:81,668,478...81,690,318
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TGFB2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of TGFB2 mRNA
Coumestrol results in decreased expression of TGFB2 mRNA

NCBI chr13:100,691,540...100,793,227
Ensembl chr13:98,160,087...98,261,405

G

transforming growth factor, beta receptor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TGFBR1 mRNA

NCBI chr 5:66,449,348...66,506,371
Ensembl chr 5:61,653,233...61,710,777

G

TGFB-induced factor homeobox 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TGIF1 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of TGIF1 mRNA
Coumestrol results in decreased expression of TGIF1 mRNA

NCBI chr 9:110,748,094...110,757,714
Ensembl chr 9:110,720,921...110,757,802

G

TGFB-induced factor homeobox 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TGIF2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TGIF2 mRNA
Coumestrol results in increased expression of TGIF2 mRNA

NCBI chr 3:145,333,152...145,348,599
Ensembl chr 3:145,333,418...145,348,596
Ensembl chr17:145,333,418...145,348,596

G

thrombospondin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of THBS1 mRNA

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:105,056,292...105,071,440

G

thioesterase superfamily member 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of THEM6 mRNA

NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746

G

THO complex subunit 5

increases expression

Coumestrol results in increased expression of THOC5 mRNA

NCBI chr14:83,982,302...84,016,193
Ensembl chr14:79,758,917...79,792,718

G

thimet oligopeptidase 1

increases expression

Coumestrol results in increased expression of THOP1 mRNA

NCBI chr 7:9,283,617...9,295,957
Ensembl chr 7:8,632,916...8,645,275

G

thrombospondin type 1 domain containing 4

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of THSD4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of THSD4 mRNA
Coumestrol results in increased expression of THSD4 mRNA

NCBI chr 8:60,384,636...60,984,419
Ensembl chr 8:60,386,875...61,024,995

G

TOPBP1-interacting checkpoint and replication regulator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TICRR mRNA

NCBI chr 1:143,006,989...143,048,836
Ensembl chr 1:133,597,716...133,639,523

G

TP53 induced glycolysis regulatory phosphatase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TIGAR mRNA

NCBI chr 4:161,613,306...161,632,248
Ensembl chr 4:159,927,139...159,946,029
Ensembl chr 6:159,927,139...159,946,029

G

timeless circadian regulator

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TIMELESS mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TIMELESS mRNA
Coumestrol results in increased expression of TIMELESS mRNA

NCBI chr 7:1,239,388...1,263,344
Ensembl chr 7:654,822...678,738

G

translocase of inner mitochondrial membrane 21

increases expression

Coumestrol results in increased expression of TIMM21 mRNA

NCBI chr18:80,589,775...80,594,237
Ensembl chr18:78,314,909...78,319,454

G

TIMP metallopeptidase inhibitor 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TIMP2 mRNA
Coumestrol results in decreased expression of TIMP2 mRNA

NCBI chr10:104,041,604...104,089,214
Ensembl chr10:103,531,505...103,590,611

G

TIMP metallopeptidase inhibitor 3

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of TIMP3 mRNA
Coumestrol results in decreased expression of TIMP3 mRNA

NCBI chr 7:19,408,539...19,459,558
Ensembl chr 7:17,521,919...17,571,839

G

timeless interacting protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TIPIN mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of TIPIN mRNA
Coumestrol results in increased expression of TIPIN mRNA

NCBI chr 8:73,676,020...73,696,620
Ensembl chr 8:64,780,828...64,801,352
Ensembl chr 9:64,780,828...64,801,352

G

thymidine kinase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TK1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TK1 mRNA
Coumestrol results in increased expression of TK1 mRNA

NCBI chr10:103,533,449...103,544,818
Ensembl chr10:103,031,521...103,046,920

G

triokinase and FMN cyclase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TKFC mRNA

NCBI chr 1:216,664,446...216,677,815
Ensembl chr 1:207,236,557...207,252,737

G

TLC domain containing 1

increases expression

Coumestrol results in increased expression of TLCD1 mRNA

NCBI chr10:63,572,541...63,574,574
Ensembl chr10:63,074,469...63,076,501

G

TLC domain containing 3A

multiple interactions

[Coumestrol co-treated with Resveratrol] results in increased expression of TLCD3A mRNA

NCBI chr10:61,556,193...61,563,529
Ensembl chr10:61,058,042...61,065,283

G

TLE family member 1, transcriptional corepressor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TLE1 mRNA

NCBI chr 5:90,898,182...90,982,118
Ensembl chr 5:85,851,827...85,934,774

G

tousled-like kinase 2

decreases expression

Coumestrol results in decreased expression of TLK2 mRNA

NCBI chr10:90,154,449...90,248,562
Ensembl chr10:90,156,813...90,248,561

G

talin rod domain containing 1

decreases expression

Coumestrol results in decreased expression of TLNRD1 mRNA

NCBI chr 1:137,864,340...137,866,359
Ensembl chr 1:137,864,343...137,866,359

G

transmembrane 4 L six family member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TM4SF1 mRNA

NCBI chr 2:141,456,950...141,466,146
Ensembl chr 2:141,453,310...141,466,146

G

transmembrane 6 superfamily member 1

decreases expression

Coumestrol results in decreased expression of TM6SF1 mRNA

NCBI chr 1:135,799,844...135,828,515
Ensembl chr 1:135,786,381...135,828,443

G

transmembrane channel-like 4

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of TMC4 mRNA
Coumestrol results in decreased expression of TMC4 mRNA

NCBI chr 1:74,455,135...74,467,043
Ensembl chr 1:65,539,721...65,551,677

G

transmembrane and coiled-coil domain family 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TMCC1 mRNA

NCBI chr 4:150,738,966...150,912,256
Ensembl chr 4:149,069,260...149,239,620

G

transmembrane p24 trafficking protein family member 8

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMED8 mRNA
Coumestrol results in increased expression of TMED8 mRNA

NCBI chr 6:106,806,973...106,841,271
Ensembl chr 6:106,810,420...106,843,216

G

transmembrane protein 106B

decreases expression

Coumestrol results in decreased expression of TMEM106B mRNA

NCBI chr 4:41,328,125...41,347,315
Ensembl chr 4:41,327,994...41,345,619

G

transmembrane protein 106C

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM106C mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TMEM106C mRNA
Coumestrol results in increased expression of TMEM106C mRNA

NCBI chr 7:129,088,468...129,094,128
Ensembl chr 7:129,088,498...129,094,130

G

transmembrane protein 107

increases expression
multiple interactions

Coumestrol results in increased expression of TMEM107 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of TMEM107 mRNA

NCBI chr10:54,268,218...54,273,520
Ensembl chr10:53,771,784...53,774,676

G

transmembrane protein 150A

decreases expression

Coumestrol results in decreased expression of TMEM150A mRNA

NCBI chr 4:104,410,271...104,414,630
Ensembl chr 4:104,410,516...104,429,349

G

transmembrane protein 150C

decreases expression

Coumestrol results in decreased expression of TMEM150C mRNA

NCBI chr14:9,759,028...9,829,588
Ensembl chr14:9,508,515...9,525,298

G

transmembrane protein 164

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM164 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TMEM164 mRNA

NCBI chr X:111,084,830...111,245,419
Ensembl chr X:106,289,371...106,448,640

G

transmembrane protein 168

increases expression

Coumestrol results in increased expression of TMEM168 mRNA

NCBI chr 4:41,830,623...41,858,763
Ensembl chr 4:41,830,624...41,858,776

G

transmembrane protein 181

decreases expression

Coumestrol results in decreased expression of TMEM181 mRNA

NCBI chr 1:46,830,812...46,885,173
Ensembl chr 1:46,830,710...46,884,295

G

transmembrane protein 19

increases expression

Coumestrol results in increased expression of TMEM19 mRNA

NCBI chr 7:50,958,884...50,985,601
Ensembl chr 7:50,958,888...50,986,809

G

transmembrane protein 230

increases expression

Coumestrol results in increased expression of TMEM230 mRNA

NCBI chr 3:119,473,109...119,497,617
Ensembl chr 3:119,480,735...119,497,614

G

transmembrane protein 237

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM237 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TMEM237 mRNA
Coumestrol results in increased expression of TMEM237 mRNA

NCBI chr 9:68,027,481...68,066,731
Ensembl chr 9:60,535,233...60,572,567

G

transmembrane protein 30A

decreases expression

Coumestrol results in decreased expression of TMEM30A mRNA

NCBI chr 8:89,608,975...89,637,421
Ensembl chr 8:80,729,619...80,753,248

G

transmembrane protein 38B

increases expression
multiple interactions

Coumestrol results in increased expression of TMEM38B mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM38B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TMEM38B mRNA

NCBI chr 5:68,460,304...68,496,026
Ensembl chr 5:68,460,304...68,496,025

G

transmembrane protein 45b

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TMEM45B mRNA
Coumestrol results in decreased expression of TMEM45B mRNA

NCBI chr 8:29,865,276...29,910,453
Ensembl chr 8:29,865,278...29,910,453

G

transmembrane protein 64

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM64 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TMEM64 mRNA
Coumestrol results in increased expression of TMEM64 mRNA

NCBI chr 5:33,495,992...33,542,390
Ensembl chr 5:28,698,918...28,745,330

G

transmembrane protein 65

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TMEM65 mRNA

NCBI chr 7:90,336,997...90,378,930
Ensembl chr 7:90,274,142...90,379,474

G

transmembrane protein 97

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM97 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TMEM97 mRNA
Coumestrol results in increased expression of TMEM97 mRNA

NCBI chr10:63,936,276...63,945,359
Ensembl chr10:63,438,222...63,589,730

G

thymopoietin

increases expression
multiple interactions

Coumestrol results in increased expression of TMPO mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMPO mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TMPO mRNA

NCBI chr 7:27,529,977...27,554,980
Ensembl chr 7:25,586,725...25,667,727

G

transmembrane serine protease 3

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMPRSS3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TMPRSS3 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA]
Coumestrol results in increased expression of TMPRSS3 mRNA

PMID:18310284 PMID:19167446

NCBI chr20:9,254,102...9,273,808
Ensembl chr20:9,254,109...9,274,363

G

thymosin beta 15B2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMSB15A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TMSB15A mRNA

NCBI chr X:105,090,980...105,093,094
Ensembl chr X:100,298,514...100,300,886

G

thiol methyltransferase 1A

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMT1A mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of TMT1A mRNA
Coumestrol results in increased expression of TMT1A mRNA

NCBI chr 7:131,452,099...131,460,154
Ensembl chr 7:131,451,641...131,460,154

G

transmembrane O-mannosyltransferase targeting cadherins 2

decreases expression
multiple interactions

Coumestrol results in decreased expression of TMTC2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TMTC2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of TMTC2 mRNA

NCBI chr 7:40,392,377...40,806,685
Ensembl chr 7:40,394,220...40,807,298

G

thioredoxin-related transmembrane protein 1

increases expression
multiple interactions

Coumestrol results in increased expression of TMX1 mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of TMX1 mRNA

NCBI chr 6:94,696,699...94,707,751
Ensembl chr 6:88,960,695...88,971,301

G

thioredoxin-related transmembrane protein 4

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of TMX4 mRNA

NCBI chr 3:142,309,026...142,352,415
Ensembl chr 3:121,856,261...121,899,641

G

tumor necrosis factor

multiple interactions

Coumestrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TNFAIP1 mRNA

NCBI chr10:63,915,824...63,930,514
Ensembl chr10:63,417,775...63,432,466

G

TNF receptor superfamily member 12A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TNFRSF12A mRNA

NCBI chr10:13,211,670...13,213,666
Ensembl chr10:12,689,890...12,709,045

G

TNF receptor superfamily member 21

decreases expression
multiple interactions

Coumestrol results in decreased expression of TNFRSF21 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TNFRSF21 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of TNFRSF21 mRNA

NCBI chr 9:25,376,400...25,451,323
Ensembl chr 9:17,879,156...17,954,085

G

transducer of ERBB2, 2

decreases expression

Coumestrol results in decreased expression of TOB2 mRNA

NCBI chr 7:115,242,843...115,251,563
Ensembl chr 7:113,361,148...113,372,688

G

target of EGR1, exonuclease

increases expression

Coumestrol results in increased expression of TOE1 mRNA

NCBI chr 5:135,507,116...135,510,682
Ensembl chr 5:130,262,319...130,274,050

G

DNA topoisomerase II alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TOP2A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA]

PMID:18310284 PMID:19167446

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:83,945,735...83,976,874

G

DNA topoisomerase II binding protein 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TOPBP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TOPBP1 mRNA
Coumestrol results in increased expression of TOPBP1 mRNA

NCBI chr 8:112,766,791...112,815,203
Ensembl chr 8:103,887,865...103,931,674

G

tumor protein p53 inducible nuclear protein 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TP53INP1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of TP53INP1 mRNA
Coumestrol results in decreased expression of TP53INP1 mRNA

NCBI chr 5:29,051,267...29,069,486
Ensembl chr 5:24,260,568...24,267,968

G

tumor protein p53 inducible nuclear protein 2

decreases expression

Coumestrol results in decreased expression of TP53INP2 mRNA

NCBI chr 3:143,881,427...143,890,104
Ensembl chr 3:143,882,021...143,890,097

G

tumor protein D52

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TPD52 mRNA

NCBI chr 2:94,642,514...94,723,442
Ensembl chr 2:92,735,620...92,816,622

G

TPD52 like 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TPD52L1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TPD52L1 mRNA
Coumestrol results in increased expression of TPD52L1 mRNA

NCBI chr 1:27,991,114...28,109,767
Ensembl chr 1:26,172,170...26,291,109

G

triosephosphate isomerase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TPI1 mRNA

NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:157,615,386...157,619,541

G

tropomyosin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TPM1 mRNA

NCBI chr 8:76,516,654...76,543,661
Ensembl chr 8:67,635,479...67,662,802

G

tumor protein p63 regulated 1-like

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of TPRG1L mRNA

NCBI chr 5:170,004,577...170,007,784
Ensembl chr 5:164,710,285...164,725,425

G

TPX2, microtubule nucleation factor

increases expression
multiple interactions

Coumestrol results in increased expression of TPX2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TPX2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TPX2 mRNA

NCBI chr 3:161,778,709...161,820,941
Ensembl chr 3:141,318,455...141,360,468

G

transformer 2 beta

increases expression

Coumestrol results in increased expression of TRA2B mRNA

NCBI chr11:92,293,403...92,311,651
Ensembl chr11:78,788,884...78,807,249

G

Tnf receptor associated factor 4

multiple interactions

[Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA]

NCBI chr10:63,552,251...63,558,356
Ensembl chr10:63,054,181...63,060,284

G

trafficking protein particle complex subunit 2

decreases expression

Coumestrol results in decreased expression of TRAPPC2 mRNA

NCBI chr X:28,004,051...28,015,336
Ensembl chr X:27,994,054...28,015,346

G

trafficking protein particle complex subunit 8

decreases expression

Coumestrol results in decreased expression of TRAPPC8 mRNA

NCBI chr18:12,103,874...12,180,422
Ensembl chr18:12,103,877...12,180,107

G

transcriptional regulating factor 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TRERF1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of TRERF1 mRNA
Coumestrol results in decreased expression of TRERF1 mRNA

NCBI chr 9:21,131,772...21,355,830
Ensembl chr 9:13,634,126...13,857,029

G

tribbles pseudokinase 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of TRIB1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TRIB1 mRNA

NCBI chr 7:93,096,001...93,102,547
Ensembl chr 7:91,206,579...91,214,731

G

tripartite motif-containing 59

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TRIM59 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TRIM59 mRNA

NCBI chr 2:153,269,210...153,281,185
Ensembl chr 2:153,268,584...153,281,031

G

TRIO and F-actin binding protein

decreases expression

Coumestrol results in decreased expression of TRIOBP mRNA

NCBI chr 7:112,386,371...112,452,130
Ensembl chr 7:110,506,248...110,562,474

G

thyroid hormone receptor interactor 13

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TRIP13 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TRIP13 mRNA
Coumestrol results in increased expression of TRIP13 mRNA

NCBI chr 1:31,185,700...31,230,638
Ensembl chr 1:29,357,130...29,402,074

G

tRNA methyltransferase 10A

decreases expression

Coumestrol results in decreased expression of TRMT10A mRNA

NCBI chr 2:226,669,445...226,684,166
Ensembl chr 2:226,669,832...226,684,151

G

tRNA methyltransferase 5

increases expression

Coumestrol results in increased expression of TRMT5 mRNA

NCBI chr 6:91,963,558...91,987,660
Ensembl chr 6:91,943,724...91,987,555

G

tRNA methyltransferase 6 non-catalytic subunit

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of TRMT6 mRNA

NCBI chr 3:120,074,899...120,086,639
Ensembl chr 3:120,074,911...120,086,559

G

trophinin associated protein

increases expression
multiple interactions

Coumestrol results in increased expression of TROAP mRNA
[Coumestrol co-treated with resveratrol] results in increased expression of TROAP mRNA

NCBI chr 7:132,111,892...132,121,296
Ensembl chr 7:130,234,544...130,242,365

G

TSC complex subunit 2

decreases expression

Coumestrol results in decreased expression of TSC2 mRNA

NCBI chr10:14,125,679...14,160,317
Ensembl chr10:13,621,136...13,655,951

G

TSC22 domain family, member 3

decreases expression
multiple interactions

Coumestrol results in decreased expression of TSC22D3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TSC22D3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of TSC22D3 mRNA

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:104,217,925...104,276,861

G

tRNA splicing endonuclease subunit 15

increases expression

Coumestrol results in increased expression of TSEN15 mRNA

NCBI chr13:64,490,216...64,505,591
Ensembl chr13:64,490,218...64,505,617

G

translin

increases expression
multiple interactions

Coumestrol results in increased expression of TSN mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TSN mRNA

NCBI chr13:29,366,405...29,377,251
Ensembl chr13:29,364,110...29,377,599

G

tetraspanin 1

multiple interactions

[Coumestrol co-treated with resveratrol] results in decreased expression of TSPAN1 mRNA

NCBI chr 5:129,646,139...129,659,383
Ensembl chr 5:129,646,993...129,652,017

G

tetraspanin 31

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TSPAN31 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of TSPAN31 mRNA
Coumestrol results in decreased expression of TSPAN31 mRNA

NCBI chr 7:62,889,552...62,892,428
Ensembl chr 7:62,889,552...62,898,388

G

TSPY-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TSPYL1 mRNA

NCBI chr20:38,082,003...38,084,562
Ensembl chr20:38,081,951...38,084,554
Ensembl chr20:38,081,951...38,084,554

G

tetratricopeptide repeat domain 39B

decreases expression
multiple interactions

Coumestrol results in decreased expression of TTC39B mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TTC39B mRNA

NCBI chr 5:102,649,259...102,754,092
Ensembl chr 5:97,609,392...97,736,270

G

tetratricopeptide repeat domain 9

multiple interactions
decreases expression

[Coumestrol co-treated with resveratrol] results in decreased expression of TTC9 mRNA
Coumestrol results in decreased expression of TTC9 mRNA

NCBI chr 6:107,064,527...107,099,361
Ensembl chr 6:101,333,141...101,368,110

G

transcription termination factor 2

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of TTF2 mRNA

NCBI chr 2:191,054,942...191,086,331
Ensembl chr 2:188,366,331...188,397,689

G

Ttk protein kinase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TTK mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TTK mRNA
Coumestrol results in increased expression of TTK mRNA

NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:84,754,315...84,792,651

G

tubulin, beta 2A class IIa

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TUBB2A mRNA

NCBI chr17:31,002,186...31,006,057
Ensembl chr17:30,747,503...30,800,714

G

tubulin, beta 4B class IVb

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBB4B mRNA
Coumestrol results in increased expression of TUBB4B mRNA

NCBI chr 3:28,435,999...28,438,455
Ensembl chr 3:8,037,799...8,040,296

G

tubulin, beta 5 class I

increases expression
multiple interactions

Coumestrol results in increased expression of TUBB mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBB mRNA

NCBI chr20:2,917,577...2,921,726
Ensembl chr20:2,912,778...2,916,940

G

tubulin, delta 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBD1 mRNA
Coumestrol results in increased expression of TUBD1 mRNA

NCBI chr10:71,367,936...71,391,387
Ensembl chr10:71,368,133...71,391,266

G

tubulin, gamma 1

increases expression
multiple interactions

Coumestrol results in increased expression of TUBG1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBG1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TUBG1 mRNA

NCBI chr10:86,553,143...86,559,733
Ensembl chr10:86,052,743...86,059,433

G

tubulin gamma complex component 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBGCP4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TUBGCP4 mRNA

NCBI chr 3:108,141,081...108,172,207
Ensembl chr 3:108,141,625...108,169,437

G

tuftelin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TUFT1 mRNA

NCBI chr 2:184,949,437...184,995,321
Ensembl chr 2:182,260,398...182,306,192

G

taurine up-regulated 1

decreases expression

Coumestrol results in decreased expression of TUG1 mRNA

NCBI chr14:82,743,501...82,750,534
Ensembl chr14:78,522,506...78,526,927

G

TUB like protein 4

decreases expression
multiple interactions

Coumestrol results in decreased expression of TULP4 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TULP4 mRNA

NCBI chr 1:46,682,416...46,813,167
Ensembl chr 1:46,682,863...46,809,688

G

twist family bHLH transcription factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TWIST1 mRNA

NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:50,674,678...50,677,653

G

thymidylate synthetase

increases expression
multiple interactions

Coumestrol results in increased expression of TYMS mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TYMS mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of TYMS mRNA

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:113,313,452...113,329,536

G

UBA-like domain containing 2

decreases expression

Coumestrol results in decreased expression of UBALD2 mRNA

NCBI chr10:101,662,507...101,667,089
Ensembl chr10:101,658,127...101,667,061

G

ubiquitin-conjugating enzyme E2B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2B mRNA

NCBI chr10:36,749,365...36,764,335
Ensembl chr10:36,248,438...36,264,665

G

ubiquitin-conjugating enzyme E2D 1

decreases expression

Coumestrol results in decreased expression of UBE2D1 mRNA

NCBI chr20:17,309,315...17,343,770
Ensembl chr20:17,309,315...17,342,295

G

ubiquitin-conjugating enzyme E2D 2

decreases expression

Coumestrol results in decreased expression of UBE2D2 mRNA

NCBI chr18:27,364,325...27,406,322
Ensembl chr18:27,364,303...27,406,181

G

ubiquitin-conjugating enzyme E2H

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2H mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of UBE2H mRNA
Coumestrol results in decreased expression of UBE2H mRNA

NCBI chr 4:59,802,102...59,897,583
Ensembl chr 4:58,834,674...58,930,156

G

ubiquitin-conjugating enzyme E2, J1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2J1 mRNA

NCBI chr 5:52,218,807...52,237,805
Ensembl chr 5:47,422,587...47,441,461

G

ubiquitin-conjugating enzyme E2N

increases expression

Coumestrol results in increased expression of UBE2N mRNA

NCBI chr 7:32,041,190...32,071,252
Ensembl chr 7:30,154,616...30,184,355

G

ubiquitin conjugating enzyme E2 QL1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2QL1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of UBE2QL1 mRNA

NCBI chr 1:33,548,814...33,589,174
Ensembl chr 1:33,548,814...33,589,174

G

ubiquitin-conjugating enzyme E2T

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UBE2T mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of UBE2T mRNA
Coumestrol results in increased expression of UBE2T mRNA

NCBI chr13:48,955,166...48,965,668
Ensembl chr13:46,403,375...46,414,835

G

ubiquitin-conjugating enzyme E2W

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2W mRNA
Coumestrol results in decreased expression of UBE2W mRNA

NCBI chr 5:2,690,742...2,754,491
Ensembl chr 5:2,690,763...2,814,965

G

ubiquitin protein ligase E3 component n-recognin 7

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UBR7 mRNA
Coumestrol results in increased expression of UBR7 mRNA

NCBI chr 6:121,898,613...121,918,480
Ensembl chr 6:121,898,623...121,918,477

G

ubiquitin C-terminal hydrolase L5

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UCHL5 mRNA
Coumestrol results in increased expression of UCHL5 mRNA

NCBI chr13:58,070,947...58,106,825
Ensembl chr13:55,520,729...55,556,502

G

uridine-cytidine kinase 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UCK2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of UCK2 mRNA
Coumestrol results in increased expression of UCK2 mRNA

NCBI chr13:81,913,732...81,971,036
Ensembl chr13:79,383,846...79,438,352

G

UDP-glucose 6-dehydrogenase

decreases expression

Coumestrol results in decreased expression of UGDH mRNA

NCBI chr14:43,202,480...43,226,002
Ensembl chr14:42,848,854...42,872,354

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

UGT1A1 protein results in increased glucuronidation of Coumestrol

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation

UGT1A9 protein results in increased glucuronidation of Coumestrol

NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:88,713,184...88,808,465

G

U2AF homology motif kinase 1

decreases expression

Coumestrol results in decreased expression of UHMK1 mRNA

NCBI chr13:84,929,418...84,949,194
Ensembl chr13:82,401,187...82,416,292

G

ubiquitin-like with PHD and ring finger domains 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UHRF1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of UHRF1 mRNA
Coumestrol results in increased expression of UHRF1 mRNA

NCBI chr 9:1,220,162...1,241,792
Ensembl chr 9:1,134,909...1,154,631

G

uridine monophosphate synthetase

increases expression

Coumestrol results in increased expression of UMPS mRNA

NCBI chr11:80,311,269...80,321,678
Ensembl chr11:66,806,045...66,821,903

G

uracil-DNA glycosylase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UNG mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of UNG mRNA
Coumestrol results in increased expression of UNG mRNA

NCBI chr12:48,145,838...48,154,789
Ensembl chr12:42,485,276...42,494,206

G

UPF3B, regulator of nonsense mediated mRNA decay

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UPF3B mRNA
Coumestrol results in increased expression of UPF3B mRNA

NCBI chr X:121,200,993...121,219,059
Ensembl chr X:116,335,308...116,353,236

G

ubiquinol-cytochrome c reductase complex assembly factor 2

increases expression

Coumestrol results in increased expression of UQCC2 mRNA

NCBI chr20:5,202,837...5,214,541
Ensembl chr20:5,202,837...5,214,164
Ensembl chr17:5,202,837...5,214,164

G

ubiquinol-cytochrome c reductase complex assembly factor 3

increases expression

Coumestrol results in increased expression of UQCC3 mRNA

NCBI chr 1:215,202,700...215,203,478
Ensembl chr 1:205,772,780...205,774,376

G

ubiquitin specific peptidase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of USP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of USP1 mRNA
Coumestrol results in increased expression of USP1 mRNA

NCBI chr 5:118,703,056...118,714,426
Ensembl chr 5:113,587,564...113,598,932

G

ubiquitin specific peptidase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of USP3 mRNA

NCBI chr 8:75,973,278...76,049,151
Ensembl chr 8:67,079,927...67,154,111

G

ubiquitin specific peptidase 4

decreases expression

Coumestrol results in decreased expression of USP4 mRNA

NCBI chr 8:117,912,576...117,957,934
Ensembl chr 8:109,036,099...109,080,427

G

ubiquitin specific peptidase 40

decreases expression

Coumestrol results in decreased expression of USP40 mRNA

NCBI chr 9:88,607,920...88,678,940
Ensembl chr 9:88,607,930...88,678,914

G

ubiquitin specific peptidase 5

increases expression

Coumestrol results in increased expression of USP5 mRNA

NCBI chr 4:159,305,927...159,321,345
Ensembl chr 4:157,619,643...157,634,711

G

ubiquitin specific peptidase 54

decreases expression

Coumestrol results in decreased expression of USP54 mRNA

NCBI chr15:3,659,345...3,757,703
Ensembl chr15:3,659,240...3,757,711

G

uronyl-2-sulfotransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UST mRNA

NCBI chr 1:2,666,983...2,962,276
Ensembl chr 1:2,669,592...2,962,044

G

valyl-tRNA synthetase 1

increases expression

Coumestrol results in increased expression of VARS1 mRNA

NCBI chr20:3,810,427...3,825,193
Ensembl chr20:3,805,776...3,820,298

G

valyl-tRNA synthetase 2, mitochondrial

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VARS2 mRNA
Coumestrol results in increased expression of VARS2 mRNA

NCBI chr20:3,081,869...3,092,907
Ensembl chr20:3,077,132...3,087,994

G

vesicle amine transport 1

decreases expression

Coumestrol results in decreased expression of VAT1 mRNA

NCBI chr10:86,889,793...86,897,411
Ensembl chr10:86,389,545...86,397,224

G

voltage-dependent anion channel 1

increases expression

Coumestrol results in increased expression of VDAC1 mRNA

NCBI chr10:37,029,377...37,060,542
Ensembl chr10:36,532,244...36,559,640

G

vascular endothelial growth factor A

decreases expression
multiple interactions

Coumestrol results in decreased expression of VEGFA mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of VEGFA mRNA

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641

G

vestigial-like family member 4

decreases expression

Coumestrol results in decreased expression of VGLL4 mRNA

NCBI chr 4:149,598,151...149,711,186
Ensembl chr 4:147,927,034...148,038,471

G

vitamin K epoxide reductase complex, subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VKORC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of VKORC1 mRNA

NCBI chr 1:191,932,969...191,935,490
Ensembl chr 1:182,500,844...182,505,008

G

vacuolar protein sorting 13 homolog C

decreases expression

Coumestrol results in decreased expression of VPS13C mRNA

NCBI chr 8:77,359,499...77,533,009
Ensembl chr 8:68,478,395...68,651,895

G

VPS41 subunit of HOPS complex

decreases expression

Coumestrol results in decreased expression of VPS41 mRNA

NCBI chr17:50,758,732...50,923,129
Ensembl chr17:46,063,124...46,227,791

G

vacuolar protein sorting 45 homolog

increases expression

Coumestrol results in increased expression of VPS45 mRNA

NCBI chr 2:186,244,839...186,305,177
Ensembl chr 2:183,555,921...183,616,295

G

VRK serine/threonine kinase 1

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VRK1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of VRK1 mRNA
Coumestrol results in increased expression of VRK1 mRNA

NCBI chr 6:124,914,770...124,981,508
Ensembl chr 6:124,914,855...124,981,436

G

vexin

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of VXN mRNA

NCBI chr 5:9,659,213...9,684,684
Ensembl chr 5:9,659,213...9,684,684

G

WASH complex subunit 4

decreases expression

Coumestrol results in decreased expression of WASHC4 mRNA

NCBI chr 7:22,075,546...22,127,847
Ensembl chr 7:20,187,922...20,240,226

G

WW domain binding protein 1

decreases expression

Coumestrol results in decreased expression of WBP1 mRNA

NCBI chr 4:117,182,880...117,185,279
Ensembl chr 4:115,625,168...115,627,624

G

WD repeat and HMG-box DNA binding protein 1

increases expression
multiple interactions

Coumestrol results in increased expression of WDHD1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of WDHD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of WDHD1 mRNA

NCBI chr15:22,957,492...23,002,820
Ensembl chr15:20,489,291...20,523,096

G

WD repeat domain 4

increases expression

Coumestrol results in increased expression of WDR4 mRNA

NCBI chr20:9,588,532...9,604,718
Ensembl chr20:9,587,207...9,603,581

G

WD repeat domain 54

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of WDR54 mRNA
Coumestrol results in increased expression of WDR54 mRNA

NCBI chr 4:117,212,677...117,236,456
Ensembl chr 4:115,654,968...115,661,562

G

WD repeat domain 76

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of WDR76 mRNA
Coumestrol results in increased expression of WDR76 mRNA

NCBI chr 3:128,910,500...128,945,241
Ensembl chr 3:108,456,815...108,490,840

G

WD repeat domain, phosphoinositide interacting 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of WIPI1 mRNA
Coumestrol results in decreased expression of WIPI1 mRNA

NCBI chr10:95,042,451...95,079,679
Ensembl chr10:94,542,946...94,579,846

G

WD repeat domain, phosphoinositide interacting 2

decreases expression

Coumestrol results in decreased expression of WIPI2 mRNA

NCBI chr12:17,024,876...17,053,306
Ensembl chr12:11,911,337...11,939,794

G

WIZ zinc finger

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of WIZ mRNA

NCBI chr 7:12,017,374...12,045,812
Ensembl chr 7:11,367,035...11,395,490

G

WD repeat containing, antisense to TP53

increases expression

Coumestrol results in increased expression of WDR79 mRNA

NCBI chr10:54,780,873...54,797,919
Ensembl chr10:54,282,105...54,298,929

G

WD repeat and SOCS box-containing 2

decreases expression

Coumestrol results in decreased expression of WSB2 mRNA

NCBI chr12:44,878,483...44,899,474
Ensembl chr12:39,217,648...39,238,640

G

WW and C2 domain containing 2

decreases expression

Coumestrol results in decreased expression of WWC2 mRNA

NCBI chr16:50,991,096...51,154,529
Ensembl chr16:44,258,372...44,421,812

G

WWC family member 3

decreases expression

Coumestrol results in decreased expression of WWC3 mRNA

NCBI chr X:23,584,204...23,701,864
Ensembl chr X:23,584,424...23,700,513

G

WW domain containing E3 ubiquitin protein ligase 1

decreases expression

Coumestrol results in decreased expression of WWP1 mRNA

NCBI chr 5:37,889,280...37,982,743
Ensembl chr 5:33,098,494...33,186,046

G

exportin 7

increases expression

Coumestrol results in increased expression of XPO7 mRNA

NCBI chr15:52,151,743...52,237,729
Ensembl chr15:45,742,053...45,828,050

G

X-ray repair cross complementing 6

increases expression

Coumestrol results in increased expression of XRCC6 mRNA

NCBI chr 7:115,423,026...115,443,884
Ensembl chr 7:113,543,057...113,563,762

G

Y box binding protein 1

increases expression

Coumestrol results in increased expression of YBX1 mRNA

NCBI chr 5:138,167,444...138,188,155
Ensembl chr 5:132,882,145...132,898,862

G

yippee-like 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of YPEL2 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of YPEL2 mRNA
Coumestrol results in decreased expression of YPEL2 mRNA

NCBI chr10:72,243,591...72,301,124
Ensembl chr10:71,746,311...71,803,911

G

yippee-like 5

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of YPEL5 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of YPEL5 mRNA
Coumestrol results in decreased expression of YPEL5 mRNA

NCBI chr 6:22,656,284...22,671,741
Ensembl chr 6:22,656,285...22,671,691

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta

decreases expression

Coumestrol results in decreased expression of YWHAB mRNA

NCBI chr 3:173,078,904...173,101,508
Ensembl chr 3:152,659,651...152,682,105

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of YWHAE mRNA

NCBI chr10:61,082,934...61,120,618
Ensembl chr10:60,584,652...60,671,589

G

zinc finger and BTB domain containing 1

decreases expression

Coumestrol results in decreased expression of ZBTB1 mRNA

NCBI chr 6:100,832,506...100,864,019
Ensembl chr 6:95,096,387...95,118,996

G

zinc finger and BTB domain containing 10

decreases expression

Coumestrol results in decreased expression of ZBTB10 mRNA

NCBI chr 2:92,475,254...92,509,892
Ensembl chr 2:92,479,014...92,512,515

G

zinc finger and BTB domain containing 26

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZBTB26 mRNA

NCBI chr 3:21,195,319...21,207,925
Ensembl chr 3:21,195,319...21,207,942

G

zinc finger and BTB domain containing 38

decreases expression

Coumestrol results in decreased expression of ZBTB38 mRNA

NCBI chr 8:106,124,181...106,231,215
Ensembl chr 8:97,280,993...97,485,625

G

zinc finger and BTB domain containing 4

decreases expression
multiple interactions

Coumestrol results in decreased expression of ZBTB4 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZBTB4 mRNA

NCBI chr10:54,480,698...54,501,492
Ensembl chr10:54,485,071...54,501,492

G

zinc finger and BTB domain containing 46

decreases expression

Coumestrol results in decreased expression of ZBTB46 mRNA

NCBI chr 3:188,874,826...188,949,005
Ensembl chr 3:168,499,583...168,568,782

G

zinc finger and BTB domain containing 8 opposite strand

increases expression

Coumestrol results in increased expression of ZBTB8OS mRNA

NCBI chr 5:141,675,595...141,687,148
Ensembl chr 5:141,675,857...141,688,660

G

zinc finger, C2HC-type containing 1A

decreases expression
multiple interactions

Coumestrol results in decreased expression of ZC2HC1A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZC2HC1A mRNA

NCBI chr 2:94,287,352...94,324,655
Ensembl chr 2:94,287,354...94,324,882

G

zinc finger CCCH type containing 12A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZC3H12A mRNA

NCBI chr 5:142,661,193...142,670,051
Ensembl chr 5:137,376,564...137,385,351

G

zinc finger CCHC-type containing 10

increases expression

Coumestrol results in increased expression of ZCCHC10 mRNA

NCBI chr10:37,971,459...37,981,860

G

zinc finger DHHC-type palmitoyltransferase 17

decreases expression

Coumestrol results in decreased expression of ZDHHC17 mRNA

NCBI chr 7:48,256,269...48,320,000
Ensembl chr 7:46,369,988...46,433,764

G

zinc finger DHHC-type palmitoyltransferase 6

increases expression

Coumestrol results in increased expression of ZDHHC6 mRNA

NCBI chr 1:264,340,883...264,361,435
Ensembl chr 1:254,335,113...254,356,108

G

zinc finger DHHC-type palmitoyltransferase 7

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZDHHC7 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ZDHHC7 mRNA
Coumestrol results in decreased expression of ZDHHC7 mRNA

NCBI chr19:65,048,140...65,065,286
Ensembl chr19:48,139,527...48,156,673

G

zinc finger AN1-type containing 2A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZFAND2A mRNA

NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677

G

zinc finger protein 111

decreases expression

Coumestrol results in decreased expression of ZNF226 mRNA

NCBI chr 1:79,762,897...79,774,274
Ensembl chr 1:79,762,782...79,775,608

G

zinc finger protein 12

decreases expression

Coumestrol results in decreased expression of ZNF12 mRNA

NCBI chr12:11,316,971...11,330,498
Ensembl chr12:11,316,872...11,330,558

G

zinc finger protein 260

decreases expression

Coumestrol results in decreased expression of ZNF260 mRNA

NCBI chr 1:94,469,861...94,477,377
Ensembl chr 1:85,336,618...85,350,067

G

zinc finger protein 277

decreases expression
multiple interactions

Coumestrol results in decreased expression of ZNF277 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF277 mRNA

NCBI chr 6:57,383,454...57,512,785
Ensembl chr 6:57,383,951...57,512,765

G

zinc finger protein 292

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF292 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ZNF292 mRNA
Coumestrol results in decreased expression of ZNF292 mRNA

NCBI chr 5:54,184,174...54,264,454
Ensembl chr 5:49,387,893...49,468,265

G

zinc finger protein 354A

decreases expression
multiple interactions

Coumestrol results in decreased expression of ZNF354A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF354A mRNA

NCBI chr10:35,897,217...35,909,063
Ensembl chr10:35,396,231...35,408,068

G

zinc finger protein 367

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ZNF367 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ZNF367 mRNA
Coumestrol results in increased expression of ZNF367 mRNA

NCBI chr17:970,896...990,025
Ensembl chr17:965,161...984,287

G

zinc finger protein 385B

multiple interactions

[Coumestrol co-treated with resveratrol] results in increased expression of ZNF385B mRNA

NCBI chr 3:62,355,182...62,640,417
Ensembl chr 3:62,355,196...62,640,510

G

zinc finger protein 395

decreases expression

Coumestrol results in decreased expression of ZNF395 mRNA

NCBI chr15:39,581,603...39,621,911
Ensembl chr15:39,608,080...39,619,950

G

zinc finger protein 467

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF467 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ZNF467 mRNA
Coumestrol results in decreased expression of ZNF467 mRNA

NCBI chr 4:77,385,752...77,394,709
Ensembl chr 4:77,385,758...77,392,229

G

zinc finger protein 496

decreases expression

Coumestrol results in decreased expression of ZNF496 mRNA

NCBI chr10:44,268,923...44,287,795
Ensembl chr10:44,268,928...44,287,651

G

zinc finger protein 623

decreases expression

Coumestrol results in decreased expression of ZNF623 mRNA

NCBI chr 7:107,627,334...107,636,254
Ensembl chr 7:107,627,267...107,636,321

G

zinc finger protein 641

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF641 mRNA

NCBI chr 7:129,434,576...129,444,847
Ensembl chr 7:129,434,576...129,444,644

G

zinc finger protein 654

decreases expression

Coumestrol results in decreased expression of ZNF654 mRNA

NCBI chr11:2,500,892...2,565,552
Ensembl chr11:2,503,508...2,565,637

G

zinc finger protein 68

multiple interactions

[Coumestrol co-treated with Resveratrol] results in decreased expression of ZNF84 mRNA

NCBI chr12:16,026,058...16,040,995
Ensembl chr12:16,026,079...16,040,995

G

zinc finger protein 703

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ZNF703 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ZNF703 mRNA
Coumestrol results in increased expression of ZNF703 mRNA

NCBI chr16:65,076,507...65,080,677
Ensembl chr16:65,076,507...65,080,677

G

zinc finger protein, multitype 1

decreases expression

Coumestrol results in decreased expression of ZFPM1 mRNA

NCBI chr19:67,242,922...67,299,149
Ensembl chr19:50,334,682...50,390,591

G

zinc finger FYVE-type containing 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of ZFYVE1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZFYVE1 mRNA

NCBI chr 6:103,184,938...103,234,111
Ensembl chr 6:103,184,938...103,234,039

G

zymogen granule protein 16B

decreases expression

Coumestrol results in decreased expression of ZG16B mRNA

NCBI chr10:12,970,888...12,984,170
Ensembl chr10:12,979,020...12,983,572

G

Zic family member 1

decreases expression

Coumestrol results in decreased expression of ZIC1 mRNA

NCBI chr 8:100,785,282...100,797,716
Ensembl chr 8:91,908,576...91,912,731

G

zinc finger with KRAB and SCAN domains 1

decreases expression
multiple interactions

Coumestrol results in decreased expression of ZKSCAN1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZKSCAN1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ZKSCAN1 mRNA

NCBI chr12:16,966,287...16,987,680
Ensembl chr12:16,966,654...16,983,865

G

zinc finger, MIZ-type containing 1

decreases expression

Coumestrol results in decreased expression of ZMIZ1 mRNA

NCBI chr16:1,033,983...1,239,425
Ensembl chr16:1,027,325...1,232,597

G

zinc finger MYM-type containing 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZMYM5 mRNA

NCBI chr15:30,920,479...30,941,249
Ensembl chr15:30,923,241...30,941,240

G

zinc finger protein 750

decreases expression

Coumestrol results in decreased expression of ZNF750 mRNA

NCBI chr10:106,772,162...106,781,186
Ensembl chr10:106,772,669...106,781,200

G

zinc finger, SWIM-type containing 8

decreases expression
multiple interactions

Coumestrol results in decreased expression of ZSWIM8 mRNA
[Coumestrol co-treated with resveratrol] results in decreased expression of ZSWIM8 mRNA

NCBI chr15:3,623,040...3,638,748
Ensembl chr15:3,573,780...3,589,487

G

zwilch kinetochore protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ZWILCH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ZWILCH mRNA
Coumestrol results in increased expression of ZWILCH mRNA

NCBI chr 8:73,532,968...73,566,214
Ensembl chr 8:64,637,672...64,675,916

G

ZW10 interacting kinetochore protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ZWINT mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ZWINT mRNA
Coumestrol results in increased expression of ZWINT mRNA

NCBI chr20:15,502,559...15,953,701
Ensembl chr20:15,938,157...15,953,957

G

zinc finger, X-linked, duplicated B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZXDB mRNA

NCBI chr  X:63,710,381...63,716,353
Ensembl chr  X:59,701,178...59,703,871
Ensembl chr  X:59,701,178...59,703,871

G

zyxin

decreases expression

Coumestrol results in decreased expression of ZYX mRNA

NCBI chr 4:71,236,767...71,246,553
Ensembl chr 4:71,237,451...71,246,553

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19909
role	19880
chemical role	19506
antioxidant	16196
coumestrol	1767
coumestrol diacetate	0
isosojagol	0
Path 2
Term	Annotations
CHEBI ontology	19909
subatomic particle	19907
composite particle	19907
hadron	19907
baryon	19907
nucleon	19907
atomic nucleus	19907
atom	19907
main group element atom	19846
p-block element atom	19846
carbon group element atom	19784
carbon atom	19781
organic molecular entity	19781
heteroorganic entity	19540
organochalcogen compound	19301
organooxygen compound	19216
ester	17582
carboxylic ester	16981
lactone	13311
delta-lactone	4213
coumestan	1787
coumestrol	1767
coumestrol diacetate	0
isosojagol	0

paths to the root